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SUMMARY 
 
Purpose: The traditional approach of Quality by Testing (QbT) limits the assurance of 
product quality to in-process and post-production testing. To overcome these limitations, a 
more proactive and systematic means to product development and optimisation is required. 
Quality by Design (QbD) is an example of such an approach which focuses on 
understanding the product and its manufacturing process and emphasises that quality 
should be built into the product and not merely tested. The study aims to optimise 
ethionamide tablets, an immediate release oral solid dosage form using QbD. 
 
Methodology: A dynamic summary of the product characteristics was established to ensure 
the desired quality is achieved. The critical quality attributes (cQAs) of the product were 
identified. The risk assessment was first performed by using qualitative descriptors followed 
by the failure mode effects analysis (FMEA) method to identify the risk factors that may 
affect the product cQAs. Design of Experiments (DoE) were performed and analysed using 
Minitab® statistical software version 16.0 (Minitab Inc., United Kingdom). An initial screening 
of the risk factors was completed using a 26-3 fractional factorial design to identify the 
significant factors affecting the cQA. Response surface methodology (RSM), by means of a 
central composite rotatable design (CCRD) was used to investigate the effects of the 
significant factors on the response and to create the design space. All experimental runs 
were randomised to avoid any subjective decisions.  
 
Results: The risk assessment identified six factors that had the highest risk of affecting 
dissolution (cQA). These include, the active pharmaceutical ingredient (API) particle size, 
the quantity of povidone binder, impeller speed during dosing, massing time, impeller speed 
during wet mix and the moisture content after drying the wet granule. Pareto ranking and 
analysis of variance (ANOVA) indicated that the impeller speed during dosing and the 
moisture content after drying the wet granule were the significant factors affecting the cQA. 
Optimisation with the CCRD further clarified the relationship between the significant factors 
and the cQA and the design space was established based on the constraints set on the 
response. The optimised manufacturing process was chosen using the desirability factor 
and identified the optimal setting for impeller speed during dosing at 115 rpm and the 
moisture content at 2.5% m/m. The optimised product was prepared and results showed 
that the batch corresponded reasonably well with those predicted for the desired quality 
attribute. The control strategy was developed to better mitigate the risks and the updated 
risk assessment showed that all the potential failure modes were lowered. 
 xiv 
 
Conclusion: DoE and risk assessment tools provided an effective and efficient means to 
build quality into the manufacture of ethionamide tablets. Therefore, the study ascertains the 
concept of QbD for an immediate release tablet that was first introduced onto the market in 
the 1960s.  
 
Keywords: Ethionamide, Quality by Design (QbD), risk assessment; failure mode effects 
analysis (FMEA); Design of Experiments (DoE); fractional factorial designs; response 
surface methodology (RSM); design space; control strategy 
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CHAPTER 1 – INTRODUCTION 
 
1.1 Background 
 
Quality is measured by its degree of excellence. Quality assured products are safe, effective 
and fit for their intended purposes. However, if the quality of pharmaceutical products is 
measured by its fitness for purpose, then safety and efficacy are not separate from quality, 
but form part of it. In instances when a pharmaceutical product is classified as unsafe, or not 
efficacious, then it is not fit for its intended purpose. Accordingly, quality must be taken to 
include safety and efficacy (Sharp, 2000). Quality is a comprehensive system, involving 
personnel, equipment and resources providing assurance that those products will be 
consistently fit and appropriate for their intended use (Soulebot et al., 1997; World Health 
Organisation, 2007). Continuous quality improvement is a critical step for the pharmaceutical 
industry to maintain a competitive advantage in the market place. Therefore, the aim of 
pharmaceutical development is to produce a product of an acceptable quality (International 
Conference on Harmonisation, 2009a). 
 
Under the traditional approach of Quality by Testing (QbT), a product specification is set by 
observing data from a small number of batches believed to be an acceptable quality and 
then setting acceptance criteria that require future batches to be the same. Specifications 
are tight because it is used to assure consistency of the manufacturing process. Testing of 
products can only be performed on a small sample, simply because the majority of the tests 
are destructive in nature and if the entire batch were tested to assure its quality, there would 
be no product. Since a few tablets out of a batch of several million are tested, industries are 
usually expected to conduct extensive in-process tests and post-production tests to ensure 
the outcome meets the predefined specifications, if not, batches are reworked or discarded. 
The combination of stringent manufacturing steps and excessive testing is what assures 
quality under the traditional approach (Karanokov et al., 2011; Sharp, 2000; Travedi, 2012; 
Yu, 2008). In addition, the traditional one-factor-at-a-time (OFAT) approach to 
experimentation has a lot of constraints as it does not determine interactions among the 
factors considered for experimentation, it requires more experimental runs and requires a lot 
more resources (Tanco et al., 2007). This limits the opportunities for statistical and basic 
problem analysis. Therefore, product testing is retrospective, and is based on detection 
rather than prevention (Yu, 2008). 
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Pharmaceutical manufacturing is a highly regulated industry compared to the food or 
automotive industry and the cost of current good manufacturing practice (cGMP) compliance 
is high. In this era of competition, quality has prime magnitude, and failure to meet such 
quality-allied goals produces challenges for industry (Woodcock, 2010). The Food and Drug 
Administration (FDA) acknowledges that more controls are required for pharmaceutical 
manufacturers and better regulatory decision-making. The FDA therefore adopted a more 
methodical approach to product development emphasising on product and process 
understanding which improves interaction with regulatory authorities at a scientific level 
instead of a process level (Varu & Khanna, 2010). 
 
Quality by Design (QbD) is an example of such an approach. The core objective of QbD is to 
develop a robust formulation and manufacturing process that facilitates any adjustment of 
potential variables within a design space (International Conference on Harmonisation, 
2009a). Critical quality attributes (cQAs) are characteristics that need to be controlled within 
an appropriate range to ensure product quality. An attribute is critical when it falls outside the 
acceptable range and has the potential to cause harm to the patient (Food and Drug 
Administration, 2012). The risk assessment is a science-based process used to identify the 
material attributes and process parameters that potentially have an effect on the product‟s 
cQAs. Subsequently optimisation of these factors, using Design of Experiments (DoE) 
should be used to determine the relationship among the factors that can influence the 
product‟s cQAs. Therefore, QbD provides a holistic approach to product development and 
optimisation (International Conference on Harmonisation, 2006, 2009a; Roy, 2012; Tanco et 
al., 2007; Wahid & Nadir, 2013). 
 
As the science of pharmaceutical manufacturing evolves, the application of QbD improves 
the efficacy and the effectiveness of risk management; decision-making, and creates a 
regulatory framework that can accommodate process change and improvement. The 
advantages of this approach are reduced batch failures and an increase in manufacturing 
flexibility, therefore, patient safety and product efficacy become the focus (Eon-Duval et al., 
2012; Nasr, 2007).  
 
The concept of QbD was first outlined in the 1960s and then pioneered by Toyota to improve 
their early automobiles. Since then, industries like technology, telecommunications, 
aeronautics and companies manufacturing medical devices began incorporating QbD into 
their products, which significantly improved their product efficacy (Avellant, 2008). The 
concept of QbD being adopted by the FDA only occurred at the beginning of the early 
2000‟s. Ethionamide, an immediate release tablet was introduced to the market at about the 
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same time as QbD, thus creating the opportunity of taking a long existing product i.e. a 
legacy product, and optimising and reengineering it using the QbD approach.  
 
In order to optimise the formulation and manufacturing process of an immediate release 
tablet, QbD will be applied. The model drug selected for this study is ethionamide, a second-
line drug used in the treatment of multiple drug resistant tuberculosis (MDR-TB) (Gibbon, 
2013). At present, there is only one South African pharmaceutical company manufacturing 
ethionamide 250 mg tablets (Gibbon, 2013). With the growing number of MDR-TB cases in 
South Africa, the need to fulfil the demand requires the manufacture of the drug on a wider 
scale. Hence, the need to implement QbD in the manufacture of ethionamide to ensure 
market demands are satisfied without compromising product quality, effectiveness and cost. 
Furthermore, QbD provides faster regulatory approval, improves interaction between 
pharmaceutical industry and regulatory authorities at a scientific level and provides a better 
overall business model.  
 
1.2 Problem Statement 
 
Traditional pharmaceutical development involves an empirical approach that uses trial and 
error with selective or limited process optimisation. The development process limits the 
assurance of quality to in-process and end product testing, requiring regulatory approval 
when changes to the manufacturing process are made. Batch release is also dependent on 
the results of these tests. Products formulated using robust QbD principles are void of these 
limitations. Implementing QbD will aid in designing a robust manufacturing process for 
ethionamide tablets. 
 
1.3 Aim and objectives 
 
1.3.1  Aim of the study 
 
The aim of this study was to optimise the formulation and manufacturing process of an 
immediate release oral solid dosage form of an antimycobacterial drug i.e. ethionamide 250 
mg tablets, using a systemic approach of applying the principles of QbD. 
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1.3.2 Objectives 
 
The objectives derived from the aim are therefore to: 
 
1. Establish a Quality Target Product Profile (QTPP) for ethionamide 
2. Identify the critical quality attributes (cQAs) of the product 
3. Identify the material attributes and process parameters that will impact the product 
cQAs 
4. Apply design of experiments (DoE) to assess the influence of the selected formulation 
and manufacturing process variables on the product cQAs as follows: 
4.1 Create a design space using the outcome of the DoE analysis 
4.2 Identify optimal settings of the selected input variables within the design space 
5. Propose a formulation and manufacturing process that meets specifications 
6. Establish a control strategy after evaluating and optimising the product 
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CHAPTER 2 – LITERATURE REVIEW 
 
2.1 Introduction 
 
Tablets are the most widely used dosage form due to its convenience in terms of its self-
administration, compactness and ease of manufacturing and since oral solid dosage forms 
do not require sterile conditions they are less expensive to manufacture. Immediate release 
tablets are designed to disintegrate and release their medicament and are widely used for 
their better therapeutic availability (Nyol & Gupta, 2013; Reddy et al., 2010). The leading 
technique of forming tablets is by powder compression that relies on acceptable powder flow 
into die cavities during compression and in order to improve powder flow, powders are 
usually granulated. Wet granulation is considered to be the most effective in terms of 
production time and cost to prepare good granules (Alderborn, 2013). Tablet design is not 
always a simple and straightforward process and it should meet the needs of the 
pharmaceutical industry, regulatory bodies and patients. Tablet product design embraces the 
QbD initiative because this systematic approach incorporates the most current regulatory 
science thinking (Al-Achi et al., 2013). The criteria in QbD represent a logical progression of 
activities encompassing the optimisation of pharmaceutical products.  
 
Tuberculosis (TB) remains a major global health problem. According to the World Health 
Organisation (WHO) (2013), globally 3.6% (95% CI: 2.1 – 5.1%) of new TB cases and 20.2% 
(95% CI: 13.3 – 27.2%) of previously treated cases are estimated to have MDR-TB. In South 
Africa, the percentage of new TB cases with MDR-TB is 1.8% (95% CI: 1.4 – 2.3%) and an 
estimated number of retreatment TB cases with MDR-TB is 6.7% (95% CI: 5.4 – 8.2%). 
These estimates are unchanged since 2011 (World Health Organisation, 2013a). 
Development of TB drug resistance caused by the successful adaptation of the pathogen to 
the first line anti-TB drugs are mainly associated with inadequate therapy, poor patient 
compliance, interrupted drug supply and inappropriate drug regimens. This has necessitated 
the selection of second-line drugs to replace the ineffective first line drugs (Brossier et al., 
2010; Ongaya et al., 2012; Seyoum et al., 2014). 
 
Ethionamide, a second-line antimycobacterial drug is a structural thionamide analogue of 
isoniazid, the cornerstone of first line TB treatment. Ethionamide is considered to be the 
most active anti-TB drug after aminoglycosides and fluoroquinolones and is a component of 
most of the drug regimens used for treating MDR-TB or suspected MDR-TB (Brossier et al., 
2010). Ethionamide is used in combination with other anti-TB drugs and is never and should 
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not be used alone and is used as part of South Africa‟s standard regimen to treat MDR-TB 
and extensively drug resistant TB (XDR-TB) (Gibbon, 2013). Ethionamide is efficacious, 
relatively non-toxic and has been used since the 1960s (Ongaya et al., 2012). By nature, a 
large historical database of the API, excipients and process data exists for legacy products. 
This data can be used to improve product and process understanding and that this 
information can be used to reengineer and optimise pharmaceutical products (Yacoub et al., 
2011). 
 
2.2 Quality by design in the pharmaceutical industry 
 
In 2002, the FDA identified a succession of continuing issues in the pharmaceutical industry 
that the traditional approach to pharmaceutical development had not solved. These 
problems include among others, the lack of mitigation of potential risks, and the lack of 
process understanding. The FDA acknowledged that more control for drug manufacturing 
processes and better regulatory decision-making are required. As a result, the FDA initiated 
a course of action that encouraged risk mitigation through predicting potential problems early 
enough for both manufacturers and regulatory authorities (Rathore & Winkle, 2009; 
Sangshetti et al., 2014; Woodcock, 2010). 
 
In order to improve the competence and modernise the pharmaceutical industry, in 2004, the 
FDA initiated a significant initiative titled, “Pharmaceutical cGMPs for the 21st century: A risk-
based approach”. An important part of this initiative was to shift the focus of the 
pharmaceutical industry away from the empirical approach of QbT to a more systematic and 
holistic approach of product development, which is QbD (Ahmed et al., 2014). QbD is a 
concept first outlined by quality expert Joseph Moses Juran who stated that quality could be 
planned and that most quality crises and problems relate to the way quality is initially 
planned. Although QbD has been used before in various industries like the food and 
automotive industry to enhance and sustain the quality of their products, it is only at the start 
of the 21st century that the FDA has adopted it (Ahmed et al., 2014; Kale & Bajaj, 2014). 
 
In the past few years, the FDA has made significant progress in implementing the concept of 
QbD. The FDA‟s Office of Generic Drugs (OGD) has published reports and presented at 
public industry forums, focusing and defining QbD specifically for generic companies. The 
OGD has issued specific product development examples for immediate release and modified 
release dosage forms, summarising the elements of QbD for implementation. 
Pharmaceutical manufacturers can implement QbD at the early product development stages, 
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the pilot scale and at later stages of the commercial scale (Food and Drug Administration, 
2011, 2012; Rodriguez-Perez, 2012; Sangshetti et al., 2014). 
 
The International Conference on Harmonisation (ICH) guidelines, Q8: Pharmaceutical 
Development, ICH Q9: Quality Risk Management and ICH Q10: Pharmaceutical Quality 
System provides the roadmap on how QbD affects, ensures, maintains and optimises 
product quality. Implementation of QbD is an innovative challenge for generic companies. 
The FDA OGD has assigned QbD for generic industry with opportunities for robust 
processes, cost reduction, lower rate of batch failure and faster science-based regulatory 
assessment and approval (International Conference on Harmonisation, 2006, 2009a, 2009b; 
Karanokov et al., 2011; Varu et al., 2010). The concept of building quality into a product is 
emphasised by the ICH Q8 guideline, which states that “quality cannot be tested into 
products, i.e., quality should be built in by design” (International Conference on 
Harmonisation, 2009a). 
 
QbD is the successor to the traditional approach of QbT that the FDA agency has employed 
until the late 1900s and early 2000s. QbD focuses on building quality into the product 
through proper planning and highlights that the mere analysis of the final product, post-
production, will not suffice. This is achieved by understanding the product and its 
manufacturing process, the risks involved in product manufacturing and the best method to 
mitigate those risks. Understanding the product and its process aids in detecting quality-
associated problems early enough to permit actions without compromise to cost, available 
resources or product quality (Ahmed et al., 2014; Rodriguez-Perez, 2012; Sangshetti et al., 
2014).  
 
Previous experience is a valuable tool to the accumulation of institutional knowledge. 
Researchers and formulation teams can learn from the mistakes and successes of historical 
production data (Roy, 2012). The FDA has stated that QbD is an amalgamation of quality 
risk management, prior knowledge and experience, and DoE, with emphasis on a control 
strategy to achieve robustness (Nasr, 2007; Woodcock, 2010). Implementing the principles 
of QbD does not eliminate product and process variability, however, it allows the formulator 
and the team to develop and optimise a product that can accommodate the range of 
variability (Roy, 2012). Hence, the emphasis is on preventing quality problems and not on 
just correcting them.  
 
According to the FDA‟s risk-based approach to pharmaceutical development, the goal of the 
regulatory system is to ensure that patients should not feel hesitant about the quality of their 
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medicines. In the current state, uncertainty during the review process delays approval of 
certain drug delivery systems (Food and Drug Administration, 2004). This challenge is 
expected to increase and is likely to result in multiple review cycles of new drug product 
applications and delaying the approval of generic drug products in a timely manner. 
Furthermore, FDA resources spent debating issues relating to acceptable variability, need 
for additional testing control and determining how specification acceptance limits are 
established. These debates are avoidable if the application included a more science-based 
approach, such as QbD. The FDA believes that the ICH guidelines will encourage industry 
and regulators to increase the use of risk management tools to ensure drug quality and 
address current pressures felt by both regulatory authorities and the pharmaceutical industry 
with respect to post approval changes. For the regulatory authority, there is a need to reduce 
the burden of supplement review and provide review oversight to only certain changes using 
risk assessment (Food and Drug Administration, 2004; Sangshetti et al., 2014). 
 
Although there is a specification for drug products under both the QbT and QbD, the roles of 
the specification are completely different. Under QbT, each batch has to be tested against 
the specification to ensure its quality and manufacturing consistency. Under the QbD 
approach, specifications are solely used for the confirmation of product quality not 
manufacturing consistency and process control. (Fraser & Kerboul, 2012; Roy, 2012; Yu, 
2008).  
 
There are parallel opportunities of applying QbD to analytical methods as that of 
manufacturing process. Though it is not adopted by all pharmaceutical industries, it has 
future perspective because it may become mandatory by regulatory bodies. However, QbD 
approach by pharmaceutical companies starting 1st January 2013 is recommended. The 
interim phase of FDA adoption and legal implementation of QbD has given industries 
opportunities to familiarise and apply QbD principles to current methods (Sangshetti et al., 
2014). 
 
South Africa is a member of the Pharmaceutical Inspection Convention and Pharmaceutical 
Inspection Co-operation Scheme (jointly referred to as PIC/S) and follows the PIC/S 
guidelines, as well as the guidelines issued by the South African Medicine Control Council 
(PIC/S, 2014). „The Guide to Manufacturing Practice in South Africa’ by the South African 
Medicines Control Council is a commonly used guideline by pharmaceutical manufacturers, 
which has been adapted for South Africa from the PIC/S guideline. It provides a guidance to 
facilitate compliance to cGMP and encompasses the proactive approach of Quality Risk 
Management (QRM) and pharmaceutical quality systems discussed in the ICH Q9 and Q10 
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guidelines, respectively. The GMP Annex 20 corresponds to ICH Q9 guideline on QRM. It 
provides guidance on the systematic approach to QRM facilitating compliance with GMP and 
other quality requirements. It includes principles to be used and options for processes, 
methods and tools which may be used when applying formal risk management approaches. 
In addition, the GMP guideline highlights QRM as part of development, a concept discussed 
in the ICH Q8 guideline (Medicines Control Council, 2010). In addition, implementing QbD 
has several opportunities for the pharmaceutical industry which includes, 
 
 opportunities for facilitating continuous improvement throughout the product life-
cycle, 
 contributes a better understanding of scientific and risk-based regulatory assessment 
and approval, 
 reduced batch failure rates, 
 lower operating costs from fewer failures and deviation investigations, and 
 increased predictability of manufacturing output and quality robust processes which 
gives industry opportunities for robust processes (Varu et al., 2010). 
The comparison between the traditional approach of QbT and the modern approach of QbD 
is summarised in Table 2.1. 
 
Table 2.1  Comparison between the traditional state and the desired QbD state 
(Adapted: McCurdy, 2011) 
Aspect Traditional state Desired QbD state 
Pharmaceutical 
development  
Empirical Systematic 
Manufacturing 
process 
Secluded: validation on three 
batches  
Adjustable within design space; 
continuous verification within a design 
space; focus on control strategy 
Process control 
In-process testing; offline analysis; 
end product testing 
Process Analytical Technology (PAT); 
real time release testing 
Product 
specifications 
Primary means of quality control; 
based on batch data 
Part of overall quality control strategy; 
based on product performance 
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Aspect Traditional state Desired QbD state 
Control strategy 
Mainly by intermediate and end 
product testing 
Risk-based; control shifted upstream 
Life-cycle 
management  
Reactive to problems and out of 
specifications; post approval 
changes needed 
Proactive approach; Continual 
improvement enabled within design 
space 
 
The ability of building quality into the product aids in identifying product characteristics that 
are critical to quality from the perspective of the patient and translates them into the 
attributes that the drug product should have (Patil & Pethe, 2013). QbD confirms product 
quality and not just the manufacturing consistency and process control. The initiative 
challenges the pharmaceutical industry to look beyond end product testing for ensuring 
product quality and performance (Roy, 2012; Yu, 2008). The product and process design 
and development can however not be separated because a formulation cannot become a 
product without a process i.e. a formulation without a process is, for all intents and purposes, 
a pile of powder (Yu, 2008). The various constituents of QbD are discussed under the 
following headings and are summarised in Figure 2.1: 
 
 Quality Target Product Profile 
 Critical Quality Attributes 
 Quality Risk Management 
 Design of Experiments 
 Design Space 
 Control Strategy 
 Product Life-cycle Management 
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Figure 2.1  A flowchart illustrating the process of applying the principles of QbD 
(Adapted: Travedi, 2012) 
 
 
2.2.1  Quality target product profile 
 
In terms of the prescribing information goals, the Target Product Profile (TPP) summarises 
the drug development program. The TPP presents all relevant medical and scientific 
information in relation to the drug‟s labelling such as its indication, contraindications, 
description and clinical pharmacology. The TPP is a tool for setting the strategic foundation 
for drug development which emphasis the statement „planning with the end in mind‟ (Yu, 
2008). Addressing these concerns in the early stages of the drug development process 
reduces failure at the later stages of development. However, the TPP changes as knowledge 
•Product characteristics that ensures quality, safety 
and efficacy is achieved 
Establish Quality Target 
Product Profile (QTPP) 
•cQAs for active pharmaceutical product (API) 
excipients, manufacturing process and drug product 
Identify critical quality 
attributes (cQAs) 
•Linking material attributes and process parameters 
to cQAs 
Perform Risk Assessment 
•Linking input variables and cQAs using Design of 
Experiments (DoE) 
Create Design Space 
•Planned set of controls that assures product quality 
•Based on process understanding and quality risk 
management 
Control Strategy 
•Continuous improvement 
Product life-cycle 
management 
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of the drug increases. Therefore, updating the TPP is required during the drug development 
program to reflect new information or any changes in the clinical development program 
which should include the new safety and efficacy data (Food and Drug Administration, 2007; 
Sangshetti et al., 2014). 
 
The QTPP is a natural extension of the TPP for product quality. The QTPP is a summary of 
the quality characteristics of a drug product to ensure that the desired quality of the product 
is achieved (Food and Drug Administration, 2007). In order to reproducibly deliver the 
therapeutic benefit promised on the label, the QTPP ensures that the formulation strategies 
are well established and keeps the formulation effort focused and efficient (Fahmy et al., 
2012; Roy, 2012; Sangshetti et al., 2014; Yu, 2008). QTPP may include targets such as 
impurities and stability, release profiles and other product specific performance requirements 
(Lionberger et al., 2008).  
 
Generic drugs are similar or bioequivalent to the innovator counterpart with respect to the 
pharmacokinetics and pharmacodynamic properties. Furthermore, an approved generic drug 
is considered identical in dosage form, strength, route of administration and intended use 
(Varu et al., 2010). For the reason that a generic drug product must contain the same active 
pharmaceutical ingredients (API) as the original formulation, the QTPP can readily be 
determined from the reference product, scientific literature and pharmacopoeial 
monographs. The predefined quality product specifications make the product and process 
design and development more objective and efficient (Charoo et al., 2012; Sangshetti et al., 
2014; Varu et al., 2010; Yu, 2008). The FDA recommends that tablets to be swallowed intact 
should be of a similar size and shape to their reference counterpart for comparable ease of 
swallowing as well as patient acceptance and compliance with the treatment regimens. This 
should also be considered when establishing the QTPP (Food and Drug Administration, 
2013). 
 
2.2.2  Critical quality attributes  
 
A cQA is a physical, chemical and microbiological characteristic that must be controlled 
directly or indirectly to ensure the quality of the product (International Conference on 
Harmonisation, 2009a; Kharad et al., 2011; Yu, 2008). According to the ICH Q8 guideline 
(2009), cQAs are an essential part of pharmaceutical product development and should be 
within an appropriate limit, range or distribution. The identification of a cQA from the QTPP is 
based on the severity of the risk to a patient should the attribute fall outside the appropriate 
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range (Food and Drug Administration, 2012). The cQAs include aspects that may affect 
product purity, strength and drug release for oral solid dosage forms. For raw materials, the 
attributes that may affect the drug product cQAs include those properties such as particle 
size distribution (PSD) and bulk density (Sangshetti et al., 2014; Yu, 2008). All quality 
attributes are identified through a risk management system and it is imperative to investigate 
the subset of cQAs that also have a high potential to influence the formulation and process 
variables.  
 
2.2.2.1 Critical material attributes and process parameters 
 
Manufacturing processes consist of a succession of unit operations to produce the desired 
drug product. These discrete activities involve physical changes, such a milling, mixing, 
granulation or drying. Critical process parameters (cPPs) and critical material attributes 
(cMAs) are potential variables that may negatively influence product quality if there are any 
changes in that attribute. In order for processes to reach and maintain its desired quality, 
potential cPPs and cMAs are controlled. Process parameters include the type of equipment 
and equipment settings, batch size, operating and environmental conditions. The quality, 
physicochemical characteristics and quantity of the API, excipients and intermediate bulk 
material are examples of material attributes (International Conference on Harmonisation, 
2009a; Kharad et al., 2011; Yu, 2008). Ideally, data used to identify cPPs should be derived 
from commercial scale processes to avoid any potential impact of scale-up. However, in 
reality these studies are often conducted on laboratory or pilot scale batches (Yu, 2008). 
 
2.2.3  Quality risk management 
 
During the development stages, where the formulation and processes have not been 
established and finalised, there are numerous sources of variability. This is a matter of 
concern, since statistical methodologies suffer from a limitation in that each variable added 
to the study, additional experiments need to be completed. This may not always be feasible, 
as studying too many variables, increase experimental costs (Fahmy et al., 2012). QRM is a 
key enabler for the application of QbD as it serves as a tool to prioritise the potential cQAs 
for subsequent evaluation and focuses resources on the perceived critical areas 
(International Conference on Harmonisation, 2009a).  
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A hazard is a situation that poses a level of threat. Generally most hazards are dormant with 
only a theoretical risk of causing harm to people, product, processes or the environment and 
is an ever-present property (Sandle, 2012). A risk is the combination of the probability of 
occurrence of harm and the severity of that harm (International Conference on 
Harmonisation, 2006). 
 
QRM is a systematic means of identifying, scientifically evaluating, and controlling potential 
risks to product quality throughout its life-cycle (International Conference on Harmonisation, 
2006; Rodriguez-Perez, 2012). An iterative process of QRM and formal experimental 
designs identifies the significant cMAs and cPPs. Predicting the manner in which the 
sources of variation of the identified cMAs and cPPs will impact on the product cQAs and the 
ability to control these variables is the primary goal of process understanding (International 
Conference on Harmonisation, 2006; McCurdy, 2011; World Health Organisation, 2010).  
 
The challenge for pharmaceutical teams is identifying the selected formulation and 
manufacturing input variables that potentially have the greatest impact on the product cQAs. 
The approach of risk assessment centres on identifying a risk, assessing the severity of 
harm and calculating the probability of the risk occurring. Attempts are made to mitigate the 
risks by eliminating the hazard, reducing the potential for harm and/or monitoring it. 
Therefore, the above constituents a proactive method to risk assessment (Sandle, 2012). 
Information used for risk identification and analysis can include historical data, theoretical 
analysis, informed opinions and the concerns of those impacted by the decisions 
(International Conference on Harmonisation, 2006). 
 
The ICH Q9 guideline (2006) highlights the various risk management tools that 
pharmaceutical industries and regulators may use to access and manage risks. Examples 
include, flow charts, Ishikawa (fish bone) diagrams, Fault Tree Analysis (FTA), Failure Mode 
Effects and Criticality Analysis (FMECA), Hazard Analysis and Critical Control Points 
(HACCP) and Failure Mode Effects Analysis (FMEA) (International Conference on 
Harmonisation, 2006). Each QRM tool has its distinct characteristics and not one tool or set 
of tools is acceptable to every situation of QRM. The QRM tools selected should be 
compatible with the data and should be capable of delivering and communicating a cohesive 
risk control plan. Successful QRM tool selection begins with an awareness of the 
interrelationship between understanding the risks and the choice of the risk management 
tool. Risk understanding influences QRM tool selection and similarly, QRM tool selection 
enhances risk understanding. However, this interrelationship may seem illogical as it is 
premature to select a QRM tool before knowing the nature of the risk to be assessed. To 
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overcome this challenge, the multidisciplinary team involved in the risk assessment should 
define the scope and boundaries of the risk assessment and identify available data to 
support the assessment. QRM tools can be selected by an informal means such as an 
unstructured discussion, therefore, QRM leverages lessons from previous experience of a 
multidisciplinary team (Murray & Reich, 2011). 
 
QRM tool selection is rarely an objective process and each QRM has its unique attributes. 
QRM tools are designed to translate data into knowledge that enhances the overall quality 
decisions and risk controls (Murray et al., 2011). There is a spectrum of methods available 
for assessment, ranging from quantitative to qualitative. Qualitative exposure assessments 
are descriptive or categorical, whereas quantitative assessments are mathematical analysis 
of numerical data. Quantitative approaches can be ranked or measured against another and 
compared to a predetermined scale. A qualitative assessment may be undertaken as part of 
the first evaluation to determine if the risks are significant enough to warrant a more detailed 
analysis. At minimum the evaluation criteria should address the probability and severity of 
risk (Sandle, 2012). Table 2.2 shows the risk matrix with evaluation levels for probability and 
severity to potential failures (Frank et al., 2008).  
 
Table 2.2  Two level risk matrix with evaluation for probability and severity 
(Source: Frank et el., 2008)  
 Probability 
Severity Low Medium High 
High potential to impact 
product quality 
Medium High High 
Medium potential to 
impact product quality 
Medium Medium High 
Low potential to impact 
product quality 
Low Low Medium 
*This table has been amended and sourced from the Product Quality Research Institute (PQRI), 2107 Wilson 
Blvd, Suite 700, Arlington, Virginia 22201-3042, United States of America; website: http://www.pqri.org/index.asp 
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The risk assessment of the API, excipients and manufacturing process evaluates the impact 
of each material attribute and process parameter on the product cQAs. According to ICH Q9 
guideline (2006), three fundamental questions are often helpful to define the risks:  
 
 What is the risk? 
 What is the likelihood of the risk occurring? 
 What is the severity of the risk should it happen? 
 
The relative risk that each attribute presents is ranked using the qualitative descriptors „low‟, 
„medium‟ or „high‟. The „low‟ risk attributes do not require any further analysis, whereas the 
„high‟ risk attributes are unacceptable and require further analysis. In general, „medium‟ risks 
are also considered acceptable; however investigations may be conducted in order to 
reduce such risks (International Conference on Harmonisation, 2006). Table 2.3 explains the 
relative risk ranking system. 
 
Table 2.3  Overview of the relative risk ranking system (Adapted: Food and Drug 
Administration, 2012)  
Risk 
Ranking 
Acceptable? 
(Y/N) 
Further 
investigation? (Y/N) 
Justification 
Low Y N Generally acceptable risk attributes 
Medium Y Y 
Further investigation may be 
needed in order to reduce risk. 
High N Y 
Risk attributes are unacceptable 
and will require further analysis 
 
Some of the simpler QRM tools are flow charts and Ishikawa (fish bone) diagrams. The flow 
chart method shows how actions are interrelated and is able to integrate interfaces into the 
flow providing a simple visual representation of the steps involved. Therefore, this method 
facilitates understanding, explaining and systematically analysing complex processes and 
associated risks. The advantage of the Ishikawa diagram is systematically displaying all the 
influencing variables on one page. Fish bone diagrams are more effective for analysing a 
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single step rather than complex systems, which is a disadvantage when using this risk 
assessment tool (Sandle, 2012). 
 
FTA is a logical diagram that shows the relation between system failure as well as failures of 
the components of the system and is widely used in the engineering industry. Thus, FTA 
provides a graphical depiction of all chains of failure of a system and results in a fault tree 
with a varying number of branches and sub-branches, depending on its complexity. At each 
level in the tree, combinations of the fault modes are described. However, the challenge to 
using this QRM tool is, if the wrong cause is selected, the sub-branches may fail to detect 
the actual issue. Furthermore, FTA is a better retrospective analytical tool rather than a 
preventative measure (Sandle, 2012). 
 
FMEA is a method whereby each potential failure mode in a system is analysed to determine 
its effects on the system. The power of FMEA lies in its ability to prioritise risks based on the 
risk severity, probability, and ability to detect the risks and is a popular and well-accepted 
QRM tool in the pharmaceutical industry (Murray et al., 2011). The risks are rated on a scale 
of 1 to 5 or on a scale of 1 to 10 for each of the causes i.e. severity, probability and 
detection. Based on this scaling system, a high severity event would be given a high score, 
whereas a low severity event would be given a score of 1. With probability, if something 
were quite certain to happen, then a higher score would be given, whereas if something 
were very unlikely to happen, then a score of 1 would be given. With detection, if there is a 
good detection system in place, a score of 1 is given, whereas a non-existent detection 
system would be given a higher score. These three factors are multiplied together to give a 
risk priority number (RPN). The RPN is generated for all risk factors and the factors with the 
highest RPN follows greater priority and are evaluated first. With the calculated RPN, a cut-
off value is often used, whereby each failure mode above this value must be addressed as a 
potential major risk. Whereas failure mode with a RPN below this value are a lower risk and 
do not require immediate action (Sandle, 2012). A more detailed numerical scoring for 
prioritising risks may be completed according to ICH Q9 Guideline “Quality Risk 
Management ICH Q9 Annex I: Methods and Tools” (2006).  
 
When the FMEA is extended by a criticality analysis, the technique is then called FMECA. In 
order for FMECA to be performed, the product or process specification should be 
established. FMECA can identify places where additional preventative actions might be 
appropriate to minimise potential risks (International Conference on Harmonisation, 2006). 
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HACCP is a management system, developed by the food industry. Product or process safety 
can be addressed through the analysis and control of biological, chemical and physical 
hazards from raw material production to manufacturing, distribution and use of the finished 
product. HACCP focuses more on prevention and can be used to reduce the reliance upon 
in-process monitoring or end product testing. HACCP systems are generally useful for 
examining changes, such as advances in equipment design, processing procedures, or 
technological developments. The advantages of the HACCP approach includes a systematic 
overview of the process for the evaluation of each processing step, allows each step to 
examine the possible risks, and allows for the specification of the measures required for 
controlling each risk. Unlike the FMEA, HACCP cannot be used to rank or prioritise risks and 
is also less effective for focusing on an aspect for the process, as the objective of the 
HACCP is to map out an entire process (Sandle, 2012). 
 
QRM does not take precedence over industry‟s obligation to comply with regulatory 
requirements. However, effective QRM facilitates better and more informed decisions, 
provide regulators with greater assurance of a company‟s ability to deal with potential risks 
and potentially affects the extent and level of direct regulatory oversight. In addition, QRM 
may facilitate better use of resources by manufactures and regulators (Rodriguez-Perez, 
2012). 
 
While an effective risk management system is essential in ensuring that a process yields 
products of acceptable quality, these systems are not able to ensure that the process being 
managed is optimal. This requires that the process itself is designed in a way that ensures 
quality products are produced reproducibly. This type of process design can be facilitated 
more effectively using DoE along with a host of analytical and statistical tools that will be 
discussed in the following sections.  
 
2.3.4  Design of Experiments 
 
Optimisation refers to the science of allocating available resources to the best possible 
effect. The development and optimisation of a pharmaceutical product are important 
techniques whereby the cMAs and cPPs are analysed in order to achieve the desired 
product quality (Sharma & Pancholi, 2011).  
 
Formulation of pharmaceutical products was previously performed mainly on the basis of the 
experience of the formulator and often in combination with the univariate method. The 
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traditional method of OFAT is less dependable and more time consuming. The drawback 
with the traditional approach is that to keep the number of experiments on an adequate level, 
only a few variables can be used at the cost of omitting valuable information. It is challenging 
to evolve an ideal formulation using this classical technique since the combined effects of 
the independent variables are not considered (El-Say et al., 2011; Mahdavi et al., 2013; 
Wahid et al., 2013).  
 
DoE is a structured and organised method to determine the relationship among factors that 
influence the response variables. The applications of DoE are often sequential in nature. A 
well designed DoE provides valuable information and can result in identification of cause and 
effect relationship between variables, therefore, these systematic techniques are preferable. 
In today's competitive market, DoE in product development and optimisation are becoming 
increasingly necessary because they are quick and cost-effective (Ahmed et al., 2014). 
Analysis of data from designed experiments enables formulation scientists to create a 
mathematical model and contour plots that represent the cMAs and cPPs affecting the 
product cQAs (Myers & Montgomery, 1995; Sharma et al., 2011; Wahid et al., 2013).  
 
The overall approach towards process characterisation involves three key steps 
(International Conference on Harmonisation, 2006; Myers et al., 1995; Yu, 2008). 
 
1. Phase zero: Screening experiments 
2. Phase one: Pivotal trial experiments  
3. Phase two: Identifying the optimal setting of the selected input variables  
 
Attention to the experimental design is important as the validity of an experiment is affected 
by its construction and execution. An experimental design involves selecting the combination 
of factors (input variables) and the levels of each factor to be tested. The formulation 
scientist may choose a number of experimental designs such as a full factorial, fractional 
factorial, orthogonal composite or central composite design to name a few (Myers et al., 
1995). 
 
Factorial designs are widely used in experiments involving several factors on the response 
variables. A special case of the factorial design where each factor of the k factors of interest 
has only 2 levels are named 2k factorial designs. These are often used to fit a first order 
response surface model and are basic building blocks used to create other response surface 
designs. However, two level factorial designs are inherently constrained to identify a first 
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order linear model between factors and the response variable; and it will be inadequate to 
fully characterise data if the relationship between the response variable and one or more 
factors is non-linear (Ledolter & Swersey, 2007; Myers et al., 1995; Reddy, 2011). 
 
As the number of factors in a 2k factorial design increases, the number of runs required 
increases exponentially. Attempting to study all the possible contributing factors becomes 
unfeasible because as the number of factors in a 2k factorial design increases the number of 
experimental runs required increases. As a result, this may exceed the resources of most 
experimenters. Fractional factorial designs may be used in these circumstances to depict 
value information from fewer runs and is among the most widely used experimental designs 
in industrial organisations. A major use of fractional factorials is in screening experiments 
(Dashtianeh et al., 2013; Myers et al., 1995). 
 
Screening experiments are designed to investigate the factors with the intention of reducing 
the list of candidate factors to a significant few so that the subsequent experiments will be 
more efficient. Screening adds value in developing a design with a minimal number of 
experiments yet capturing the target formulation and processing conditions. The pivotal 
experiments determine if the levels of the significant factors from the screening experiments 
will produce a response that is near the optimum or in a region that is in close proximity to 
the optimum. Phase two of DoE begins with designing a model that will accurately 
approximate the true response function. The predictive model may be analysed to determine 
the optimum settings (Myers et al., 1995). 
 
Response surface methodology (RSM) is an efficient mathematical approach that is widely 
applied in product optimisation. RSM explores the relationship between several input 
variables and one or more response variables. A central composite design (CCD) is an 
experimental design useful in RSM in which a multi-level factorial design, augmented with 
axial points and central points allows estimation of polynomial effects and permits the design 
to be rotatable. A Box-Behnken design (BBD) is an efficient option to CCD. The BBD is a 
proficient 3-level design for second order responses and is comparable in a number of 
design points to the CCD, when there is three or four input variables (k=3, k=4). There are 
however, no BBD when the experimental plan involves two input variables (k=2) (Myers et 
al., 1995). The use of RSM in the pharmaceutical industry aids in mapping the response 
surface over a particular region of interest, thus predicting, in advance, the changes in 
response that will result if there are any adjustments to the input variable. When the 
mathematical relationship between the factors and the response needs to be fully 
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characterised, these multi-level designs are more appropriate, as they are flexible and can 
take a wider variety of functional forms (Dashtianeh et al., 2013; Myers et al., 1995). 
Full factorial designs and CCD models perform equally well and both experimental designs 
lead to the same conclusions regarding the optimum setting of the selected input variables. 
However, the CCD tends to be more conservative than the factorial design. Theoretical 
consideration and the fact that the CCD requires fewer experimental units, the range of 
experimental data is wide enough to detect a statistically significant variation; thus justifying 
the recommended use of CCD. In general, all required information should be obtained from 
as few experiments as possible while not compromising the desired goals (El-Say et al., 
2011; Myers et al., 1995; Panneton et al., 1999). 
 
There has been a significant increase amongst industrial organisations in the United States 
of America and in Europe using DoE in quality improvement. Many industries like the 
automotive, biotechnology, pharmaceutical, medical devices and chemical industries where 
design methodology has been implemented, has shown an improvement in their ease of 
manufacture, higher reliability and enhanced field performance (Ahmed et al., 2014; 
Dashtianeh et al., 2013). Although the concepts of QbD, RSM and QRM are not new 
concepts to quality improvement, however the culmination of these concepts is unique to the 
QbD paradigm in the pharmaceutical industry as adopted by the FDA. Figure 2.2 illustrates 
the juxtapose relationship between quality risk assessment and DoE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
 
Risk Assessment 
Ranking/Prioritising risks 
Create experimental plan 
Screening DoE 
Response surface DoE 
Design Space 
Control Strategy 
Design of Experiments 
Brainstorm risks, focus on 
higher risks 
Craft experiments needed to 
understand effect of higher 
risks 
Reduce risk uncertainty 
(confirm medium/high risks) 
Achieve process 
understanding 
Integrate knowledge, 
establish boundaries for 
process 
Identify critical control points 
and apply appropriate 
monitoring and control systems 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.4.1 Creating a design space  
 
A combination of proven acceptable ranges does not constitute a design space. However, a 
proven acceptable range based on univariate experimentation provides useful information 
about the process and is useful during the initial risk assessment (International Conference 
on Harmonisation, 2009a). The risk assessment and DoE leads to an understanding of the 
linkage and effects of cPPs and cMAs on product cQAs. The QbD approach has encouraged 
formulation scientist to reach the desired state of drug manufacturing. The emphasis has 
changed from the need to demonstrate that the products will consistently meet tight 
specifications to a new situation of being able to demonstrate that the product quality is 
controlled within a broader design space (International Conference on Harmonisation, 
2009a; Karanokov et al., 2011). 
 
Figure 2.2  Representation of the relationship between risk assessment and 
DoE (Adapted: McCurdy, 2011) 
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A design space is a multidimensional combination and interaction of material attributes and 
process parameters that have proven to provide quality assurance. The ranges of the cMAs 
and cPPs and their impact on the response outcome defines the design space. In addition, a 
design space can be described through mathematical relationships i.e. prediction algorithm, 
which is a mathematical representation of the design space. Regardless of how a design 
space is established, it spans the entire process, providing more operational flexibility. The 
result is that production processes are adaptable and scale up of pharmaceutical batches 
should be straightforward (International Conference on Harmonisation, 2009a; Karanokov et 
al., 2011). However, design space may be potentially scale and equipment dependent as the 
design space determined at small scale may not be relevant to the process at commercial 
scale. It may be necessary to provide additional information to demonstrate that the design 
space is scale independent, if possible in terms of dimensionless numbers (Kayrak-Talay et 
al., 2013; Mukharya et al., 2012; Travedi, 2012). 
 
The design space is subjected to regulatory approval once the design space has been 
established. Movement within the design space is not considered a change (from a 
regulatory filing perspective). In certain instances, the parameters that positioned at the 
perimeter of the design space are termed the edge of failure. It can be helpful to determine 
the edge of failure for cPPs and cMAs, beyond which the relevant quality attributes, cannot 
be met. Movement outside the design space is the proposed area for cMAs and cPPs not 
meeting identified product cQAs and would generally require a regulatory change post 
approval. Changes made in the formulation and manufacturing process during development 
and life-cycle management should be considered as opportunities to gain additional 
knowledge and further support the establishment of the design space (Dashtianeh et al., 
2013; International Conference on Harmonisation, 2009a; Kharad et al., 2011; Roy, 2012). 
 
2.3.4.2 Control Strategy 
 
It is essential to determine the edge of failure. In these situations, it is necessary to set 
boundaries at acceptable tolerance intervals around the edges of failure to better mitigate 
the risks near such edges. The control strategy is a planned set of controls that assures that 
the manufacturing process will remain in control within the normal variation in material 
attributes and process operating ranges (International Conference on Harmonisation, 2009a; 
McCurdy, 2011). Using risk assessment in creating the control strategy is unique to the QbD 
paradigm. The control strategy justifies that the culmination of in-process controls, input 
material specifications, container closure systems and post-production product testing will 
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produce a quality drug product. The investigation of QRM and DoE collates an appropriate 
control strategy (Avellant, 2008; McCurdy, 2011; Roy, 2012; Yu, 2008).  
 
2.3.4.3 Life-cycle Management  
 
Although QbD may seem like a predominantly statistical-focused approach, this concept is 
much broader (Fraser et al., 2012). QbD is a product and process life-cycle approach 
founded on continuous improvement as illustrated in Figure 2.3. 
 
 
Figure 2.3  Illustration demonstrating the continuous improvement of product and 
process performance using QbD and Product Life-cycle Management 
(Source: Fraser & Kerboul, 2012)  
 
QbD is a cycle in which product and process design and performance create a close loop of 
knowledge and continuous improvement. Even in a vast complex pharmaceutical 
environment, product life-cycle management (PLM) makes production more efficient. The 
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PLM platform brings together all relevant elements and delivers a structured process by 
which all disciplines can work together to proactively improve product quality. The ability to 
build knowledge, from every aspect of the process contributes to the success of PLM. Using 
structured approaches reduces product and process variation, reduces risks and allows 
flexibility for continuous improvement within a design space. In the pharmaceutical industry, 
this reduces regulatory oversight ensuring that the natural outcome of QbD and PLM are 
safe and efficacious products (Fraser et al., 2012; International Conference on 
Harmonisation, 2009a, 2009b). 
 
The ICH Q10 guideline of pharmaceutical quality system, provides tools to facilitate continual 
improvement of drug products such as change management systems, corrective action and 
preventative action (CAPA) systems, quality monitoring systems, and management review 
systems (International Conference on Harmonisation, 2009b). PLM has proven to be an 
effective tool, not only in the pharmaceutical industry, but also in industries with human 
safety issues, aerospace regulations and the automotive industry. Companies implementing 
PLM are reaping the benefits of fewer problems, lower cost, higher yields, employees 
equipped to make worthy decisions and are more confident during the audit process (Fraser 
et al., 2012; Nasr, 2011). Continuous improvement is an essential element in a modern 
quality system with an aim to improve efficacy by optimising a process and reducing waste in 
production. Executing these methods in a structured manner focuses on reducing variability 
in processes and product quality characteristics. Therefore, the fundamental design of a 
manufacturing process does not change. The pharmaceutical manufacturing for the 21st 
century provides a systems review of the current system and describes the desired state and 
explains how the combined work products of the cGMP initiative are positioned to provide a 
comprehensive set of regulatory tools to facilitate the journey to the desired state i.e. the 
design space (Food and Drug Administration, 2004).  
 
2.3  Tablet Manufacturing Process 
 
The most convenient method and preferred method of drug administration for the vast 
majority of patients is via the oral route. The ease of delivery, combined with a relatively 
rapid onset of action, along with lower cost per dose, makes this route an ideal way of 
augmenting the therapeutic effects. Amongst the oral dosage forms, tablets are the most 
widely used due to its convenience in terms of compactness and self-administration by 
patients (Pathak et al., 2011). 
 
 26 
 
The purpose of tablet design is to create a drug delivery system that meets specific 
functional and performance criteria. However, tablet design is not always simple and 
straightforward. The optimum performance of the tablet depends on a number of criteria that 
often have competing objectives, which results in complex and significant interaction effects 
that cannot be easily predicted or managed (Al-Achi et al., 2013; Pathak et al., 2011). For 
example, the hardness influences the compaction of substances inside the tablets; the 
higher the hardness, the higher the compaction of the tablets. The higher compaction may 
cause a decrease in the porosity of the tablet matrix. Hence, the tablets with high 
compaction have a high ability to retard the water penetration into the core, resulting in a 
slower drug release, and vice versa (Nanjwade et al., 2010; Saeio et al., 2007). Therefore 
tablets must have an acceptable degree of hardness and friability to prevent breakage prior 
to use, in addition the tablets should disintegrate in the required time period and the API 
should be released in order to exhibit its therapeutic effect.  
 
Commonly, tablets are formed by powder compression. An applicable method of improving 
the powder flow is granulation (Alderborn, 2013). Wet granulation is a common unit 
operation in the pharmaceutical industry, a complex process with many parameters which 
may affect product quality (Kayrak-Talay et al., 2013). Wet granulation is a process in which 
fine particles are bound together by forming agglomerates by agitation of the powder by 
convection in the presence of a liquid, followed by drying. High shear mixers are often 
equipped with an impeller turning at moderate to high speeds which facilitates the contact 
between the mass of the fine particles and the binder mass and an additional smaller 
chopper blade turning at high speeds cutting down large agglomerates that can form in the 
process. Wetted powder particles are mixed, densified and agglomerated under the action of 
shear and compaction forces imposed by the impeller (Chitu et al., 2011b; Kayrak-Talay et 
al., 2013). 
 
Granulation improves mixing homogeneity, improves tablet compression by adding a 
solution binder, increases bulk density, improves the flow characteristics of formulations 
consisting of cohesive powders, reduces dust problems and reduces segregation. Wet 
granulation is an effective means in terms of production time and cost to produce granules of 
an acceptable quality. Of the various equipment used for wet granulation, high shear mixer 
granulators and fluidised bed granulators are most common (Alderborn, 2013; Kayrak-Talay 
et al., 2013).  
 
The function and characteristics of excipients are critical to tablet formulation, as this may 
affect the product proficiency. Any incompatibilities with the excipients may hinder the 
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excipients to perform their specific function; therefore information on excipient performance 
can be used to justify the use of those excipients. The successful formulation of a stable and 
effective solid dosage form depends on the careful selection of excipients (Rus et al., 2012). 
The goal of product design is to gain timely regulatory approval that meets the needs of 
patients, health care providers and manufacturing industries. In order to meet and sustain 
this goal, product design must incorporate the most current regulatory science thinking which 
is often provided in the FDA and ICH guidance documents. Therefore, product design 
embraces the QbD initiative (Al-Achi et al., 2013).  
 
In order for effective formulation and product design to take place, not only should a 
thorough knowledge of the manufacturing process be obtained but also the API. A review of 
ethionamide, the model drug, with reference to its pharmacological and physicochemical 
properties will be discussed and forms part of understanding the product as a whole. 
 
2.4   Review of ethionamide 
2.4.1  Pharmacological profile of ethionamide  
2.4.1.1 Mechanism of action 
 
Ethionamide is a prodrug that needs to be activated by mycobacterial enzymes to exert its 
antimycobacterial effect. The gene responsible for this activation step is EthA, which 
encodes a NADPH-specific FAD-containing monooxygenase that oxidises ethionamide to 
form an s-oxide metabolite (ETA-SO, in Figure 2.4). The oxidised form adducts with NAD+ 
which binds and inhibits the enzyme, InhA, which is an NADH-dependent enoyl-acyl carrier 
protein reductase of the fatty acid biosynthesis II system required for mycolic acid synthesis 
which is involved in the cell wall synthesis of Mycobacterium tuberculosis. Inhibition of InhA 
leads to cell wall defects that rapidly kill Mycobacterium tuberculosis, as shown in Figure 2.5 
(Brossier et al., 2010; Frenois et al., 2004; Gray, 2013; Vale et al., 2012; Wolff & Nguyen, 
2012).  
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Figure 2.4  Chemical structure of ethionamide (left) and its s-oxide metabolite 
(right) (Source: Vale et al., 2012) 
 
 
2.4.1.2 Side Effects 
 
The most common side effects include, gastrointestinal (GI) effects, nervous system effects 
and hepatic effects. The poor GI tolerance causes nausea, vomiting, diarrhoea, abdominal 
pain, metallic taste and excessive salavation. Side effects of the central nervous system 
Figure 2.5  Graphical illustration of the mechanism of action of ethionamide 
(Source: Gray et al., 2013) 
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include psychotic disturbances, mental depression, restlessness, drowsiness and dizziness. 
Ethionamide is hepatotoxic and is generally reversible on discontinuation of treatment. The 
rare side effects include hypoglycaemia, gynecomastia, alopecia, impotence, menorrhagia 
and hypersensitivity reactions including rash and photosensitivity (Antituberculosis Agents, 
2001; Deck & Winston, 2012; Dipiro et al., 2011; Gibbon, 2013; Sweetman, 2011). 
 
2.4.1.3 Pharmacokinetics 
 
An estimated 80% of an oral dose of ethionamide is absorbed from the GI tract and its 
absorption is unaffected by food. It is also widely distributed into bodily tissues and fluids, 
reaching concentrations in the cerebrospinal fluid equal to those in the plasma with 30% of 
the drug bound to plasma proteins. Ethionamide is extensively metabolised in the liver to the 
active and inactive metabolites, with 1.0% unchanged drug eliminated renally. Plasma Tmax 
is reached at 2 hours with a Cmax of 2 µg/ml. The plasma half-life (t½) of ethionamide is 2 to 
3 hours (Antituberculosis Agents, 2001; Gibbon, 2013; Thee et al., 2011).  
 
2.4.2   Physicochemical properties of ethionamide 
 
The chemical names for ethionamide include, 2-ethylpyridine-4-carbothioamide; 2-ethyl-4-
thiopyridylamide; ethionamide; 2-ethylisonicotine thioamide; 2-ethyl-thioisonicotinamide; 2-
ethylisonicotinthioamide; 2-ethylthioisonicotinamide (Pubmed Compound Database, 2014). 
 
Ethionamide contains not less than 98.5% and not more than the equivalent of 101.0% of 2-
ethylpyridine-4-carbothioamide, calculated with reference to the dried substance (British 
Pharmacopoeia Commision, 2014). 
 
Ethionamide is composed of small yellow crystals or a yellow crystalline powder (Ph. 
Eur.6.8) that has a slight sulphide-like odour. Ethionamide is soluble in methyl alcohol; 
sparingly soluble in alcohol; practically insoluble in water and is achiral and non-hygroscopic 
(Sweetman, 2011; World Health Organisation, 2005). It has a partition coefficient 
(octanol/water) Log P value of 0.3966 and a dissociation constant (pyridyl nitrogen) pKa 
value of 4.49 (Pubmed Compound Database, 2014). The chemical structure of ethionamide 
is shown in Figure 2.6 below. 
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Figure 2.6  Chemical structure of ethionamide [2-ethylpyridine-4-carbothioamide] 
(Source: Sweetman, 2011) 
 
The molecular weight and chemical formula of ethionamide is C8H10N2S = 166.24 g/mol 
(Sweetman, 2011). Ethionamide has a melting point of ~ 163 °C ("Ethionamide," 2008) and 
the pH of a 1% slurry in water is between pH 6.0 to 7.0 (Sweetman, 2011). Based on the 
revised WHO criteria for Biopharmaceutics Classification System (BCS), ethionamide is 
classified as a Class III drug (high solubility, low permeability) (World Health Organisation, 
2005).  
 
2.4.4  Marketed products 
 
The international markets of oral formulations containing 250 mg ethionamide are listed in 
Table 2.4. To date, there is only one formulation available in South Africa.  
 
Table 2.4  International commercially available ethionamide 250 mg tablets  
Brand names Pharmaceutical manufacturers Country 
Ethatyl Sanofi-Aventis South Africa 
Ethide Lupin India 
Ethiokox 
 
 
Radicura India 
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Brand names Pharmaceutical manufacturers Country 
Ethionamide Medopharm Medopharm Thailand 
Ethomid 
 
 
Vesalius Pharma Colombia 
Etionamida AC Farma Peru 
Etomid Macleods Georgia 
Eton Umeda Thailand 
Etyomid 
 
Koçak Turkey 
Myobid Panacea India 
Trecator Wyeth 
 
United States of America 
Tubermin 
 
Meiji Seika Kaisha 
 
Japan 
 
 
2.4.5   Challenges to previous formulations 
 
In 2005, Wyeth pharmaceuticals in the United States released notification that Trecator – SC 
sugar coated tablets have been reformulated to a film coated tablet and renamed to 
Trecator. The new formulation was designed to improve dissolution and stability (Tucker, 
2005). To compare the bioavailability of film-coated and sugar-coated formulations of 
ethionamide, 40 healthy individuals were assigned to receive either of the formulations, in 
randomised order. Seven subjects reported a total of 10 adverse events (5 with each 
formulation), all of which were mild and considered possibly related to drug treatment. None 
of the events resulted in discontinuation from the study. Comparing the area under the curve 
(AUC) values, the formulations were bioequivalent. The mean standard deviation (SD) 
pharmacokinetic properties observed with the film- and sugar-coated tablets, respectively, 
where Cmax was 2160 (614) and 1484 (636) ng/ml and Tmax was 1.0 (0.5) and 1.5 (0.9) hours 
(Korth-Bradley et al., 2014). 
 
The implication of these differences in pharmacokinetics may potentially lead to patient 
intolerance when the film coated formulation is introduced at the same initial dose as the 
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sugar coated formulation. It was advisable that health care professionals monitor patients 
and have their dosages re-titrated when switching to the film coated formulation (Tucker, 
2005).  
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CHAPTER 3 – METHODOLOGY 
 
3.1 Introduction 
 
Tablets are a common and widely used pharmaceutical dosage form in which the drug 
substance is in its prescribed amount, so it is more stable, compact and easier to administer. 
Patient compliance, high precision dosing and manufacturing efficiency makes tablets the 
dosage form of choice (Harbir, 2012; Nyol et al., 2013; Pathak et al., 2011). The 
manufacturing process should be controlled to ensure tablets are aesthetically appealing 
and have the physical stability to maintain their physical attributes, meet the predetermined 
specifications and yield their therapeutic efficacy.  
 
Designing a product and its manufacturing process to consistently deliver the intended 
performance of the product is the focus of pharmaceutical development. QbD are void of the 
limitations of the traditional approach to pharmaceutical development and optimisation and 
focus on building quality into the product. Previous experience and knowledge provide the 
scientific understanding to support the establishment of the design space, specifications and 
manufacturing controls (International Conference on Harmonisation, 2009a). Final properties 
of tablets depend on the choice of the excipients and the process parameters of both the 
granulation process and tablet equipment. This chapter will discuss the application of QbD to 
the optimisation of ethionamide tablets, its manufacturing process and quality testing.  
 
3.2 Application of quality by design  
 
Institutional knowledge is key to the application of QbD (Roy, 2012). A panel discussion was 
arranged with subject matter experts to discuss the various sectors of the QbD paradigm. 
The panel consisted of at least eight personnel who had pharmaceutical experience in either 
technical support, production or regulatory affairs. The experience of the team of formulation 
scientists ranged from 3 to 40 years in the industry.The team provided insight and expertise 
based on their knowledge and experience in the pharmaceutical industry, about this product 
and other products that may assist with understanding the product. The discussions were 
structured and carried out according to the ICH Q8 and Q9 guidelines and the template 
examples as shown in the FDA document, “Abbreviated New Drug Application (ANDA): 
immediate release dosage forms” (Food and Drug Administration, 2012; International 
Conference on Harmonisation, 2006, 2009a). Meetings were scheduled for 1 to 2 hours and 
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were held at Aspen Pharmacare, Port Elizabeth. The number of meetings required were 
subject to covering all components of the QbD process. The templates were subject to 
alteration to be more specific to the study; such alterations were based on the outcome of 
the discussion and results. The design involved, establishing a QTPP, identifying the product 
cQAs, performing a risk assessment, performing DoE and establishing a control strategy. 
Figure 3.1 illustrates the plan of work for optimising ethionamide tablets and details of each 
step will be discussed in the following sections.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1  A flow diagram illustrating the plan of work for optimising 
ethionamide tablets 
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 3.2.1  Establishing a quality target product profile  
 
The purpose of this exercise was to identify the quality characteristics that ethionamide 
should possess in order to deliver the desired therapeutic effect as assured on the product 
label. The QTPP will present all the relevant medical and scientific information to ensure that 
the desired quality, and thus efficacy and safety of ethionamide tablets are achieved. The 
elements of the QTPP are listed in Figure 3.2 below. 
 
Figure 3.2   Graphical representation of the QTPP for ethionamide 250 mg tablets
   
3.2.2  Identifying the product critical quality attributes  
 
Once the QTPP for ethionamide was defined and translated into the relevant targets, the 
cQA was determined. The identification of a cQA from the QTPP is based on the severity of 
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harm to a patient should the drug product fall outside the acceptable range for that attribute 
(Food and Drug Administration, 2012). The list of potential cQAs are shown in Figure 3.3 
below. Subsequently, the subset of cQAs that have a higher potential to be impacted by the 
input variables will be further investigated. 
  
Figure 3.3  Illustration of the process of identifying the potential cQAs of 
ethionamide 250 mg tablets 
 
3.2.3  Quality risk management  
 
The process of developing a pharmaceutical drug product can be thought of as a funnel, 
whose top represents the many unknowns that are present at the start of the development 
process. As the process continues to move towards the narrow opening of the funnel, the 
number of unknowns are reduced. As a result, the variables that have a significant influence 
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on the response variables are identified (Al-Achi et al., 2013). QRM forms the foundation of 
this process. Risk identification and risk analyses are the two basic components of risk 
assessment as outlined in the ICH Q9 guideline. The goal of these two assessments is to 
obtain the variables posing the highest risk to the cQAs. The output of the risk assessment is 
both a quantitative estimate of the risk and a qualitative description of a range of risk (Al-Achi 
et al., 2013; International Conference on Harmonisation, 2006). 
 
3.2.3.1 Quality Risk Assessment 
 
A qualitative risk assessment was used as part of the first evaluation to determine if the risks 
are significant enough to warrant a more detailed analysis. At minimum, the evaluation 
criteria addressed the probability and severity of the risks as discussed in Section 2.2.3. The 
risk assessment of the API, excipients and manufacturing process were performed to 
evaluate the impact each material attribute and process parameter has on the product cQAs 
(Figure 3.4). Risks were categorised using qualitative descriptors such as „low‟, „medium‟ 
and „high‟, as described in Table 2.2 and Table 2.3 in Chapter 2 above. 
 
Figure 3.4  Illustration of the material attributes and process parameters that may 
influence the product cQA 
 
API 
• Particle size distribution 
• Solubility 
• Impurity 
• Residual solvent 
• Chemical instability 
Excipients 
• Sodium starch glycolate 
quantity 
• Magnesium stearate quantity 
• Microcrystalline cellulose 
quantity 
• Lactose monohydrate quantity 
• Microcrystalline cellulose: 
lactose monohydrate ratio 
• Purified water quantity 
• Povidone binder quantity 
Process 
stages (wet 
granulation) 
• Dry mixing 
• Dosing 
• Wet mixing 
• Wet milling 
• Drying 
• Dry milling 
• Blending 
• Compression 
 
cQAs of ethionamide 250 
mg tablets 
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After the „medium‟ and „high‟ risks were identified, these were further examined using a 
quantitative risk assessment. FMEA was used to prioritise the risk factors that may have the 
greatest potential of not meeting the QTPP. The failure modes were categorised into those 
from the API, excipients and the manufacturing process. The manufacturing process failure 
modes were further categorised by unit operations. Table 3.1 summarises the steps involved 
in creating the FMEA.  
 
Table 3.1  Summary of the steps used in creating the FMEA (Adapted: 
International Conference on Harmonisation Q9 Guideline, 2006) 
Completing the FMEA 
1. List the potential failure modes for each process step 
2. List the effects of the failure mode 
3. Rate the severity of the effect 
4. Identify the causes of the failure mode/effects 
5. Identify the controls in place to detect the failure modes and rank its effectiveness 
6. Multiply the severity, occurrence and detection numbers to determine the RPN 
7. Sort by RPN and identify the most critical issues. The higher the RPN, the higher the potential 
risk 
8. Develop an action plan and assign specific action 
9. Once actions have been completed, severity, occurrence and detection are rescored 
 
The risks were rated on a scale of 1 to 10 for each of the causes i.e. severity (S), probability 
of occurrence (O) and detection (D). Based on this scaling system, a high severity event 
would be given a 10, whereas a low severity event would be given a score of one. With 
probability, if something were quite certain to happen, then a 10 would be given, whereas if 
something were very unlikely to happen, a score of one would be allocated. For detection, if 
there is a good detection system in place, a score of one is given, whereas a non-existent 
detection system would be given 10. A review of the FMEA scoring system is shown in Table 
3.2. These severity, occurrence and detection numbers were multiplied together to give a 
risk priority number (RPN). The RPN was generated for all risk factors and the factors with 
the highest RPN were the main priority and were evaluated. The cMAs and cPPs with a RPN 
> 50 were further examined in the subsequent DoE. 
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Table 3.2  A review of the FMEA scoring system (Adapted: International Conference on Harmonisation Q9 Guideline, 2006)  
Severity 
10 Dangerously high Failure could lead to death or permanent injury to the patient. Severe impact to quality. Product recall  
9 Extremely high Failure could lead to injury to the patient. Failure would create noncompliance with registered specifications. May lead to recall 
8 Very high Failure could lead to adverse reactions for patient. Failure would create noncompliance with GMP regulations. May cause stop in 
production flow 
7 High Failure leads to patient perception of safety issue. Failure renders individual units unusable. Failure causes high degree of customer 
dissatisfaction. May cause significant impact to quality 
6 Moderate Failure causes a high degree of customer dissatisfaction and numerous complaints. Failure unlikely to lead to recall 
5 Low Failure likely to cause isolated customer complaints 
4 Very Low Failure relates to non-dosage form issues and can easily overcome by the patient 
3 Minor Failure could be noticed by the customer but is unlikely to be received as significant to warrant a complaint. Failure to meet specification 
may cause minor impact on quality 
2 Very minor Failure not readily apparent to the patient 
1 None Failure would not be noticeable to the patient. Quality within specification. May result in a deviation  
Occurrence 
10 Very high: failure is almost inevitable More than once occurrence per day or a probability of more than 3 occurrences in 10 units 
9  One occurrence every 3 to 4 days or a probability of 3 occurrences in 10 units 
8 High: repeated failures One occurrence per week or a probability of 5 occurrences in 100 units 
7  One occurrence every month or 1 occurrence in 100 units 
6 Moderate: Occasional failures One occurrence every 3 months or a probability of 3 occurrences in 100 units 
5  One occurrence every 6 months to 1 year or one occurrence in 10000 units 
4  One occurrence per year or 6 occurrences in 100 000 units 
3 Low relatively few failures One occurrence every 1 to 3 years or six occurrences in 10 000 000 units 
2 Occasional failures: Infrequently  One occurrence every 3 to 5 years or 2 occurrences in 1 000 000 000 units 
1 Remote: Failure is unlikely  One occurrence in greater than 5 years or less than 2 occurrences in 1000 000 000 units 
Detection 
10 Absolute uncertainty  The product is not inspected or the defect caused by the failure is not detectable (virtually impossible to detect) 
9 Very remote Product is sampled, inspected and released based on acceptable quality level 
8 Remote Product is accepted based on no defects in a sample. Failure will only be detected at finished product testing 
7 Very low Product is 100% manually inspected in the process 
6 Low Product is 100% manually inspected using go/no-go or other mistake proofing gauges 
5 Moderate  Some statistical process control is used in the process and product is final inspected off-line 
4 Moderately high Statistical process control is used and there is an immediate reaction to out-of-control conditions 
3 High An effective statistical process control is in place with process capabilities greater than 1.33 
2 Very high  All product is 100% automatically inspected 
1 Almost certain  The defect is obvious and there is 100% automatic inspection with regular calibration and preventative maintenance of the inspection 
equipment. Failure will definitely be detected. 
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3.2.4  Experimental design 
 
The focus of the DoE was to identify the significant factors affecting the product cQA, i.e. 
dissolution and to determine the optimal level settings for the manufacturing process. 
Therefore, obtaining a manufacturing process that produces tablets with a low friability, 
acceptable crushing strength, low disintegration time and an acceptable dissolution profile. 
Two experimental designs were developed in order to optimise the formulation and 
manufacturing process of ethionamide tablets. The first screening study was developed in 
order to determine the factors to be used in the optimisation phase. Secondly, the pivotal 
experiments will determine if the levels of the significant factors from the screening 
experiments will produce a response that is in close proximity to the optimum and select the 
optimum settings of the selected variables. Statistical designs and analysis were carried out 
using the software package Minitab® statistical software version 16.0 (Minitab Inc., United 
Kingdom). Experimental runs for the screening trial batches and the pivotal trial batches 
were randomised to avoid any subjective decisions. 
 
In order to evaluate the effect of the high risk factors on the considered responses, Analysis 
of Variance (ANOVA) was applied. ANOVA has the ability to identify main and interaction 
effects of independent factors on the response. ANOVA uses a calculated probability value 
(p-value) to determine if the main effects of the independent variables on the response were 
statistically significant. A p-value less than or equal to 0.05 (p<0.05) is considered significant 
for statistical analysis at a 95% confidence interval (CI). ANOVA does not only help to 
determine the main effects of independent variables on the responses but also evaluates the 
interactions amongst these factors. Occasionally a statistically significant value would 
indicate that the effect of one factor on the response is not statistically significant (p>0.05) 
but may indicate an interaction with another factor where the interaction is significant 
(p<0.05). 
 
3.2.4.1 Screening trial batches 
 
As the number of possible combinations in a complete factorial design increase, the number 
of experimental runs increases; thus it may be necessary to reduce the size of such 
problems in order to undertake practical work in the field. Reduced design refers to any 
design approach that involves experimental manipulations of all the independent variables, 
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but includes fewer experimental conditions than a complete factorial design with the same 
number of variables. Reduced designs are often necessary to make simultaneous 
investigation of multiple independent variables feasible. However, any removal of 
experimental conditions to form a reduced design involves some loss of statistical 
information which may have substantial scientific effects. Generally a design is selected to 
achieve a particular aliasing structure while considering the cost (Louviere et al., 2000). 
 
Fractional factorial designs merit serious consideration because of the economy and its 
versatility. Fractional factorial designs involve selection of a particular subset of the complete 
factorials, so that particular effects of interest can be established as efficiently as possible. 
That is, all fractions require assumptions about non-significance of higher-order effects i.e. 
interactions between two or more attributes (Louviere et al., 2000). 
 
The screening trial batches were completed with the purpose of identifying those factors 
from the risk assessment to have a significant effect. The preliminary screening trial was 
conducted using a 26-3 fractional factorial design. A 26-3 fractional factorial design is a 2-3 = ⅛ 
fraction of the complete factorial. This model contained no interactions because these 
cannot be estimated in a resolution III design. A fractional factorial design minimises 
experimentation during the screening phase of the study as the aim was simply to determine 
which of the high risk factors chosen would impact the product cQA and would then be 
further examined during the optimisation phase (pivotal study). The selected formulation and 
manufacturing input variables selected for the screening trial batches include: API particle 
size, povidone binder quantity, impeller speed during dosing, massing time, impeller speed 
during wet mix and moisture content after drying the wet granule. Two levels for each factor 
were set at either low (-) or high (+) according to results of preliminary investigations, the 
outcome of the panel discussion with the subject matter experts and literature are 
summarised in Table 3.3. The range of each factor is wide enough to detect a significant 
variation but not so wide that the edge of failure is exceeded. Experimental runs for the 
screening trial batches are shown in Table 3.4. 
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Table 3.3  Formulation and process factors and their levels for the screening trial 
batches using a 26-3 fractional factorial design  
Independent variables (factors) 
Levels 
Units Low (-1) High (+1) 
1 API particle size D50 (µm) 95.18 267.00 
2 Povidone binder quantity % m/m 3 5 
3 Impeller speed during 
dosing 
rpm 100 200 
4 Massing time s 120 360 
5 Impeller speed during wet 
mix 
rpm 100 200 
6 Moisture content  % m/m 1 3 
 
Table 3.4 Experimental plan for the screening trial batches using a 26-3 fractional 
factorial design 
Standard 
Order 
Run Order 
(Formulation) 
 
Critical material attributes and process parameters 
API   
particle 
size 
Binder 
quantity  
(povidone) 
Impeller 
speed 
during 
dosing 
Massing 
time 
Impeller 
speed 
during 
wet mix 
Moisture 
content 
Units D50 (µm) % m/m rpm s rpm % m/m 
1 1 267.00 3 100  360 200  3 
5 2 267.00  3  200  360  100  1 
8 3 95.18   5  200  360  200  3  
7 4 267.00  5  200  120  100  3  
6 5 267.00  3  200  120  200  1  
4 6 95.18   5  100  360 100  1  
3 7 267.18 5  100  120  200 1  
2 8 95.18   3  100  120  100 3  
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The data generated by the experiments indicated only the levels used for the risk factors. 
The composition and parameters were computed based on the experimental plan. The 26-3 
fractional factorial design is a resolution III design, subsequently only the main effects of the 
factors were considered. The software was used to determine model fit and was defined as 
a p-value, derived from the ANOVA analysis, of less than 0.05. Pareto ranking analysis was 
used to select the significant factors for further studies and the p-value calculated using an 
F-test was less than 0.05 (Myers et al., 1995). 
 
3.2.4.2 Response surface methodology 
 
Based on the results of the screening trial, three significant factors were identified, which 
included povidone binder quantity, impeller speed during dosing and moisture content. 
Povidone binder can be controlled at the recommended 4% m/m quantity; thus complies with 
pharmaceutical formulation requirements (Rowe et al., 2006). Therefore pivotal trial batches 
focused primarily on process optimisation. The factors selected to be included in the pivotal 
trial batches (optimisation phase) were impeller speed during dosing and moisture content. 
 
In order to optimise the manufacturing process, RSM was employed as the statistical tool for 
design and analysis. RSM, using a central composite rotatable design (CCRD) was selected. 
A graphical representation of the CCRD model is shown in Figure 3.5, illustrating the 
factorial, axial and centre points (Myers et al., 1995, p. 299). 
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An alpha value (α-value) was chosen so that all the points outside the origin are of the same 
distance from the centre, in order to achieve a spherical or rotatable design. The α-value 
was calculated using Equation 3.1, where n = number of factors. 
             [Equation 3.1] 
The α-value of 1.414 was used to define the axial points (Minitab® statistical software). A 
summary of the factors and levels are shown in Table 3.5. 
 
Table 3.5   Factors and their levels for the CCRD 
Factors Units 
Factor Level 
-α -1 0 +1 +α 
Impeller speed 
during dosing  
X1 rpm 89.64 100.00 125.00 150.00 160.36 
Moisture content X2 % m/m 2.40 2.50 2.75 3.00 3.10 
Figure 3.5  Schematic representation of the CCRD model where k=2 (Adapted: 
Myers et al., 1995) 
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Levels of these risk factors were set at either low (-1), centre point (0) and high (+1) for the 
optimisation phase (pivotal trial batches).The experimental plan for the CCRD capitulated 13 
experimental runs, containing four cubes points, five centre points in cube, four axial points 
and zero centre points in axial. A single replicate (unreplicated) was employed for the 
design. As a result, there is no estimate of error. An approach to the analysis of an 
unreplicated factorial design is to assume that certain high order interactions are negligible 
and combine their mean squares to estimate the error. Daniel (1959) in Myers & 
Montgomery (1995) suggests plotting the estimates of the effects on the normal probability 
graph and the effects that are negligible are normally distributed (Myers et al., 1995). Table 
3.6 illustrates the experimental plan for the pivotal trial batches. 
 
Table 3.6   Experimental plan of the CCRD for the pivotal trial batches 
Run Order 
(Formulation) 
Standard 
Order 
Point Type Blocks 
Risk Factors 
Impeller 
speed during 
dosing 
Moisture 
content 
1 10 0 1 125.00 2.75 
2 6 -1 1 160.36 2.75 
3 1 1 1 100.00 2.50 
4 5 -1 1 89.64 2.75 
5 7 -1 1 125.00 2.40 
6 11 0 1 125.00 2.75 
7 4 1 1 150.00 3.00 
8 9 0 1 125.00 2.75 
9 13 0 1 125.00 2.75 
10 12 0 1 125.00 2.75 
11 3 1 1 100.00 3.00 
12 8 -1 1 125.00 3.10 
13 2 1 1 150.00 2.50 
 
ANOVA analysis was used to determine the most appropriate model to fit each response 
and product cQA; and lack of fit and R2 statistics calculated for each model were used to aid 
in choice of the model. Once data was fitted to an appropriate model, a design space was 
created by the overlay of the contour plots and optimisation of the manufacturing process 
was calculated based on the product cQA. Criteria for the product were set such that an 
optimum manufacturing process would be obtained. Criteria for the design are shown in 
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Table 3.7. The optimised manufacturing process was determined using the desirability 
function (D-function) using the response optimiser in Minitab® statistical software. 
 
Table 3.7   Criteria used for the optimisation of factors in the RSM design 
Product cQA Criteria Importance Weight Minimum Maximum 
Dissolution Maximise High 1 90 105 
 
 
3.2.4  Establishing a control strategy 
 
The control strategy in the QbD paradigm is established via the risk assessment that takes 
into account the criticality of the selected input variables. Based on the outcome of the DoE, 
the initial risk assessment would be updated according to the severity of the risk, probability 
of occurrence and the ability to detect these potential risk factors. The planned set of 
controls would ensure that the previously selected risk factors are maintained within the 
design space to ensure product quality is maintained. 
 
3.3  Materials and Methods 
 
3.3.1  Materials 
 
The function and characteristics of excipients are critical to tablet formulation, as this may 
affect the product proficiency. Excipient compatibility is an important part of understanding 
the role of inactive pharmaceutical ingredients (IPI) in the product. These drug-excipient 
studies were performed as part of the pre-formulation studies to confirm the drug-excipient 
interaction and have shown that there were no incompatibilities between the API and the 
proposed excipients.  
 
The following raw materials were utilised in this study: ethionamide (Liaoning Beiqi 
Pharmaceutical Co. Ltd, China); microcrystalline cellulose (Flocel® 101) (Gujurat Microwax, 
India); lactose monohydrate (Pharmatose 200M) (DMV – Fonterra Exc, New Zealand); 
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sodium starch glycolate (Amishi Drugs and Chemicals, India); Povidone K25 (Kollidon K25) 
(BASF SE, Germany); magnesium stearate VEG EP 05 (Faci Asia Pacific PTE Ltd, 
Singapore). All raw materials were kindly donated by Aspen Pharmacare, Port Elizabeth. 
 
3.3.2   Preparation of ethionamide tablets 
 
The proposed method of manufacture is by wet granulation. Wet granulation is the oldest 
and most accustomed method of tablet manufacturing (Agrawal & Naveen, 2011). In wet 
granulation, the addition of a liquid binder is generally adequate to aid in the bonding of the 
raw materials. For each DoE batch, the raw materials were weighed (Mettler Toledo balance 
SR 32001; Switzerland) in accordance with the experimental plan. The DoE batches were 
manufactured at a 10 litre scale using Granulator Rapid Mixer and Wet Granulator (RMG 10 
LTR, India).  
 
Granulating medium was prepared by mixing Povidone K25 and purified water (Heidolph 
Electrical Stirrer; Model Number: 50115; Germany). Ethionamide, lactose monohydrate, 
sodium starch glycolate (SSG) and microcrystalline cellulose (MCC) were dry mixed with the  
impeller speed set at 200 rpm and chopper speed set at 2500 rpm for 240 seconds (Rapid 
Mixer & Wet Granulator; Model Number: RMG 10 LTR; India). The granulating medium was 
added to the bowl over a 90 second period (dosing time) at a chopper speed of 1500 rpm 
and the impeller speed set according to the experimental plan. The granules were wet milled 
through a 6.0 mm screen at 300 rpm (Quadro Co-Mill; Model Number 197; Canada) and 
dried in a 40 °C pre-heated fluid bed dryer (Retsch Fluid Bed Dryer: Model Number TG100; 
Germany) until a specified percentage moisture content (loss on drying) was reached. After 
being dry milled through a 1.5 mm screen, SSG was sieved through a size 40-mesh screen, 
added to the bulk material and blended (IMA Pharma Canguro Turbula Bin; Model Number: 
J50; Italy) for 10 minutes at 11 rpm. The lubricant, magnesium stearate, was screened 
through a size 40-mesh, added to the granules and blended for 5 minutes at 11 rpm. The 
final blend was subsequently compressed into tablets using a Karnavati Mini Press 
(Karnavati Mini Press II; Model Number: UNIK – PC 20 MT; India). Machine parameters 
were kept constant. The tooling used to compress tablets was 11.10 mm round shape, 
shallow concave, embossed and scored punches (Eliza-Tool, India). The manufacturing 
processing is presented graphically in Figure 3.6. 
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3.3.3  Evaluation of granule moisture content 
 
The moisture content after drying the wet granule was measured using a Moisture Analyser 
(Mettler Toledo LJ16, Switzerland). The granule sample (2 g – 5 g) was placed in a heating 
pan, weighed and heated at a temperature of 105 °C and a drying time set to the automatic 
switch-off criterion (2 mg/30 seconds) The percent reduction in the weight due to moisture 
loss i.e. loss on drying (LOD) was determined. 
                      
                           
             
      
[Equation 3.2]   
Loading of raw materials 
into granulator mixer 
Dry mix 
Dosing 
Wet Mix 
Wet Milling 
Drying 
Dry Milling 
Blending 
Compression 
Figure 3.6  A flow diagram illustrating the process involved in the manufacturing 
of ethionamide 250 mg tablets 
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3.3.4  Evaluation of tablets 
 
The quantitative assessments of tablets are important in the design of tablets and to monitor 
the product quality. Evaluating these properties, assures that the tablets do not vary from 
one formulation batch to another; consequently controlling the quality attributes. Tablets 
were evaluated according to the product cQA. For this product, dissolution is the identified 
cQA that have the potential to be impacted by the formulation and process variables. 
Conversely, physical attributes such as tablet friability, hardness, and disintegration time 
were not identified as a potential cQA for ethionamide tablets, these are still considered 
important elements of the QTPP. Tablet friability is closely related to tablet hardness and is 
designed to evaluate the ability of the tablet to withstand abrasion in handling. The 
resistance of tablets to capping or breaking before usage depends on its hardness. 
However, if tablets are too hard, it may not disintegrate in the required time period under test 
conditions. The disintegration test does not offer any guarantee that the resultant particles 
will release the drug substance in solution at the correct rate. These physical attributes will 
be monitored. All the response variables and their specifications are listed in Table 3.8 
below. 
 
Table 3.8  Summary of the specifications for the in-process control tests of each 
response variable 
Response variables (dependent) Specification 
Tablet friability Not more than 1% m/m loss after 4 minutes, 
rotating at 25 rpm 
Disintegration time Not more than 15 minutes (900 seconds) 
Dissolution profile Not less than 80% of active is released per 
dosage unit within 45 minutes 
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3.3.4.1 Dissolution  
 
Although the disintegration time is a useful tool for production control, it does not necessarily 
imply that the drug has dissolved in its entirety. A tablet may have a rapid disintegration time 
yet it may be biologically unavailable. An imperative means for characterising the 
biopharmaceutical quality of a product is to perform in vitro dissolution testing. Therefore, the 
dissolution rate is a more indicative of the availability of the drug than the disintegration test; 
thus is an essential factor in drug absorption (Hanson, 1982). 
 
Dissolution testing is a regular quality control procedure in cGMP. The standard dissolution 
test is a simple and inexpensive indicator of the product‟s physical consistency. Specifying 
dissolution limits ensures batch-to-batch consistency within a specific range. Meeting these 
specifications assures an acceptable in vivo biopharmaceutical performance. If one batch 
differs extensively from others in its dissolution characteristics, or if the dissolution times of 
the production batches show consistent trend upwards or downwards, it serves as a warning 
that either the raw material, formulation or process may not be in control (Hanson, 1982; 
Huang et al., 2011). 
 
Dissolution studies were performed in-house according to validated standard operating 
procedures (SOP) using a United States Pharmacopoeia (USP) I dissolution apparatus 
(Hanson SR II 6-flask Dissolution Test Station; Model Number 64-705-045, United States of 
America), equipped with six vessels. Nine hundred millilitres (ml) of 0.1 M hydrochloric acid 
(HCl), as the dissolution medium was added to each of 6 vessels sited in the water bath at a 
temperature of 37 °C ± 0.5 °C. Baskets were set to rotate at 100 rpm. One tablet was 
transferred to each of the six baskets and at time zero, the baskets were immersed in the 
dissolution medium. Ten ml aliquots were withdrawn at 10, 15, 20, 30 and 45 minute 
intervals from each vessel into separate test tubes. Two ml of the filtered sample was 
transferred into a 50 ml volumetric flask and made up to volume with the 0.1 M HCl. The 
solution was filtered through a 0.45 µm Pall AcrodiscGxF/GHP filter.  
 
The dissolution medium was prepared by transferring 8.5 ml of HCl (32% v/v) (Merck KGaA, 
Germany) into 10 litres of purified water (Riggtek DissoPrep X8, Germany). The standard 
solution was prepared by weighing and transferring approximately 55 mg of ethionamide 
working standard into a 100 ml volumetric flask, adding 60 ml of the dissolution medium and 
sonicating until dissolved (Branson Ultasonic 8510, United States of America). The solution 
was allowed to cool to room temperature and the solution was made to volume with 
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dissolution medium. Two ml of this solution was transferred into a 100 ml volumetric flask 
and made up to volume with the dissolution medium. The solution was filtered through a 
0.45 µm Pall Acrodisc PSF GxF/GHP filter, discarding the first 5 ml of the filtrate. 
 
The dissolution of ethionamide from tablets was measured using a UV-VIS 
Spectrophotometer (UV-Pharmaspec 1700 UV-visible spectrophotometer, Japan). 
Ethionamide concentration of each sample (n=6) at each time interval and the absorbance of 
the standard (five replicates) was spectrophotometrically determined at 274 nm with a 1 cm 
cell and the dissolution medium as the blank. Data acquisition was performed using UV 
Probe® 2.43 software. Microsoft Excel® was used to calculate the percentage drug released 
using Equation 3.3. The parameters used in the formula for the dissolution test are 
summarised in Table 3.9. 
 
                                   
                                         
                                   
  
[Equation 3.3] 
 
Table 3.9   Parameters used in the formula for the dissolution test 
Asam Absorbance of ethionamide in the sample solution 
Astd Average absorbance of ethionamide in the standard solution 
Mass of standard Mass of ethionamide working standard taken to prepare the standard solution 
(55 mg) 
C Potency of the ethionamide working standard, expressed in percentage 
(100.6%) 
Label Claim Amount of ethionamide present in each tablet i.e. dosage unit, expressed in 
mg (250 mg) 
Requirement: Not less than 80% of active is release per dosage unit within 45 minutes 
*Note: The values in the brackets represent the mass weighed, volume of the standard 
solution, volume of the dissolution medium, label claim and the potency of ethionamide. 
 
 
 
 
 52 
 
3.3.4.2  Tablet Hardness  
 
Tablets are manufactured by compressing a powder formulation in a die between rigid 
punches. Following the compression process, the tablets are subjected to bulk handling and 
other post-compaction operations; thus bioavailability behaviour and mechanical integrity 
should be maintained until administration. Tablet compression is an important unit operation 
because the shape, strength and tablet weight are determined. A practical method to ensure 
the strength is the compression test also known as the tablet hardness test (Sinka et al., 
2009). Tablet hardness is an essential evaluation tool during manufacturing as it may 
influence parameters such as disintegration and dissolution properties (Huang et al., 2011). 
 
Ten tablets were randomly selected from each formulation batch and tablet breaking 
strength i.e. hardness, was measured using a hardness tester (Erweka Hardness tester; 
Model Number: TBH 320TD; Germany). The average hardness and mean standard 
deviation (SD) of the 10 tablets from each batch was calculated. In addition to the hardness 
testing, the tablet thickness (including ± SD) was simultaneously calculated.  
 
3.3.4.3  Friability 
 
Friability is a measure of the tablets ability to withstand shock and abrasion without 
crumbling during handling of manufacturing, packing, shipping and consumer use. Twenty 
tablets were randomly taken from each formulation batch. Tablet samples were weighed 
accurately (Mettler Toledo AG204; Switzerland) and placed in a friabilator (PharmaTest 
Friabilator PTF 3; Germany). Tablets were rotated at 25 rpm for 4 minutes, totalling 100 
revolutions. Finally tablets were removed from the friabilator, de-dusted and weighed. The 
weight difference between the initial and final weight was recorded. The loss in tablet weight 
indicates the ability of the tablets to withstand abrasion in handling. The percent friability was 
determined by using Equation 3.4 below. 
 
              
                           
             
       
[Equation 3.4] 
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3.3.4.4 Disintegration time 
 
Active absorption of oral dosage forms depend on adequate releases of the API from the 
product. Disintegration is evaluated to ensure that the API is completely accessible for 
dissolution and absorption from the gastrointestinal tract (Bushra et al., 2008). 
 
Tablet disintegration was tested using Erweka Tablet Disintegration Test Unit (Model 
Number: ZT 304; Germany). Six tablets were randomly selected from each batch (n=6) for 
the disintegration test. One tablet was introduced on each of the cylindrical (glass) tubes. 
Water was used as the disintegration medium at 37 °C ± 0.5 °C, with the apparatus 
suspended so that when it was in the highest position the wire mesh was at least 15 mm 
below the surface of the medium and 25 mm above the bottom of the beaker when 
suspended in the lowest position. The upper open ends of the tubes remained above the 
surface of the water. The time it took for each tablet to disintegrate such that all particles had 
passed through the mesh screen was recorded as the disintegration time and presented in 
seconds. 
 
3.4  Statistical analysis 
 
3.4.1  General descriptive statistics 
 
Replicate measurements were represented as a means ± standard deviation (SD) and 
tabulated using Microsoft Excel® 2013. 
 
3.4.2  Multifactorial analysis 
 
Statistical design and analysis were carried out mainly using the software package Minitab® 
statistical software version 16.0 (Minitab Inc., United Kingdom). The software was used to 
determine model fit regression coefficient (R2), adjusted R2 (R2 adj) and predicted R2 (R2 
pred). Appropriate fit was defined as a p-value of 0.05 or less. The 26-3 fractional factorial 
design is a resolution III design and only the main effects were considered. Main effects for 
the variables chosen were analysed using Pareto ranking analysis where the length of the 
horizontal bar represented the impact of the input variable on the response. ANOVA analysis 
was used to select the significant factors for further studies where the p-value calculated 
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using an F-test was 0.05 or less (where the confidence interval was 95%). For the RSM 
design, ANOVA analysis was used to determine the most appropriate model to fit each 
response and lack of fit were calculated. The lack of fit estimates the error variance 
independently of the model. A significant lack of fit (p>0.05) indicates that the model 
accurately fits the model. Once data was fitted to an appropriate model, optimisation of the 
manufacturing process was calculated within the design space.  
 
3.5  Ethical consideration 
 
Ethical clearance was not required, as the research did not involve any human and/or animal 
subjects. Data gathered for the purpose of the study were focused on optimising a 
pharmaceutical product. 
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CHAPTER 4 – RESULTS AND DISCUSSION 
 
4.1 Introduction  
 
QbD builds quality into pharmaceutical products by identifying characteristics that are critical to 
quality from the patient‟s perspective and translates those characteristics into attributes that the 
product should have (Lionberger et al., 2008; Patel et al., 2013). Establishing the QTPP of 
ethionamide tablets forms a roadmap for the optimisation process and it supports the notion of 
„planning with the end in mind‟ (Roy, 2012; Yu, 2008). Identifying the cQA from the QTPP is 
based on the severity of harm to the patient should the attribute fall outside its acceptable range 
(Food and Drug Administration, 2012). The quality risk assessment tools categorises the critical 
material attributes and process parameters according to the potential risk this may have on the 
cQA. Furthermore, the identified high risk factors are examined in the subsequent DoE study. 
While the risk assessment is essential for identifying the high risk factors, this tool can be 
facilitated more effectively using DoE. 
 
The objective of the DoE study was to identify the significant factors from the risk assessment 
that may influence the product cQA as DoE has proven to be an effective tool in formulation and 
process development. The major advantage of using DoE for product optimisation is that it 
facilitates the screening process which allows a systematic evaluation of a large number of 
variables simultaneously with a limited number of experiments. Once these significant factors are 
identified and evaluated, the final formulation and manufacturing process can be defined by 
optimising the levels of the cMAs and cPPs within a design space. Risk mitigation and the 
implementation of a control strategy will ascertain the quality of the product based on the product 
knowledge. This chapter presents the outcome of applying a systematic approach to optimising 
an immediate release ethionamide 250 mg tablet using QbD. 
 
4.2 Quality Target Product Profile (QTPP) of ethionamide 
 
The purpose of this exercise was to identify the quality characteristics that ethionamide should 
possess in order to deliver the desired therapeutic effect as assured on the product label. Based 
on the clinical, pharmacokinetic and physicochemical characteristics of ethionamide, the QTPP 
was established, thus ensuring that the desired quality would be achieved consequently the 
desired quality of ethionamide 250 mg tablets is achieved. Table 4.1 represents the QTPP of 
ethionamide. 
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Table 4.1   QTPP of ethionamide 250 mg tablets 
QTPP Elements Target Justification 
Dosage form Tablet 
Product is pharmaceutically equivalent and has the same 
dosage form 
Dosage design Uncoated immediate release tablet 
Product is pharmaceutically equivalent and has the same 
dosage design 
Route of administration Oral 
Product is pharmaceutically equivalent and has the same 
route of administration 
Dosage strength 250 mg 
Product is pharmaceutically equivalent and has the same 
dosage strength 
Pharmacokinetics 
Immediate release tablet where plasma Tmax is reached at 2 hours with a 
Cmax of 2µg/ml. t1/2 at 2 to 3 hours. 
Bioequivalence requirement. Needed to ensure rapid onset 
and efficacy. 
Drug product 
quality attributes 
Physical attributes 
Round yellow, shallow concave, bevelled edged tablet with debossing on 
one side and scored 
Tablet identification and to facilitate the splitting of tablet into 
fractions for partial dosage 
Identification 
Targets for product identification are set according to pharmacapoeial 
standards 
Pharmaceutical equivalent requirement: must meet the same 
compendia or other applicable (quality) standards 
Assay 
250.0 mg (237.5 – 262.5 mg) 
95.0 – 105.0% label claim 
Pharmaceutical equivalent requirement: must meet the same 
compendia or other applicable (quality) standards 
Dissolution Not less than 80% of ethionamide is released within 45 minutes (Q = 75%) 
Pharmaceutical equivalent requirement: must meet the same 
compendia or other applicable (quality) standards 
Residual solvents N/A 
Formulation does not contain a solvent based damping 
medium. Purified water is the damping medium selected 
Water content LOD: to be established 
Formulation and manufacturing process should meet the 
acceptable quality standard. The moisture content after drying 
the wet granule needs to be established 
Microbial limits 
 
Total aerobic microbial count (TAMC): Not more than 103 cfu/g 
Total combined yeasts and mould (TYMC):  Not more than 102 cfu/g 
Escherichia coli: Absent 
Pharmaceutical equivalent requirement: must meet the same 
compendia or other applicable (quality) standards 
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QTPP Elements Target Justification 
Drug product 
quality 
attributes 
 
Degradation products (by thin 
layer chromatography) (TLC) 
Any secondary spot in the chromatogram obtained with the 
test solution is not more intense that the spot in the 
chromatogram obtained with test solution (a) (2.0%). 
At most one secondary spot in the chromatogram obtained 
with the test solution can be more intense that the spot in the 
chromatogram obtained with the test solution (b) (0.5%) 
As per in-house method that has been validated 
Uniformity of dosage units (by 
weight variation) 
Stage I 
The acceptance value of the first 10 dosage units is less than 
or equal to L1% 
Stage II 
The final acceptance value of the 30 dosage units is less than 
or equal to L1% and no individual content of any dosage unit 
is less than [1-(0.01) (L2)] M or more than [1 + (0.01) (L2)] M. 
(L1 = 15.0%; L2 = 25.0%; T = 100%) 
Pharmaceutical equivalent requirement: must meet the same 
compendia or other applicable (quality) standards (USP <905>) 
Stability At least 24 month shelf-life at room temperature 
Pharmaceutical equivalent requirement: Equivalent or better than 
shelf-life requirement  
Container closure system 
Container closure system qualified as suitable for this drug 
product 
Need to achieve target shelf life and to ensure tablet integrity until 
tablets are administered 
Administration/Concurrence with labelling Similar food effect as reference product 
Reference product labelling indicates that ethionamide is readily 
absorbed from the GIT and is widely distributed throughout the 
body and tissue fluids. Advised to be taken with food to minimise 
GIT irritation 
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The QTPP of ethionamide tablets is a functional summary of the product attributes to ensure 
that the product is fit for its intended use. The characteristics that make up the QTPP are 
designed into the product. The established QTPP would be a quantitative surrogate for 
aspects of clinical safety and efficacy that can be used to optimise the formulation and 
manufacturing process. The QTPP includes the dosage form, dosage design, dosage 
strength, route of administration and drug product quality attributes, all of which should be 
pharmaceutically equivalent to the reference counterparts. Although factors such as the 
stability, container closure system and administration labelling are important and have been 
identified as part of the QTPP, the focus of the study is optimising the formulation and 
manufacturing process and will not be examined and discussed. The depicted QTPP will lay 
down the basis for determining the cQAs. 
 
4.3 Identification of the critical quality attributes (cQAs) 
 
Once the QTPP for ethionamide was established, defined and translated into the relevant 
targets, the cQAs were identified. All possible process and product variants and their effect 
on safety and efficacy are listed in Table 4.2 below. 
 
Table 4.2 summarises the cQAs of ethionamide tablets and denotes that dissolution is the 
cQA that has the potential to be impacted by the formulation and process variables. 
Dissolution will be evaluated in the subsequent optimisation studies. On the contrary, 
physical attributes such as tablet friability, hardness, and disintegration time are not 
identified as  potential quality attributes for ethionamide tablets, yet these are still considered 
important elements of the QTPP and may still be essential from a business perspective i.e. 
manufacturability. The ability of tablets to resist attrition to ensure the correct amount of drug 
is administered and that the appearance of the tablet does not alter during handling is an 
important property (Alderborn, 2013). Tablet friability is closely related to tablet hardness and 
is designed to evaluate the ability of the tablet to withstand abrasion in handling. The 
resistance of tablets to capping or breaking before usage depends on its hardness. 
However, if tablets are too hard, they may not disintegrate in the required time period under 
test conditions. In addition, the disintegration test does not offer any guarantee that the 
resultant particles will release the drug substance in solution at the correct rate. The 
experimental work will increase the knowledge about these physical attributes and will be 
monitored through cGMP and quality risk management. 
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Table 4.2   Identification of the cQA for ethionamide 250 mg tablets 
Quality 
attributes of 
the drug 
product 
Target 
Is this a 
cQA? 
(No/Yes) 
Justification 
Physical 
Attributes 
Appearance 
Round yellow, shallow 
concave, bevelled edged tablet 
with debossing on one side 
and scored 
No 
Appearance, colour and shape are not directly linked to safety and efficacy. The target is to 
ensure patient acceptability. Therefore appearance is not critical. 
Odour Unpleasant No An unpleasant odour does not directly link to safety and efficacy. 
Size 
Similar to reference 
product/current dossier  
No 
For comparable ease of swallowing as well as patients‟ acceptance and compliance with 
treatment regimens, the target for the tablet dimensions are set similar to the reference 
product. Tablet size is not directly linked to safety and efficacy.  
Score 
configuration 
Scored No 
Dosage for adults is 15 mg/kg/day as a single dose (maximum of 1 g/day) and for children 
under the age of 10 years the dosage is 10 mg/kg/day increased to 15-20 mg/kg/day in two 
divided doses (maximum 1 g/day) (Gibbon, 2013). Tablets are scored for facilitate the 
splitting of the tablets as the dosage may require for half a tablet to be used. The API forms 
50% of mass of the dosage unit; thus the score configuration does not affect safety and 
efficacy. 
Friability 
Proposed: Not more than 1.0% 
m/m after 4 minutes 
No 
Routine test per compendia requirement for tablets. A target of not more than 1.0% m/m 
after 4 minutes of mean weight loss assures a low impact on safety and efficacy. Tablets 
that are no friable at the time of administration minimises customer complaints. 
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Quality attributes 
of the drug 
product 
Target 
Is this a 
cQA? 
(No/Yes) 
Justification 
Physical Attributes 
Disintegration 
Not more than 15 
minutes (900 
seconds) 
No 
Routine test per compendia requirement for tablets. Tablet disintegration testing is used as a quality 
assurance measure and may not predict how well the dosage form will release its active ingredient 
in vivo but will ultimately affect dissolution. Disintegration is a precursor to dissolution and is 
therefore not critical. 
Diameter 
11.18 mm (10.62 
– 11.74 mm) 
No 
Target for tablet dimensions are set similar to the reference product. Tablet diameter to fall outside 
of its acceptable range may not cause harm to patients. Tablet diameter is not critical to safety and 
efficacy.  
Thickness To be established No 
Tablet thickness is not directly related to safety and efficacy. Therefore tablet thickness is not critical 
since related to hardness. Dimensions should be similar to the reference product, however 
thickness needs to be established based on results from research study. 
Hardness To be established No 
Hardness is not critical since related to dissolution. To be established based on results from 
research study. 
Mass 
Proposed: 500 mg 
± 3% 
No 
Tablet mass range set between 485–515 mg tablets (target: 500 mg) Uniformity of mass is a quality 
assurance requirement, but is not directly linked to safety and efficacy. 
Identification Positive for ethionamide No 
Critical for safety and efficacy, but can be controlled by Quality Management Systems (QMS). 
Formulation and process parameters does not impact identity.  
Assay 
Half tablet 50% of label claim No 
Pre-formulation studies have shown that the assay for ethionamide is within the specification (95.0 – 
105% label claim). Therefore assay is not a critical attribute. 
Whole tablet 100% of label claim No 
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Quality attributes 
of the drug 
product 
Target 
Is this a 
cQA? 
(No/Yes) 
Justification 
Uniformity of 
dosage units 
Half tablet 
Conforms to United 
States Pharmacopoeia 
(USP) 
No Tablets are required to meet a weight variation test where the API comprises a major portion of 
the tablet and where control of weight may be presumed to be an adequate control of drug 
content uniformity. However, the weight of the API forms 50% of the tablet mass. Therefore, 
uniformity of dosage units is not critical. 
Whole 
tablet 
No 
Dissolution 
Half tablet 
Conforms to United 
States Pharmacopoeia 
(USP) 
Yes 
Dissolution is a rate-limiting step for drug absorption. Failure to meet the dissolution specification 
can impact bioavailability. Both formulation and process variables affect the dissolution profile. 
This cQA will be investigated throughout formulation and process development. 
Whole 
tablet 
Yes 
Water Content 
Loss on 
Drying 
(LOD) 
Current: N/A (To be 
established) 
No 
Pre-formulation studies suggest that degradation and microbial growth of the drug product is not 
a critical attribute. Moisture content of intermediate bulk material (after drying wet granule) needs 
to be established. 
Degradation products/related 
substances/impurities 
N/A (as per in house 
validated requirements) 
No Can be controlled based on requirements for reference product. 
Residual solvents N/A No N/A 
Microbial Limits 
Meets relevant 
pharmacopoeial criteria 
No 
Pre-formulation studies suggest that microbial limit is not a critical attribute and can be controlled 
by quality management system (QMS). 
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4.4 Quality Risk Assessment 
 
4.4.1 Risk Assessment of Excipients  
 
A risk assessment of the excipients was performed to evaluate the impact that each raw 
material could have on the drug product cQA as discussed in Section 3.2.3. The outcome of 
the risk assessment is shown in Table 4.3. 
 
Table 4.3   Initial risk assessment of the excipients 
Drug Product cQA Drug Substance Attributes Risk Ranking 
Dissolution 
SSG quantity Medium 
Magnesium stearate quantity Medium 
MCC quantity  Medium 
Lactose monohydrate quantity Low 
MCC: lactose monohydrate ratio Medium 
Purified water quantity Medium 
Povidone binder quantity High 
 
Based on the formal risk assessment of the excipients used in the proposed formulation, 
magnesium stearate is a „medium‟ risk factor. Magnesium stearate is used as the lubricant in 
the formulation. Lubricants are important for the tablet ejection take-off steps during tablet 
compression as the lubricant aids in reducing friction between the tablet and the metal 
surfaces of the compression machine. Magnesium stearate can influence tablet dissolution, 
hardness, friability and disintegration. A slow dissolution profile generates a potential risk 
and possible bio-inequivalence to the reference product. Wang et al. (2010) reported that 
studies have shown that lubricants such as magnesium stearate had a more pronounced 
adverse effect on in vitro dissolution of immediate release tablets. This is due to the 
combined effects of their large surface area and hydrophobic behaviour that hinders water 
penetration to affect dissolution. As the amount of magnesium stearate in the formulation 
increases, the amount of magnesium stearate coating the API particle surface area 
increases. The lubricant coating around the API adds an extra hydrophobic layer, which 
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further reduces dissolution rate. Therefore over processing with magnesium stearate 
reduces dissolution rates (Kushner & Moore, 2010; Moore et al., 2010; Shah & Mlodozeniec, 
1977; Wang et al., 2010). 
 
Microcrystalline cellulose (MCC) and its combined ratio with lactose monohydrate (MCC: 
lactose monohydrate) were also identified as being ‟medium‟ risks. The risk is acceptable, 
however further investigation is needed to reduce its risk. The combination of the two 
excipients is used to enhance the requirements of the single component. The ratio of MCC 
to lactose monohydrate may impact dissolution via tablet hardness; however, hardness can 
be controlled during compression. A review by Pifferi and co-workers (1999) suggests that 
when using MCC, low compressibility forces are sufficient to produce compactions that are 
resistant and yet elastic with low friability. Following compaction, the particles deform 
plastically and form hydrogen bonds between adjacent molecules, giving rise to a 
predominantly resistant compaction. Despite this resistance, these compactions disintegrate 
quickly (Pifferia et al., 1999). Lactose, a water soluble excipient act by forming pores within 
the tablet matrix and allowing rapid dissolution and the potential of the quantity of lactose to 
impact the product quality is „low‟. Although lactose is water-soluble, a study by Husen and 
co-workers (2012) demonstrated slower release behaviour compared to MCC. Though MCC 
is insoluble in water, at a higher concentration, it has a faster release rate and a shorter 
dissolution time. Due to its inherent disintegration properties this causes tablet erosion of the 
polymer matrix and faster drug release.  
 
Incorrect quantity of purified water added to the formulation may result in either over- or 
under granulation of the powder. The amount of water used for high shear wet granulation is 
essential as the process is susceptible to over wetting and uncontrollable agglomerate 
growth. This potentially influences granule and final drug product quality. An over granulated 
powder bed hinders powder flow, compression and ejection of tablets, which impacts 
hardness, disintegration and dissolution profiles (Agrawal et al., 2011; Shi et al., 2011). The 
quantity of water is a „medium‟ risk.  
 
Adding a superdisintegrant like SSG to the formulation improves tablet disintegration and 
ultimately the dissolution rate. The incorrect quantity of SSG may lead to a poor dissolution 
profile as a result of a slow disintegration time; and subsequently demonstrate an in-
equivalent bioavailability. The disintegrant is added either intragranularly, extragranularly or 
both. Lang (1982) showed that an equal distribution of superdisintegrant in both intragranular 
and extragranular phases resulted in better dissolution than total incorporation (Rahman et 
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al., 2011). The quantity of SSG is categorised as a „medium‟ risk. In addition, disintegrants 
counteracts the binder function as it opposes the efficacy of the tablet binder and the 
physical forces that act under compression to form the tablet. The stronger the binder the 
more effective the disintegrant agents should be in order for the tablet to release the API 
(Farhana et al., 2013). Povidone binder quantity impacts binder activation and ultimately 
dissolution. Potential effect of failure may hinder compression and the dissolution profile. 
Similarly, Chalmers and Elworthy (1976) has demonstrated that an increased concentration 
of povidone in the binder solution, decreased the rate of tablet dissolution. The quantity of 
povidone binder is a „high‟ risk factor. 
 
4.4.2 Risk Assessment of Manufacturing Process Stages 
 
A risk assessment of the overall manufacturing process was performed to identify the 
processing parameters that may affect tablet dissolution. The initial risk assessment of the 
process stages is shown in Table 4.4. 
 
Table 4.4  Initial risk assessment of the manufacturing process stages 
Drug Product cQA Process Stages Risk Ranking 
Dissolution 
Dry mixing Low  
Dosing High 
Wet mixing High 
Wet milling Low 
Drying Medium 
Dry milling Medium 
Blending High 
Compression High 
 
During binder addition, the granulating medium is poured into the moving powdered mix. The 
expectation is that due to the movement of the powder and the wetting properties of the 
liquid, the binder is distributed on the powered surfaces rendering them sticky enough to 
allow particle-particle coalescence upon mutual collisions. The subsequent process is wet 
 65 
 
massing, where the movement of the particles in the mixer grow and consolidate due to their 
sticky surfaces. Fluid distribution is critical as granules are bound by capillary and viscous 
forces created by liquid bridges between primary particles. When liquid droplets are imbibed 
into the dry mix, granule nuclei are formed which typically have relatively low saturation. As 
granulation proceeds, more nuclei are formed while existing nuclei begin to collide with each 
other leading to growth and consolidation (Michaels et al., 2009; Tardos, 2005). 
 
Granules are created through a combination of mechanical energy, the quantity and addition 
rate of binder and to some extent the concentration of the binder in the solution. Over 
granulating is over processing or over working the powders while the granulation medium is 
added. This occurs when the mixing time exceeds the end point and/or adding too much 
binding solution. An overworked granulation may not flow well, compress or eject properly 
and impact hardness, disintegration and dissolution. The impeller rotational speed affects 
the quality of the mixing between the powder and the granulating medium; the collisions 
between particles; and between the particles and the equipment. Controlling impeller speed 
creates an even distribution of the granulating medium over the powder bed and reduces the 
effect of localised wetting; thus creating a homogenous granulation (Benali et al., 2009). 
Failure to obtain a homogenous granulation may potentially cause over granulation and 
negatively impact tablet dissolution. Therefore, dosing and wet mix are „high‟ risk factors. 
Controlling moisture content, particularly for formulations containing hygroscopic excipients, 
such as povidone, are essential as this potentially affects process performance and 
ultimately batch reproducibility (Shi et al., 2011). An adequate moisture content level is 
required for the binding of granules during compression in the die cavity. Furthermore, tablet 
compression may potentially impact the extent of dissolution. Over drying granules can 
cause capping in compression, marking on tablets, hard granules, poor flow and negatively 
impact the content uniformity. Counter to over drying, under drying granules can cause 
sticking, marking and poor flow. As the moisture content after drying the wet granule i.e. loss 
on drying (LOD) needs to be established, the risk is graded „medium‟. 
 
The milling step controls the final granule size distribution. Particle size reduction is a simple 
means to enhance the dissolution rate of poorly soluble drugs. The percentage fines in the 
granule blend may impact tablet hardness and dissolution. Harun and co-workers (2013) 
investigated the effect of particle size on the dissolution and demonstrated that the particle 
size of the final granules in tablet formulation affected the dissolution. The risk for dry milling 
is categorised as „medium‟. 
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Effective blending is essential to ensure a homogenous mix. Exceeding the mixing time with 
a predetermined quantity of extra glidant and lubricant may potentially result in segregation. 
Over-lubrication due to excessive number of revolutions during the blending stage may 
impact disintegration and ultimately the dissolution of the tablets (Twitchell, 2013). The risk 
for this process stage is therefore classified as „high‟. 
 
Moore and co-workers (2010) reported that several other authors have demonstrated that 
the tablet hardness increases as the lubrication mixing time decreases or as the amount of 
magnesium stearate (lubricant) decreases. In addition, the extent to which the granules are 
over-lubricated can also be quantified by the amount of compression force needed to 
compress a tablet to a particular hardness. The amount of applied force required to produce 
tablets having similar hardness increases as the amount of lubrication time with magnesium 
stearate increases. Thus, increasing tablet hardness may impair dissolution (Huang et al., 
2011). Therefore, the risk is categorised as „high‟. 
 
Dry mix and wet milling are categorised a „low‟ risk factors as the severity and probability of 
these factors impacting the extent of dissolution are „low‟. These factors are controlled within 
the manufacturing process.  
 
4.4.3 Risk Assessment of Active Pharmaceutical Ingredient 
 
A risk assessment of the API was performed to identify the characteristics that may affect 
tablet dissolution. The outcome of the initial risk assessment of the API is shown in Table 
4.5.  
Table 4.5   Initial risk assessment of the API 
Drug Product cQA API attributes Risk Ranking 
Dissolution 
Particle size distribution High 
Solubility High 
Impurity Low 
Residual Solvent Low 
Chemical Instability Low 
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Particle size distribution of the API that potentially has poor flow may negatively impact the 
compression stages. Smaller particles have the tendency to agglomerate as a result of 
increased van der Waals forces and cause non uniform distribution of the API. The 
dissolution rate can differ according to different particle sizes. Particle size can have a 
significant effect on the rate of dissolution as a smaller particle size with a larger surface 
area have shown to improve the dissolution profile (Savjani et al., 2012 ).  
 
Drug solubility, dissolution and gastrointestinal permeability are important parameters that 
control the rate and extent of drug absorption and bioavailability. Water solubility is an 
essential property that has an important role in drug absorption after oral administration. The 
drug solubility is an equilibrium measure, however, the dissolution rate at which the dosage 
form passes into solution is also important when the dissolution time is limited (Khadka et al., 
2014). The solubility of the API may impact dissolution. Ethionamide is practically insoluble 
in water which may potentially cause for failure in that it may result in below therapeutic 
levels. However this is the API characteristic thus the formulation and manufacturing process 
need to mitigate this risk. Weakly basic drugs such as ethionamide would dissolve faster 
when solvent pH is relatively low and tend to have a slower dissolution at higher solvent pH. 
When solvent pH is equal to the drug pKa, this weakly basic drug will exhibit the lowest 
solubility (Song et al., 2004; Vale et al., 2012). Therefore, the API particle size distribution 
(PSD) and the solubility of the API are graded as „high‟ risk factors as these may potentially 
affect the extent of dissolution. 
 
The dissolution is mainly affected by the solubility and its particle size distribution and is 
disparate from chemical stability. The formulation does not contain a solvent based 
granulation medium, instead a granulation medium containing purified water and povidone 
will be used. Impurity levels are controlled in the drug substance specifications ranges and 
are unlikely to affect the extent of dissolution. Product history suggests that the chemical 
stability, residual solvent and chemical instability are „low‟ risk factors. 
 
4.4.4 Failure Mode Effects Analysis 
 
The FMEA method identified the cMAs and cPPS influencing the product cQA that has the 
potential of not meeting the QTPP. It also describes the effects of specific failure modes 
related to the respective formulation and process variables and it anticipates the possible 
causes of failure and the likelihood of failures before it may occur. The modes are prioritised 
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according to the seriousness of their effects, how frequently they occur and how easily they 
can be detected. 
 
Table 4.6 is a partial listing of the cMAs and cPPs considered when doing the FMEA. The 
failure modes are categorised into those from the API, excipients and the manufacturing 
process. The process failure modes were further categorised by unit operations, which 
include dosing, wet mix and drying. The cMAs and cPPs with a RPN > 50 were considered 
as high risk factors and will be further investigated using DoE. These factors include API 
particle size (µm), povidone binder quantity (% m/m), impeller speed during dosing (rpm), 
massing time (s), impeller speed during wet mix (rpm) and moisture content after drying wet 
granule (% m/m). The advantage of using this risk assessment tool, is that it facilitates 
systematically gathering the knowledge within the multidisciplinary team and it allows the 
information on the risks to be captured for future use. This is important for companies in 
which turnover results in the loss of institutional memory. 
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Table 4. 6   FMEA analysis of ethionamide 250 mg tablets depicting RPN of the failure modes 
Attributes Item 
Process 
Step/Input 
Potential 
Failure Mode 
Potential Effect of Failure Severity 
Potential 
Cause for 
Failure 
Occurrence 
Current Risk 
Control 
Detection RPN 
API  
API 
particle 
size 
Dissolution 
Low solubility in 
purified water 
Below therapeutic level 8 
Chemical 
property of API 
8 
Control 
dissolution 
1 64 
Excipients 
Povidone 
binder 
quantity 
Dissolution 
Low binding 
activation, slow 
dissolution 
Compression problem, bio 
inequivalent to reference 
product 
8 
Incorrect 
quantity of 
binder in 
formulation 
5 Quality control 2 80 
M
a
n
u
fa
c
tu
ri
n
g
  
p
ro
c
e
s
s
 
Dosing Dissolution 
Impeller speed 
during dosing 
Over granulation 8 
Equipment 
changes, 
operator training 
7 
Determine 
range for 
impeller speed 
1 56 
Wet mix 
Dissolution 
 
Massing time 
Over granulate and under 
granulate 
9 
Unknown range 
(to be 
established) 
8 Determine 
speed and 
duration of 
impeller 
3 216 
Impeller speed 
Over granulate and under 
granulate 
9 
Unknown range 
(to be 
established) 
8 3 216 
Drying Dissolution 
Moisture content 
of intermediate 
bulk material 
 
Over or under drying may 
cause physical tablet defects 
and poor granule flow. This 
may potentially affect the 
content uniformity and 
uniformity of mass  
8 
Temperature 
and time 
5 
Drying time and 
moisture content 
to be 
established 
3 120 
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4.5 Design of Experiments 
 
4.5.1 Screening trial batches 
 
A screening experimental design identifies the significant factors affecting the product cQA. 
To best use the screening design, a risk analysis was performed and six factors were 
identified as potential high risk factors. These include API particle size, povidone binder 
quantity, impeller speed during dosing, massing time, impeller speed during wet mix and 
moisture content of the intermediate bulk material (after drying the wet granule). The 
screening design used in the study was a 26-3 fractional factorial design. Being a resolution III 
design, the experimental design can estimate the significance of the main effects with high 
efficiency and accuracy, but it cannot separate the main effects from possible interactions 
(Myers et al., 1995). However, as the goal of this design is to simply determine which of the 
factors has a significant effect on the responses such a design was considered to be 
sufficient to achieve this outcome. The effect of the six factors on the responses are 
summarised in Table 4.7 below 
 
4.5.1.1 Effect of factors on the responses 
 
Table 4.7   Screening trial batches: Summary of the tablet characteristics 
Formulation 
Average 
tablet 
hardness 
Friability 
Disintegration 
time 
Average 
tablet 
mass 
Average 
tablet 
thickness 
Extent of 
dissolution 
Units N % m/m s mg mm 
% drug 
release at 
15 minutes 
F-1 
42.80 ± 
5.14 
0.90 156 
498.61 ± 
1.82 
4.89 ± 0.01 100 ± 1.3 
F-2 
34.80 ± 
2.20 
2.70 31 
501.87 ± 
3.76 
5.06 ± 0.02 105 ± 1.5 
F-3 
80.40 ± 
3.75 
0.20 538 
499.97 ± 
2.15 
4.85 ± 0.02 47 ± 11.7 
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Formulation 
Average 
tablet 
hardness 
Friability 
Disintegration 
time 
Average 
tablet 
mass 
Average 
tablet 
thickness 
Extent of 
dissolution 
Units N % m/m s mg mm 
% drug 
release at 
15 minutes 
F-4 
78.40 ± 
6.02 
0.15 524 
488.95 ± 
2.37 
4.80 ± 1.25 41 ± 4.4 
F-5 
29.80 ± 
2.49 
9.61 33 
499.50 ± 
3.32 
5.20 ± 0.03 97 ± 2.8 
F-6 
49.20 ± 
4.78 
1.07 107 
502.36 ± 
2.60 
5.03 ± 0.02 95 ± 1.4 
F-7 
39.50 ± 
6.35 
1.02 352 
488.32 ± 
1.90 
4.83 ± 0.03 102 ± 2.8 
F-8 
58.50 ± 
0.01 
1.16 37 
500.35 ± 
3.84 
5.27 ± 0.02 99 ± 1.9 
 
Table 4.7 summarises the tablet characteristics of the screening trial batches. The effect of 
the selected input variables on each response will be discussed below in section 4.5.1.1.1 to 
4.5.1.2. 
 
4.5.1.1.1 Effect on tablet hardness 
 
The Pareto chart compared the relative magnitude and the statistical significance of the main 
effects influencing tablet hardness. The effects are plotted in decreasing order of the 
absolute value of the effects as shown in Figure 4.1. The initial model F-value of 20.21 
implied that the model is non-significant, where p=0.169. Massing time (s), as a non-
significant term (p=0.951) and a term that showed the least impact on the response was 
removed from the model. Thereafter, the R2 (pred) improved from 47.64% to 86.83%. The 
adjusted model with an F-value of 48.21 indicates the model is significant, implying that 
there is only a 2.00% chance that an F-value this large could occur due to noise (R2 = 
99.18%; p = 0.020). ANOVA analysis (Table 4.8) shows the significant factors influencing 
tablet hardness are moisture content (% m/m) and povidone binder quantity (% m/m).  
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Figure 4.1  Pareto analysis of the adjusted model for the influence of the input 
variables influencing tablet hardness 
 
Table 4.8  Summary of the ANOVA results of the adjusted model for tablet 
hardness 
Term Units F-value p-value Comment 
Model - 48.21 0.020 Significant 
API particle size  D50, µm 5.90 0.136 Non-significant 
Povidone binder quantity  % m/m 78.34 0.013 Significant 
Impeller speed during 
dosing  
rpm 13.12 0.068 Non-significant 
Impeller speed during wet 
mix  
rpm 9.49 0.091 Non-significant 
Moisture content    % m/m 134.19 0.007 Significant 
 
Table 4.7 shows that tablets formulated with a 5% m/m povidone binder quantity and dried to 
a moisture content of 3% m/m had the highest tablet hardness. Tablet hardness for these 
 73 
 
batches i.e. F-4 and F-3 ranged from 78.40 N ± 6.02 to 80.40 N ± 3.75, respectively. On the 
contrary, granulation batches dried to a moisture content of 1% m/m showed lower 
compressibility and tablet hardness. This implies that moisture content after drying the wet 
granule had a prominent effect on tablet hardness. The two-dimensional contour plot Figure 
4.7Figure 4.4 represents the interactive relationship between moisture content and povidone 
binder quantity and their influence on tablet hardness. At higher povidone binder quantities 
and increased moisture content, there was an increase in the average tablet hardness. 
Mangwandi and co-workers (2012) similarly observed that increasing the concentration of 
the binder increases the viscosity of the binder solution. It is expected that the strength of the 
granules would increase as the content of the povidone binder quantity is increased 
(Mangwandi et al., 2012).  
 
Batches F-2, F-5, F-6 and F-7 were dried to a moisture content of 1% m/m and the average 
tablet hardness for these batches were 34 N, 29 N, 49 N and 39 N, respectively. At the lower 
moisture content, tablets were friable. This demonstrates that moisture content is important 
for the mechanical strength of tablets. The moisture content increases the compact strength 
by increasing the tensile strength of the powder bed through a reduction in the density 
variation within the tablet. The reduction in tablet density variation can be accredited to the 
lubrication of the die wall (Nokhodchi, 2005). Garr and Rubinstein (1992) have demonstrated 
that moisture content is an important element for the mechanical strength of tablets. 
Reducing moisture content, increases the die-wall friction which contributes to an increase in 
stress ratio (Garr & Rubinstein, 1992). At an optimum moisture level, the die-wall friction is 
reduced which is due to the reduction in stress ratio. The increase in compact strength may 
be due to the hydrodynamic lubrication effect of moisture, which promotes compaction force 
transmission and formation of hydrogen bonds.  
 
Although batches F-3 and F-4 compressed to an average tablet hardness of 80.40 N ± 3.75 
and 78.40 N ± 6.02, their extent of dissolution at 15 minutes, were 47% and 41%, 
respectively. However, after 45 minutes, the extent of dissolution for these batches was 
above 80%. A higher compression may increase the specific surface and may enhance the 
dissolution. On the other hand, the high compression may also inhibit the wettability of the 
tablet, owing to the formation of a firmer and more effective sealing layer of the lubricant. 
The higher compression may also produce slower dissolution, at least in the initial period, 
because of an increased difficulty of fluid penetration into the compressed tablets 
(Jambhekar, 1997). 
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4.5.1.1.2 Effect on friability 
 
Friability is the measure of the tablets ability to withstand abrasion and shock without 
crumbling during manufacture, packing, shipping and consumer use. This attrition resistance 
method determines the reduction in tablet mass and change in appearance by mimicking the 
kind of forces to which a tablet is subjected to during handling. Another application of the 
friability test is to detect incipient capping, as tablets with no visible defects can cap or 
laminate when stressed by an attrition method (Alderborn, 2013). The specification for tablet 
friability is not more than 1% in mass can be lost during friability testing (after 100 
rotations/drops). When capping occurs during the friability testing, irrespective of the 
percentage loss, the outcome is a non-conforming batch and the possible cause needs to be 
investigated (World Health Organisation, 2013b). 
 
The model F-value of 1.92 showed that the model is non-significant. There is only a 50.20 
chance that an F-value this large could occur due to noise (R2= 92.03%, p=0.502). The 
Pareto and ANOVA analysis shows that none of the selected input variables have a 
significant influence on friability as shown in Figure 4.2 and Table 4.9. The backward 
elimination technique did not show any significant terms in the model.  
 
Figure 4.2  Pareto chart of the standardised effect for the input variables on 
friability 
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Table 4.9 ANOVA analysis of the initial model for the effect of the input variables 
on friability 
Term Units F-value p-value Comment 
Model - 1.92 0.502 Non-significant 
API particle size  D50, µm 1.23 0.468 Non-significant 
Povidone 
binder quantity  
% m/m 3.24 0.323 Non-significant 
Impeller speed 
during dosing  
rpm 1.67 0.419 Non-significant 
Massing time  s 1.13 0.481 Non-significant 
Impeller speed 
during wet mix  
rpm 1.02 0.497 Non-significant 
Moisture 
content  
% m/m 3.26 0.322 Non-significant 
 
Table 4.7 shows friability improved as the average tablet hardness for each formulation 
increased. Although friability was lowest for formulation F-3 and F-4, povidone binder 
quantity was set at 5% m/m and the extent of dissolution at 15 minutes was slower, 
compared to the other batches. The low friability percentage for the formulations correlates 
to the average tablet hardness. Friability results showed that as the moisture content of the 
tablets decreased, the tablets became more friable. At higher povidone binder levels and 
increased moisture contents, the resistance to attrition improved. 
 
4.5.1.1.3 Effect on disintegration time 
 
The breakdown of tablets into smaller particles or granules is the first step for the drug 
substance to be in solution so it may be readily available for absorption. Disintegration tests 
are valuable in accessing the importance of material attributes and process parameters on 
the biopharmaceutical properties of tablets. However, complying with the specifications does 
not guarantee that the dosage unit will have an acceptable release profile and clinical effect 
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(Alderborn, 2013). For an uncoated immediate release tablet formulation, the 
pharmacopoeial limit for disintegration is 15 minutes (World Health Organisation, 2013b). 
 
The initial model F-value of 23.08 indicates that the model is non-significant. There is only a 
15.80% possibility that an F-value this large may occur due to noise. Massing time (s) has 
the smallest possibility of influencing disintegration (p=0.560) and as a non-significant term, 
it was removed from the model. Accordingly, the R2 (pred) increased from 54.11% to 
80.70%. The adjusted model with an F-value of 32.76 indicates the model is significant, 
implying that there is only a 3.00% chance that an F-value this large could occur due to 
noise (R2 = 98.79%, p=0.030). The Pareto chart (Figure 4.3) compared the relative 
magnitude and the statistical significance of the main effects influencing disintegration time 
and ANOVA analysis of the model are summarised in Table 4.10. The significant factors 
influencing disintegration time are povidone binder quantity (% m/m) and moisture content 
(% m/m).  
 
 
 
Figure 4.3  Pareto analysis of the adjusted model for the influence of the input 
variables influencing disintegration time 
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Table 4.10  ANOVA analysis of the adjusted model of tablet disintegration time 
Term Units F-value p-value Comment 
Model - 32.76 0.030 Significant 
API particle size D50, µm 7.56 0.111 Non-significant 
Povidone binder 
quantity 
% m/m 99.73 0.010 Significant 
Impeller speed during 
dosing 
rpm 14.02 0.064 Non-significant 
Impeller speed during 
wet mix 
rpm 9.01 0.095 Non-significant 
Moisture content % m/m 33.45 0.029 Significant 
 
According to the data obtained from the screening trial, all the formulations were well within 
the pharmacopoeial disintegration time limit (Table 4.7). Formulation F-2 had the fastest 
disintegration time of 31 seconds and the lowest average tablet hardness of 34.80 N ± 2.20 
compared to formulation F-3 that had the slowest disintegration time of 538 seconds (i.e. 8 
minutes and 58 seconds) and highest average tablet hardness of 80.40 N ± 3.75. Batches F-
6 and F-7, both contained 5% m/m povidone binder and dried to a 1% m/m moisture level 
and were compressed at 49.20 N ± 4.78  and 39.50 N ± 6.35 respectively. Although, both 
batches disintegrated within the acceptable times, friability test results were above 1% m/m. 
 
Figure 4.4 shows that at a higher moisture content and higher povidone binder quantity, 
disintegration time was longer, tablets had a lower percentage friability and a higher average 
tablet hardness. Binders impart their cohesive qualities to the tablet formulation which 
ensures tablets remain intact after compression as well as improving the free-flowing 
qualities by the formulation of granules of desired hardness (Gaikwad & Kulkarni, 2013). The 
quantity of binder used has considerable influence on the characteristics of the compressed 
tablets. A higher percentage of binder quantity causes an extended disintegration time 
(Rupp, 2006). 
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(a)       (b) 
 
 
 
 
 
                      
(c) 
 
4.5.1.2 Effects on product cQA  
 
The disintegration test simply identifies the time required for the tablet to fragment under test 
conditions. The disintegration test does not offer any guarantee that the resultant particles 
(fragments) will release the drug in solution at the correct rate. The dissolution test describes 
the overall rate of all the processes involved in the release of the product into a bioavailable 
form for its systematic absorption (Alderborn, 2013; Nyol et al., 2013). 
 
The effect on the extent of dissolution for the initial model F-value of 15.60 demonstrates 
that the model is non-significant. There is only a 19.10% possibility that an F-value this large 
may occur due to noise. Impeller speed during wet mix as a non-significant term and as a 
term that had the lowest impact on dissolution (p=0.814) was removed from the analysis. 
Figure 4.4  Contour plots showing the effect of povidone binder quantity and 
moisture content on the selected responses (a) tablet hardness (b) 
friability (c) disintegration time 
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Accordingly, the R2 (pred) increased from 32.34% to 81.56%. The adjusted model with an F-
value of 34.31 indicated that the model is significant, implying that there is only a 2.90% 
chance that an F-value this large could occur due to noise (R2= 98.85%, p=0.029). The 
significant factors were povidone binder quantity (% m/m), moisture content (% m/m) and 
impeller speed during dosing (rpm) relative to other factors influencing the extent of 
dissolution as shown in Figure 4.5 and Table 4.11. 
   
 
 
 
 
 
 
 
Figure 4.5  Pareto analysis of the adjusted model for the influence of the input 
variables influencing the extent of dissolution at 15 minutes 
 80 
 
Table 4.11  ANOVA analysis for the extent of dissolution at 15 minutes for the 
screening trial batches 
Term Units F-value p-value Comment 
Model - 34.31 0.029 Significant 
API particle  size D50, µm 0.46 0.568 Non-significant 
Povidone binder quantity % m/m 61.72 0.016 Significant 
Impeller speed during dosing rpm 51.54 0.019 Significant 
Massing time s 0.29 0.642 Non-significant 
Moisture content % m/m 57.54 0.017 Significant 
 
The dissolution samples were analysed by UV-spectrophotometry as described in Section 
3.3.4.1. The mean cumulative release dissolution profile (n=6) at time intervals 10, 15, 20, 
30 and 45 minutes are shown in Figure 4.6. 
 
 
Figure 4.6  Screening trial batches: A release dissolution profile of ethionamide 
250 mg tablets 
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At time point 15 minutes the extent of dissolution varied from 41% (F-4) to 102% (F-7) for the 
various factor combinations (Table 4.7). Screening trial batches F-3 and F-4 containing 5% 
m/m povidone binder, dosed at an impeller speed of 200 rpm and dried to a moisture content 
of 3% m/m, held the better attrition resistance (<1% m/m after 4 minutes) and tablet 
compressibility. However, at the selected input variable settings, the extent of the dissolution 
at 15 minutes was the slowest compared to the other screening trial batches. Notably, 
tablets compressed at the lower ranges, disintegrated at a faster rate and showed a higher 
% ethionamide release during dissolution testing at the 15 minute time point. At lower 
moisture content, granules were more brittle and tablets were found to be more friable. This 
may be due to an increase in the die wall friction, which contributes to an increase stress 
ratio at lower moisture content levels.  
 
During wet massing, granule coalescence and growth may take place but large granules 
may also undergo breakage until a steady state PSD is achieved. In addition, during wet 
massing granule densification may take place which can affect granule liquid saturation and 
the mechanical properties (Badaway et al., 2012). Woyna-Orlewicz and Jachowics (2011) 
reported that the impeller blade speed affects collisions between granules and at high levels 
of impeller speed during wet mix and massing time, could lead to the manufacture of tablets 
of unacceptable dissolution. However, for this study, impeller speed during wet mix and the 
duration thereof, did not impact the responses. 
 
Additionally, dosing plays an important role in the compression characteristics of the 
granules and on the extent of dissolution. Increasing the impeller speed generally leads to a 
decrease in granule size and an increase in growth rate. At higher impeller speeds better 
distribution of the binder over the powder bed is ensured (Benali et al., 2009; Chitu et al., 
2011a). A powder bed that is cohesive may flow better if its moisture content is increased. 
However, too much moisture may result in capillary bonding between particles and flow may 
be compromised by the increased particle-particle adhesion. In addition, the higher 
compression reduces the extent of dissolution due to the reduction of fluid penetration into 
the compressed tablets. Figure 4.7 (a), (b) and (c) represents a 2-dimentional graphical 
contour plot of the relationship between povidone binder quantity, impeller speed during 
dosing and moisture content, and their influence on the extent on dissolution. 
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(a) (b) 
 
 
    
  
 
 
    
  
      (c) 
  
Screening trial batches have shown that to distend the extent of dissolution while still 
maintaining an acceptable tablet hardness, a friability of less than 1% m/m loss and a 
disintegration time within the acceptable limit, the povidone binder quantity can be 
maintained constant at a recommended 4% m/m (Figure 4.8). Therefore, the RSM will focus 
primarily on the optimisation of the manufacturing process. The factors evaluated in the 
succeeding experimental plan are moisture content after drying (% m/m) and impeller speed 
during dosing (rpm).  
 
 
Figure 4.7  Contour plots showing the effect of povidone binder quantity, moisture 
content and impeller speed during dosing on the extent of dissolution at 
15 minutes 
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Although ethionamide is practically insoluble in water at neutral pH, the dissolution medium 
used during dissolution testing is a 0.1 M HCl medium that facilitates the complete 
dissolution as ethionamide is a weakly basic drug. It was shown that API particle size range 
did not impact dissolution and, therefore, does not pose a high risk of obtaining a low 
therapeutic level. By reason of having a larger quantity of API available with a particle size 
D50, 95.18 µm compared to 267.00 µm and maintaining batch to batch consistency, the low 
level (-1) was selected for the subsequent RSM study. Impeller speed during wet mix and 
duration of the wet mix did not have a significant influence on dissolution, suggesting that at 
these ranges, a homogenous granulation can be obtained. For the RSM, the non-significant 
factors, massing time was set at centre point level, API particle size at low level and impeller 
speed during wet mix at low level. The final tablet composition of ethionamide 250 mg 
tablets is summarised in Table 4.12. This formulation will be used in the subsequent 
response surface methodology. 
Figure 4.8  Graphical representation of the effects of the quantity of povidone 
binder between the range of 3% m/m to 5% m/m on (a) tablet 
hardness (b) friability (c) disintegration and (d) the extent of 
dissolution at 15 minutes 
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Table 4.12   Formulation composition of ethionamide 250 mg tablets 
Formula ingredient 
 
Quantity per 
unit dose 
Total 
Quantity 
Ethionamide 250.00 mg 1425.00 g 
Microcrystalline cellulose 64.50 mg 367.65 g 
Lactose monohydrate 150.50 mg 857.85 g 
Sodium starch glycolate 5.00 mg 28.50 g 
Povidone 20.00 mg 114.00 g 
Purified water q.s. 350.00 ml 
Sodium starch glycolate 5.00 mg 28.50 g 
Magnesium stearate   5.00 mg 28.50 g 
Total 500.00 mg 2850.00 g 
 
4.5.2  Pivotal trial batches 
 
Once the significant factors affecting the product cQA were identified, it was essential to 
optimise the levels of the selected manufacturing process variables. Optimisation is 
considered as an efficient and economical method to understand the relationship between 
independent and dependent variables (Bushra et al., 2008). Based on the screening trial 
study results, impeller speed during dosing and moisture content after drying the wet granule 
were selected for the optimisation study, using response surface methodology, more 
specifically a CCRD. In this two factor CCRD, 13 experimental runs were generated, 
containing four cube points, five centre points in cube, four axial points and zero centre 
points in the axial. The experimental runs were completed according to the experimental 
plan depicted in Section 3.2.4.2. The level for each factor is neither too close nor too far 
away from each other so that the edge of failure is exceeded. Consequently, this reduces 
the probability to miss the optimum effect. Each experiment represents a different condition 
with a different set of factors. CCRD for the pivotal trial batches were performed to create a 
broader design space. Knowing that the investigated input variables have a significant 
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impact on the product cQA, it is important to set their operational ranges at levels that 
provide a quality product with a robust manufacturing process. In contrast to the screening 
design where the generated model is only sufficient for qualitative determination of the main 
effects, the CCRD allows the generation of a more predictive model.  
 
4.5.2.1 Effect of significant factors on the responses 
 
Table 4.13 summarises the tablet characteristics of the pivotal trial batches. The effect of the 
impeller speed during dosing and the moisture content on the selected responses will be 
discussed below in Section 4.5.2.1.1 to 4.5.2.2. 
 
Table 4.13  Pivotal trial batches: Summary of the tablet characteristics 
Formulation 
Average 
tablet 
hardness 
Friability 
Disintegration 
time 
Average 
tablet 
mass 
Average 
tablet 
thickness 
Extent of 
dissolution 
(at 15 
minutes) 
Units N % m/m s mg mm % 
FT-1 
66.30 ± 
6.77 
0.08 180 
496.63 ± 
4.23 
4.81 ± 0.04 99 ± 2.20 
FT-2 
73.30 ± 
7.01 
0.08 370 
502.41 ± 
3.19 
4.91 ± 0.05 78 ± 15.50 
FT-3 
71.70 ± 
2.83 
0.15 208 
499.01 ± 
4.06 
4.77 ± 0.02 100 ± 1.00 
FT-4 
91.00 ± 
6.53 
0.07 336 
498.43 ± 
4.43 
4.82 ± 0.02 81 ± 14.50 
FT-5 
66.70 ± 
5.50 
0.11 201 
502.34 ± 
2.86 
4.89 ± 0.04 96 ± 1.00 
FT-6 
78.90 ± 
5.95 
0.09 347 
505.90 ± 
3.93 
4.88 ± 0.03 91 ± 2.40 
FT-7 
72.50 ± 
6.02 
0.05 293 
496.90 ± 
2.83 
4.82 ± 0.02 92 ± 1.70 
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Formulation 
Average 
tablet 
hardness 
Friability 
Disintegration 
time 
Average 
tablet 
mass 
Average 
tablet 
thickness 
Extent of 
dissolution 
(at 15 
minutes) 
Units N % m/m s mg mm % 
FT-8 
67.40 ± 
4.67 
0.11 305 
501.72 ± 
2.77 
4.92 ± 0.03 99 ± 1.40 
FT-9 
66.90 ± 
5.13 
0.05 276 
500.98 ± 
2.28 
4.88 ± 0.03 97 ± 0.80 
FT-10 
73.30 ± 
5.66 
0.05 250 
500.23 ± 
2.35 
4.87 ± 0.03 95 ± 2.50 
FT-11 
63.00 ± 
5.89 
0.05 345 
498.00 ± 
3.30 
4.95 ± 0.18 78 ± 11.20 
FT-12 
69.30 ± 
5.40 
0.08 230 
499.50 ± 
2.62 
4.93 ± 0.04 91 ± 10.80 
FT-13 
69.30 ± 
3.56 
0.17 227 
504.47 ± 
1.76 
4.89 ± 0.03 96 ± 1.50 
 
 
4.5.2.1.1 Effect on tablet hardness 
 
The quadratic model was used for the analysis of tablet hardness. ANOVA analysis of the 
model for the response showed that the model (quadratic) chosen for the analysis did not 
have a significant fit relative to the noise with an F-value of 1.21 (p=0.395, R2= 46.29%) and 
a lack of fit test showed that there was a non-significant lack of fit relative to the pure error 
(p=0.212). None of the terms for this model were significant (p>0.05). An Adj R2 of 7.93% 
was obtained, the Pred R2 of -1.745 (0.00%) implies that the overall mean would be a better 
predictor of tablet hardness and a signal to noise ratio of 3.79 indicates that this model will 
not be used to create the design space. ANOVA analysis for the effect on tablet hardness is 
shown in Table 4.14. 
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Table 4.14  ANOVA analysis for linear, interaction and squared effects on tablet 
hardness.  
Source F-value p-value Comment 
Regression 1.21 0.395 Non-significant 
Model Linear 0.43 0.665 Non-significant 
Terms 
Impeller speed 
during dosing 
0.86 0.386 Non-significant 
Moisture content 0.01 0.928 Non-significant 
Model Square 2.21 1.81 Non-significant 
Terms 
Impeller speed 
during dosing * 
Impeller speed 
during dosing 
2.75 0.141 Non-significant 
Moisture content * 
Moisture content 
1.13 0.322 Non-significant 
Model Interaction 0.75 0.414 Non-significant 
Terms 
Impeller speed 
during dosing * 
Moisture content  
0.75 0.414 Non-significant 
Lack of Fit 2.37 0.212 Non-significant 
 
Figure 4.9 represents the contour and surface plot of the effect of impeller speed during 
dosing and moisture content on tablet hardness which represents a saddle graph. Near the 
centre (saddle) of the graph, increasing either input variable (i.e. dosing impeller speed or 
moisture content) while decreasing the other leads to an increase in the average tablet 
hardness. The quadratic equation (Equation 4.1) derived from the model used to makes 
predictions about the response is shown below, where A is the dosing impeller speed during 
dosing and B is moisture content. 
                                                                 
[Equation 4.1] 
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Table 4.13 summarises the tablet characteristics and % drug release for dissolution at 15 
minutes for the pivotal trial batches. All the batches demonstrate an acceptable friability and 
disintegration time. Of the batches, batch FT-4 had the highest residual (8.655) and highest 
standard residual with an absolute value greater than 2 (2.06). This suggests that tablet 
hardness for batch FT-4 does not follow the proposed regression equation well, and may not 
fit well by the response surface model. However the analysis of the model has shown a non-
significant lack of fit for tablet hardness. The minimum and maximum values for the average 
tablet hardness, where the batches had shown a standard residual less than 2 may be used 
to establish a suitable hardness range. A potential range for the average tablet hardness 
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Figure 4.9  Contour plot and surface plot of the effect of impeller speed during 
dosing and moisture content on tablet hardness 
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may be set between 66 N and 78 N and a tablet thickness range between 4.77 mm and 4.95 
mm. 
 
4.5.2.1.2 Effect on friability 
 
The linear model was used for the analysis of friability. ANOVA analysis of the model for the 
response showed that the model (linear) chosen for the analysis has a significant fit relative 
to the noise with an F-value of 4.86 (p=0.034, R2= 49.29%) and a lack of fit test showed that 
there was a non-significant lack of fit relative to the pure error (p=0.379). Of the factors 
analysed, only moisture content (% m/m) was significant with an F-value of 9.59 (p=0.011). 
The Pred R2 of 8.55% is not as close to the Adj R2 of 39.15% as one would expect. The 
signal to noise ratio of 6.45 indicates adequate signal and that this model may be used to 
navigate the design space. 
 
No interaction between the factors were evident, indicating that, while moisture content had 
an effect on friability, there was no significant interaction (p=0.809). Therefore, the effect of 
dosing impeller speed on friability does not depend on moisture content and one factor can 
be changed independent of the other between impeller speed during dosing and moisture 
content. ANOVA analysis for the effect on friability is shown in Table 4.15. 
 
Table 4.15   ANOVA analysis for the linear model on friability 
Source F-value P-value Comment 
Regression 4.86 0.034 Significant 
Model Linear 4.86 0.034 Significant 
Terms 
Impeller speed 
during dosing 
0.13 0.723 Non-significant 
Moisture content 9.59 0.011 Significant 
Lack of Fit 1.43 0.379 Non-significant 
 
Figure 4.10 represents the contour and surface plot of the effect of impeller speed during 
dosing and moisture content on tablet friability, which represents a stationary ridge surface 
graph. This graph suggests that the ranges used for moisture content and impeller speed 
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during dosing will result in a friability of less than 1% m/m, which is acceptable according to 
the pharmacopeia standard. The linear equation (Equation 4.2) derived from the model used 
to makes predictions about the response is shown below, where A is the dosing impeller 
speed during dosing and B is moisture content.  
                                     
         [Equation 4.2] 
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Figure 4.10  Contour plot and surface plot of the effect of impeller speed during 
dosing and moisture content on friability 
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4.5.2.1.3 Effect on disintegration time 
 
The quadratic model was used for the analysis of the disintegration time. ANOVA analysis of 
the model for the response showed that the model (quadratic) chosen for the analysis has a 
non-significant fit relative to the noise with an F-value of 1.91 (p=0.211, R2= 57.72%) and a 
lack of fit test showed that there was a non-significant lack of fit relative to the pure error 
(p=0.766). There are no significant model terms as p>0.05, as shown in Table 4.16. An Adj 
R2 of 27.52% was obtained and the Pred R2 of -0.194 (0.00%) suggests that the overall 
mean may be a better predictor of disintegration time. The range of predicted values at 
design points to the average prediction error of 5.01 was obtained. This model will not be 
used to create the design space.  
 
Table 4.16  ANOVA analysis for the linear, interaction and squared effects on 
disintegration time 
Source F-value p-value Comment 
Regression 1.91 0.211 Non-significant 
Model Linear 1.29 0.334 Non-significant 
Terms 
Impeller speed during 
dosing 
0.01 0.924 Non-significant 
Moisture content 2.57 0.153 Non-significant 
Model Square 3.27 0.099 Non-significant 
Terms 
Impeller speed during 
dosing * Impeller speed 
during dosing 
3.23 0.115 Non-significant 
Moisture content * 
Moisture content 
2.47 0.160 Non-significant 
Model Interaction 0.43 0.531 Non-significant 
Terms 
Impeller speed during 
dosing * Moisture 
content  
0.43 0.531 Non-significant 
Lack of Fit 0.39 0.766 Non-significant 
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Figure 4.11, a contour and surface plot of moisture content and dosing impeller speed during 
dosing and their effect on the disintegration time represents a saddle graph. Near the centre 
(saddle) of the graph, increasing either input variable (i.e. dosing impeller speed or moisture 
content) while decreasing the other leads to an increase in the disintegration time. The 
polynomial equation (Equation 4.3) derived from the model used to makes predictions about 
the response are shown below, where A is the dosing impeller speed during dosing and B is 
moisture content.  
                                                                   
[Equation 4.3] 
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Figure 4.11  Contour and surface plot of the effect of impeller speed during dosing 
and moisture content on disintegration time 
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4.5.2.2 Analysis of product cQA 
 
A quadratic model (polynomial equation) was used to analyse the extent of dissolution. 
ANOVA analysis of the model for the response showed that the model (quadratic) chosen for 
the analysis had significant fit relative to the noise with an F-value of 4.90 (p=0.030) and a 
lack of fit test showed that there was a non-significant lack of fit relative to the pure error 
(p=0.125), indicating that this model may be used to evaluate the design space. Of the 
squared terms for this model, dosing impeller speed has a significant effect with an F-value 
of 14.38 (p=0.006). This implies that there is significant curvature in the response surface. 
Analysis of the main effects for the extent of dissolution showed that only moisture content 
was significant, where p=0.047. No significant interactions where noted between the 
selected factors. ANOVA analysis for dissolution at 15 minutes are summarised in Table 
4.17. 
 
Table 4.17  ANOVA analysis of the for the linear, square and interaction effects on 
the extent of dissolution at 15 minutes 
Source F-value p-value Comment 
Regression 4.90 0.030 Significant 
Model Linear 2.99 0.115 Non-significant 
Terms 
Impeller speed 
during dosing 
0.18 0.688 Non-significant 
Moisture content 5.80 0.047 Significant 
Model Square 7.54 0.018 Significant 
Terms 
Impeller speed 
during dosing * 
Impeller speed 
during dosing 
14.38 0.006 Significant 
Moisture content * 
Moisture content 
0.00 0.958 Non-significant 
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Source F-value p-value Comment 
Model Interaction 3.44 0.106 Non-significant 
Terms 
Impeller speed 
during dosing * 
Moisture content 
3.44 0.106 Non-significant 
Lack-of-Fit 3.58 0.125 Non-significant 
 
The polynomial equation (Equation 4.4) derived from the model used to makes predictions 
about the response is shown below, where A is the dosing impeller speed during dosing and 
B is moisture content.  
                                                         
[Equation 4.4] 
 
The quadratic model was adequate to characterise the data since a non-linear relationship 
exists between impeller speed during dosing and the product cQA. This demonstrates the 
benefit of using a 5-level design as opposed to a 2-level factorial design, where the range of 
experimental data was wide enough to detect the statistically significant variation. As shown 
in Figure 4.12 to maximise the extent of dissolution of the immediate release tablet above 
85% drug release at 15 minutes, impeller speed during dosing should be within the region of 
90 rpm to 150 rpm and a 2.5 % m/m to 2.8% m/m range for the moisture content level. 
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The impeller speed during dosing allowed for efficient distribution of the granulating medium 
over the powered bed, rendering the particle surfaces sticky enough to allow coalescence. 
Badaway and co-workers (2012) reported that at a higher moisture content a higher fraction 
of the void spaces within the granule are filled with liquid, which increases liquid saturation of 
Figure 4.12  Contour and surface plot of the effect of moisture content and impeller 
speed on the extent of dissolution at 15 minutes 
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the granule, thus enhancing granule coalescence. The moisture content may be required for 
the binding of granule during compression in the die cavity. The higher liquid saturation 
makes the granule easily deformable and results in more liquid available to the granule 
surface both of which increases the probability of effective coalescence upon granule 
collision (Badaway et al., 2012). In addition, moisture may act as a lubricant which reduces 
inter-particulate friction within the granule. Hence, facilitating particle movement within the 
granules in response to densifying forces in the high shear granulation (Iveson et al., 2001). 
Similarly Nokhodchi and co-workers (1995) demonstrated that moisture played a significant 
role in the compaction process. This may be due to the water forming a „monomolecular‟ 
layer around the API particles. This tightly bound water can be regarded as part of the 
surface molecular structure of the particles, which facilitates the formation of interparticle 
hydrogen bonding that may increase van der Waals forces, thus smoothing out the surface 
micro irregularities and reducing interparticle separation. In addition, the formation of 
pendular bonds on the particle surfaces would be expected to contribute to compact 
strength. At the impeller speed and moisture content ranges for the pivotal trial batches, 
tablets have shown an acceptable hardness and met the specification for friability and 
disintegration time in addition to having an acceptable dissolution profile which may be the 
consequence of adequate fluid penetration into the compressed tablet during drug release 
analysis. 
 
In general, physical defects such as capping and chipping caused by low moisture levels or 
sticking and picking caused by high moisture levels are typical tablet defects (Rana & Hari-
Kumar, 2013). However, these defects were not evident, and the physical appearances were 
found to be satisfactory. At the ranges for the selected input variables, friability and 
disintegration time were within the specifications. For a drug to be readily available to the 
body it must be in solution and the first fundamental step towards solution is the breakdown 
of a tablet into smaller particles. The limit for an uncoated immediate release tablet to 
disintegrate is 15 minutes (900 seconds). Most batches presented fast disintegration time, 
except batch F-2 that had a disintegration time of 6 minutes 10 seconds and tablets from 
batch F-11 disintegrated at 5 minutes 45 seconds, but were still well within the required limit 
of 15 minutes as shown in Table 4.13. 
 
The results of the disintegration only identified the time required for the tablet to break up 
under test conditions. Thus, it offers no assurance that the resultant particles will release the 
drug in solution at the appropriate rate. The average tablet hardness for all batches was kept 
within the range of 63 N – 91 N throughout experimentation as shown in Table 4.13. The 
dissolution profiles for all formulations are shown in Figure 4.13. The y-axis represents the % 
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ethionamide release, with the x-axis representing the time interval, in minutes. The 15 
minute interval was chosen to study the effects of the selected input variables on dissolution 
profile. All the batches demonstrated an acceptable dissolution profile as the % drug release 
after 15 minutes was above 80%. 
 
 
Figure 4.13  Pivotal trial batches: A release dissolution profile of ethionamide 250 
mg tablets 
 
Key parameters that had been demonstrated to affect ethionamide product cQA were used 
to construct the design space as shown in Figure 4.14. The design space is the acceptable 
region within which the quality of the product can be built (International Conference on 
Harmonisation, 2009a).  
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Figure 4.14   Design space: A contour plot of the interaction between the  
   significant factors on the product cQA 
 
The design space is the multidimensional interaction between impeller speed during dosing 
and moisture content, to determine their influence on the extent of dissolution. The white 
zone represents the area of acceptable quality (design space) and the red-lines represents 
the edge of failure. Movement beyond the edge of failure into the grey zone is the area of 
potential risk where the dissolution is below the acceptable internal control limit. The design 
space makes QbD a reality and the wider the design space the more robust and flexible the 
process is to accommodate the variations (Charoo et al., 2012). A vital step of product 
optimisation is to achieve an appropriate response function for both dependencies and 
independencies within the design space. 
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4.5.3  Process optimisation 
 
4.5.3.1 Optimisation using desirability function 
 
Desirability function was calculated for the extent of dissolution at 15 minutes. The 
composite desirability with the aid of Minitab® 16.0 software was 0.707. The weight and 
importance for the response were allotted 1 and 5, respectively. Figure 4.15 shows the 
response optimisation plot for dissolution where the optimal setting for impeller speed during 
dosing is 115 rpm and moisture content is 2.5% m/m. At these settings, the % drug release 
at 15 minutes is calculated at 100.6%.  
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Figure 4.15   Response optimisation plot for the extent of dissolution at 15 minutes 
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4.5.3.2  Analysis of validation batch 
 
To test the accuracy and robustness of the developed model, the model was validated by 
producing the optimised batch and testing it against the measured responses. The overall 
optimisation plot, Figure 4.15 identified the levels at which the significant factors are 
optimised in order to obtain a maximum dissolution response. This optimum point 
represented a predictive point, thus in order to validate the predictive ability of the 
hypothesised model for the product cQA around the optimised conditions, the agreement 
between predicted and measured responses were verified. Therefore, ethionamide tablets 
were prepared according to the optimised conditions and subjected to the release test. The 
confidence interval for each response at the 95% confidence level was used. The actual 
values for each response are compared to the predicted values and are summarised in 
Table 4.18. The optimised product met all the required specification. The actual % drug 
release for ethionamide is 93.0% ± 1.4 and the predicted value was 100.6%. The actual 
values were within the 95% prediction interval (PI) for each observed response, indicating 
statistical equivalence of the experimental drug release profile and the predicted one. 
 
Table 4.18  Summary of the predicted and measured responses of the 
hypothesised model at the optimised conditions 
Response Units 
Predicted 
mean 
Actual mean 95% PI low 95% PI high 
Dissolution at 
15 minutes 
% 100.6 93.0 ± 1.4 87.56 113.75 
Disintegration 
time 
S 207.00 213.00 61.60 352.00 
Friability % m/m 0.12 0.19 0.05 0.19 
Tablet 
hardness 
N 72.58 69.30 ± 2.83 53.97 91.19 
 
In order to assess the reliability of the model for product cQA, percentage bias was 
calculated. Bias (%) has the ability to access the model performance. The percentage bias 
measures the average tendency of the simulated values to be larger or smaller than the 
observed ones. The optimal value of bias (%) is 0.00, with low magnitude values indicating 
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accurate model simulation. Positive values indicate overestimation bias, whereas negative 
values indicate model underestimation bias (Moriasi et al., 2007 ). In order to assess the 
reliability of the model, the model for the product cQA was evaluated. Bias or percent relative 
error between the experimental value and predicted value was calculated by using Equation 
4.5 below. 
         
                                  
               
     
         [Equation 4.5] 
 
A bias value of 7% indicates that the model generated is over estimated as the expected 
value is greater than zero. This serves to be true as the estimated value was calculated at 
100.6% and the observed response was 93% drug release at 15 minutes. Therefore, the 
predictive equation expresses an overestimation of the influence of the significant factors on 
the extent of dissolution. However, the measured data are within the 95% confidence 
intervals and 95% prediction interval for all the responses including the product cQA. 
Therefore the model equation may be used to describe the real dependencies. 
 
The initial step in DoE is performing a screening trial to identify the significant factors and the 
fractional factorial design reduces the number of runs to a significant few. Reduced designs 
are often necessary to make simultaneous investigations of multiple independent variables 
feasible (Collins et al., 2009). However, one of the downfalls of using fractional factorial 
design (26-3), as the elimination of design points done purely for economic reasons, is that it 
limits the statistical power of the model. Therefore, any removal of experimental conditions to 
form a reduced design may have a significant effect. This may be a potential cause for the 
variance in the % drug release; however the measured data are with the 95% prediction 
interval. 
 
4.6  Risk mitigation and control strategy 
 
The control strategy is defined as a planned set of controls derived from current product and 
process understanding that assures process performance and product quality (International 
Conference on Harmonisation, 2009b). The control of quality of the finished product is 
closely linked to the criticality and therefore to each dimension of the design space. By 
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determining the extent of dissolution as the cQA, the allowed variability of impeller speed 
during dosing and moisture content after drying wet granule is indicated.  
 
The risk mitigation and control strategy is an integrated outline of how quality is built into the 
product. Although the implementation of a control strategy is no new concept in 
pharmaceutical industry, pharmaceutical products always had a more or less unequivocal 
control concept. However, the use of risk assessment in creating a control strategy is unique 
to QbD. Figure 4.16 illustrates the FMEA analysis before and after the implementation of a 
control strategy. 
 
 
Figure 4.16  FMEA analysis of ethionamide tablets depicting RPN of failure modes 
before and after implementation of control strategy 
 
Ethionamide is insoluble in water and its potential effect of failure may result in a below 
therapeutic level. Generally, weakly basic drugs like ethionamide (pKa = 4.49) tend to have 
a slower dissolution rate at higher pH levels as more drug exists in its ionised form (Pandit, 
2007; Troy et al., 2006). A study by Vale and co-workers (2012) showed that the solubility of 
pure ethionamide in an aqueous buffer at pH 1.2 was 4 mg/ml but decreased to 741 µg/ml in 
the pH range of 5.5 – 7.4. This finding concurs with the weakly basic nature of the drug 
substance (Vale et al., 2012). However, its solubility is a physicochemical property of the 
API. Nonetheless, DoE has demonstrated that API particle size distribution with a D50 range 
95.18 to 267.00 µm does not have a significant effect on dissolution in a 0.1 M HCl medium. 
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Therefore, the potential effect and cause of failure is lower. API particle size, D50 may range 
from 95.18 to 267.00 µm and remain within the design specification. The FMEA analysis of 
API particle size after implementing a control strategy is shown in Equation 4.6. 
[ ]    [ ]   [ ]             [Equation 4.6] 
 
The severity [S] that the API may have a potential effect of failure and the likelihood of 
occurrence [O] is reduced as the API particle size range has been established within the 
design space. The ability to detect [D] that the API particle size range does not meet the 
specification is almost certain, as all raw materials are analysed upon receiving and 
analysed to confirm supplier certificate of analysis. This is a quality control measure and 
forms part of cGMP (Medicines Control Council, 2010).  
 
DoE has established that a quantity of 4% m/m povidone binder is sufficient to cause optimal 
binding activation. Tablets were hard enough to withstand abrasion and handling, 
disintegrate within 15 minutes (900 seconds) and demonstrated an acceptable dissolution 
profile. Therefore, the potential effect and cause of failure is well controlled at a 4% quantity 
and should be maintained within design space specification. The FMEA analysis of the 
povidone binder quantity after implementing a control strategy is shown in Equation 4.7.  
 
  [ ]    [ ]   [ ]             [Equation 4.7] 
 
The severity [S] of the quantity of povidone binder impacting the release dissolution is 
reduced as the optimum quantity of povidone binder has been identified and the potential 
effect of failure is very minor. The probability of occurrence [O] is lowered and the ability to 
detect any variation [D] in the quantity of povidone binder is high as this will be recorded in 
the batch manufacturing record. Checking the quantity of the dispensed raw material is a 
quality control measure and recorded in accordance to good documentation practice which 
constitutes an essential part of the quality assurance system (Medicines Control Council, 
2010). 
 
Impeller speed during wet mix between 100 and 200 rpm and the massing time between 120 
and 360 seconds did not impact the extent of dissolution. For a massing duration of 180 
seconds at an impeller speed of 100 rpm during wet mix, the pivotal trial batches and the 
validation batch generated a homogenous mix and tablets were able to withstand abrasion, 
disintegrate within 15 minutes (900 seconds) and showed an acceptable dissolution profile. 
At these settings, product quality will be achieved within the design space. The potential 
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cause and effect of failure has been mitigated. The FMEA analysis of the impact of the 
impeller speed during wet mix and the time during massing time after implementing a control 
strategy is shown in Equation 4.8. 
 
[ ]    [ ]   [ ]             [Equation 4.8] 
 
The severity [S] of risk that the impeller speed during wet mix and the massing time has on 
the potential failure mode and the probability of failure occurring is reduced as both their 
effects on the product cQA are non-significant. Since the optimised settings have been 
identified and as each step of the manufacturing process is documented according to good 
documentation practice, the ability to detect the potential failure mode [D] is higher. 
 
Impeller speed during dosing has been identified as one of the significant factors to influence 
dissolution. The validation batch indicated that at the optimal setting where the granulating 
medium is added to the powered bed over the 90 second period at an impeller speed of 115 
rpm would result in 93% drug release at time point 15 minutes. The potential cause of failure 
and its effect on the product cQA is reduced and controlled within the design space 
specification. The FMEA analysis of the impeller speed during dosing after implementing a 
control strategy is shown in Equation 4.9.  
 
[ ]   [ ]   [ ]            [Equation 4.9] 
 
The optimised setting for the impeller speed during dosing has been identified, thus the 
severity of the failure mode [S] to cause over granulation or local wetting is reduced. The 
likelihood of occurrence [O] of the potential effect of failure is unlikely as this is controlled 
within the design space. The ability to detect such failure [D] is high as this will form part of 
the batch manufacturing record and recorded. Personnel involved in the batch 
manufacturing process should be involved in ongoing training session based on education, 
experience and working habits of staff, as well as on periodic assessment of previous 
training (Medicines Control Council, 2010). 
 
The control for moisture content of the intermediate bulk material after drying the wet granule 
is set within the design space specification. The DoE batches showed no physical defects to 
suggest granules are over- or under- dried. Accordingly, impeller speed is a set input value 
entered onto the human machine interface (HMI) screen of the high shear mixer granulator 
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compared to measuring the moisture content level. To mitigate the risk of not obtaining the 
target moisture content level of 2.5% m/m, it is feasible to set a tighter in-process control 
range within the design space of 2.4% m/m to 2.6% m/m. The prediction response for design 
points 2.4% m/m and 2.6% m/m using the model for dissolution are 102% and 98%, 
respectively. The predicted values are within the 95% prediction interval. Since moisture 
content has a significant role in the compaction process, the average hardness range for the 
moisture content between 2.4% m/m and 2.6% m/m should be within the range of 68 N and 
72 N. The FMEA analysis of the moisture content of the intermediate bulk material after 
drying the wet granule is shown in Equation 4.10. 
 
[ ]   [ ]   [ ]             [Equation 4.10] 
 
The severity [S] of the moisture content impacting the product cQA and the likelihood of the 
failure mode occurring [O] has been reduced as the target and range of moisture content 
has been established. The ability to detect these failures [D] are high, and controlled within 
the validated design space.  
 
The RPN for all the possible failure modes are below 50 which make them fall in the low risk 
range. The scalability of the design space can be revaluated in the transfer from pilot to 
commercial scale up batch manufacturing. Thus is may be further refined based on 
additional experience gained during the life-cycle of the product. However, certain unit 
operations are scale dependent and may require additional experimental work. Implementing 
quality risk management tools summarised in ICH Q10 guidelines (2009) may facilitate 
continual improvement of ethionamide 250 mg tablets. 
 
In addition, the control strategy for the manufacturing process stages is maintaining the in-
process tablet characteristics of hardness, friability and disintegration time within the 
required ranges. The machine settings required to produce tablets with the desired 
hardness, friability and disintegration time at the start of each run and during the in-process 
control checks within the run, will routinely check if tablet attributes are within ranges. End 
product testing will form a component of the control strategy as it confirms product quality. 
Although these tablet characteristics were not initially identified as critical to product quality, 
analysing tablet friability, hardness, and disintegration time aided in better understanding the 
product and its manufacturing process. When identifying the cQA from the drug quality 
attributes of the QTPP, the tablet thickness, hardness and moisture content needed to be 
established. Table 4.19 summarises the updated QTPP.  
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Table 4.19  Updated QTPP of the drug quality attributes after implementing the 
control strategy 
Quality 
Attributes 
of the Drug 
Product 
Target 
Is this a 
cQA? 
(No/Yes) 
Justification 
Physical 
attributes 
Hardness 
Target: 69.3 N 
Range: 68 N – 72 N 
No 
Established based on results 
from research study 
Thickness 
Range: 4.82 mm – 4.92 
mm  
No 
RSM batches have indicated 
that tablets compressed 
within the range of 68 N – 72 
N, would produce tablets with 
a thickness range between 
4.82 mm and 4.92 mm  
Water 
Content 
Loss on 
Drying (LOD) 
Target: 2.5% m/m 
Range: 2.4 – 2.6 
%m/m 
No 
 
Moisture content of 
intermediate bulk material 
(after drying wet granule) 
established based on 
outcome of research study. 
Optimum setting within 
design space specification. 
 
The risk mitigation strategy is to ensure a product consistency during production by 
monitoring the normal operating ranges for the material attributes and process parameters. 
Thus, the design space of knowledge is created and should be controlled at the optimised 
setting. Working at this setting, within the design space specification reduces the risk for all 
the potential failure modes. Under the QbD approach, these specifications are for the 
confirmation of product quality, not the manufacturing consistency and process control. In 
addition, this does not replace the review and quality control steps called for under the 
cGMP. 
 
Therefore, this project highlights the usefulness of QbD in pharmaceutical product 
optimisation by focusing on one pilot project that will create standards and set the path for 
the implementation to other pharmaceutical products in the future and ties up to the aims of 
pharmaceutical goals of providing a safe, effective and quality assured product. The QbD 
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principles provided an effective means to achieve a greater understanding of the 
ethionamide formulation and its wet granulation method of manufacture.  
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CHAPTER 5 – CONCLUSIONS AND RECOMMENDATIONS 
 
The study presented a systematic approach of optimising the formulation and manufacturing 
process of ethionamide 250 mg tablets using QbD. A historical database of the API, 
excipients and process data exist for legacy products and this information can be used to 
reengineer and optimise pharmaceutical products. Optimising a long withstanding product 
using the modernised approach is void of the limitations of the traditional approach of QbT 
which assures product quality by in-process and end product testing.  
 
Dissolution was identified as the quality attribute derived from the QTPP to be critical to 
patients should it fall outside of its acceptable range. The material attributes and process 
parameters were assessed using qualitative descriptors as part of the first evaluation 
followed by the FMEA method. API particle size, povidone binder quantity, impeller speed 
during dosing, massing time, impeller speed during massing and the moisture content after 
drying the wet granule were identified as risk factors with a high RPN . 
 
In an endeavour to accomplish the objectives, two experimental protocols were applied for 
evaluating the high risk factors and defining the relationship between the input variables and 
the quality attribute desired. Statistical designs were created and analysed using Minitab® 
statistical software. The screening trial using a fractional factorial design was used to 
estimate the significance of the main effects.  
 
ANOVA analysis revealed that impeller speed during dosing, moisture content and povidone 
binder quantity were significant factors. Results also revealed that to increase the extent of 
dissolution while still maintaining an acceptable tablet hardness that is able to withstand 
abrasion during handling and a disintegration time within the acceptable limit, povidone 
binder quantity can be maintained constant at a recommended 4% m/m. Therefore, impeller 
speed during dosing and moisture content were further examined in the subsequent 
optimisation study, using RSM, more specifically a CCRD. Tablets showed an acceptable 
hardness and met the specification for friability and disintegration time in addition to having 
an acceptable dissolution profile. Risk factors that had been demonstrated to affect 
dissolution i.e. dosing impeller speed and moisture content were used to construct the 
design space. 
 
The optimised manufacturing process was then chosen using the desirability factor and the 
optimised product corresponded reasonably well with those predicted for the desired quality 
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attribute. Impeller speed during dosing was set at 115 rpm and moisture content was set at 
2.5% m/m. In addition, the control strategy was developed to mitigate risks. The RPN of the 
updated risk assessment depicted that all the failure modes were categorised as „low‟ risk. 
Apart from identifying the factors that affect the product cQA, the study also established 
acceptable ranges for characteristics that were previously unknown, thus updating the 
QTPP. Therefore, the shift in paradigm from the traditional approach to QbD provided an 
astute insight for building quality into an immediate release oral solid dosage form. The study 
highlights the usefulness of QbD in optimising legacy products at a pilot scale. The 
information obtained from the risk assessment and the DoE can be useful to the 
accumulation of institutional knowledge and beneficial to other immediate release oral solid 
dosage forms.  
 
Recommendations for this study would be to further investigate the additional cost of a QbD 
development strategy compared with the traditional approach as the reward in the long run 
should outweigh the initial expenditure. In addition, it is recommended to further investigate 
the comparative in vitro dissolution study of the optimised product, which may be included in 
the QTPP. Dissolution testing should be carried out in USP apparatus II at 50 rpm using 900 
ml in the following dissolution media: (1) 0.1 M HCl, (2) a pH 4.5 buffer and (3) a pH 6.8 
buffer. A minimum of 12 dosage units (n=12) of the product should be evaluated. Samples 
should be collected at 10, 15, 20, 30 and 45 minutes. The moisture content of the optimised 
formulation should be determined by the Karl Fischer titration method which may be included 
in the QTPP. 
 
This study needs to be carried forward to show that QbD can be applied to not only small 
scale product development but also scaled up to full production batches. The scale up from 
small scale to production size may depend on the design of the equipment which may be 
potentially scalable in terms of its dimensionless features or components. Consequently, 
proposing the design space across scales should be described in terms of scale 
independent parameters and if possible in terms of dimensionless numbers, which are 
naturally scale independent. Once determined, the design space can be scaled by keeping 
the dimensionless numbers constant. The design space may therefore continue to evolve as 
additional knowledge and information is generated throughout the product life-cycle.  
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Abstract 
The aim of this study was to optimise ethionamide 250 mg tablets using Quality by Design 
(QbD). A quality target product profile (QTPP) was established and a risk assessment was 
performed using a qualitative risk assessment followed by the failure mode effects analysis 
(FMEA). A fractional factorial design was used to identify the significant factors affecting 
dissolution, the critical quality attribute (cQA). The central composite rotatable design 
(CCRD) was subsequently used to investigate the effects of the significant factors on the 
response. Six factors were considered as a high risk compared to others, namely the active 
pharmaceutical ingredient (API) particle size, povidone binder quantity, impeller speed 
during dosing, massing time, impeller speed during wet mix and the moisture content after 
during the wet granule. Pareto ranking analysis indicated that povidone binder quantity, 
impeller speed during dosing and moisture content after drying the wet granule were 
significant factors. Although povidone binder quantity was significant, results revealed that 
povidone binder can be maintained constant at a recommended 4% m/m. Optimisation with 
response surface methodology (RSM) clarified the relationship between impeller speed 
during dosing and moisture content and the cQA, and a design space was established. To 
test the accuracy and robustness of the developed model, the model was validated by 
producing the optimised batch. A good agreement was observed between the predicted and 
actual values; thus confirming the robustness of the model. QbD provided a judicious insight 
for building quality into ethionamide immediate release tablets. 
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1.  Introduction 
 
The aim of pharmaceutical development is to design a quality product and its manufacturing 
process to consistently deliver the intended performance of the product [1]. Continuous 
quality improvement is a critical step for the pharmaceutical industry to maintain a 
competitive advantage in the market. In this era of competition, quality has prime magnitude, 
and failure to meet such quality-allied goals produces challenges for industry [2].  
 
Under the traditional approach of Quality by Testing (QbT), product specifications are set by 
observing data from a small number of batches believed to be an acceptable quality and 
then setting acceptance criteria that require future batches to be the same. Specifications 
are tight as these are used to assure consistency of the manufacturing process. Testing of 
products can only be performed on a small sample, simply because the majority of the tests 
are destructive in nature and if the entire batch were tested to assure its quality, there would 
be no product. Since a few tablets out of a batch of several million are tested, industries are 
usually expected to conduct extensive in-process tests and post-production tests to ensure 
the outcome meets the predefined specifications, if not, batches are reworked or discarded. 
The combination of stringent manufacturing steps and excessive testing is what assures 
quality under the traditional approach [3-5]. 
 
The Food and Drug Administration (FDA) identified a succession of continuing issues in the 
pharmaceutical industry that the traditional approach of QbT had not solved. These 
problems include among others, the lack of mitigation of potential risks, and the lack of 
process understanding [6]. The FDA acknowledged that more controls are required for 
pharmaceutical manufacturers and for better regulatory decision-making. Thus, ensuring 
decisions are based on sound-science and not an empirical approach.  
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To improve the competence and modernise the pharmaceutical industry, the FDA initiated 
the, “Pharmaceutical cGMPs for the 21st century: A risk-based approach” [7]. An important 
part of this initiative was to shift the focus of the pharmaceutical industry away from the 
empirical approach of QbT to a more systematic approach. This led to the implementation of 
Quality by Design (QbD). QbD focuses on building quality into the product by identifying 
factors that are critical to patients and translating them into attributes that the product should 
have. The emphasis is on preventing quality associated problems and not just correcting 
them [1, 7-9].  
 
The concept of QbD was first outlined in the 1960s and later pioneered by Toyota to improve 
their early automobiles. Since then, industries like technology, telecommunications, 
aeronautics and companies manufacturing medical devices began incorporating QbD into 
their products, which significantly improved their product efficacy [10]. QbD is the successor 
to the traditional approach of QbT that the FDA agency has employed until the late 1900s 
and early 2000s. QbD focuses on building quality into the product through proper planning 
and highlights that the mere analysis of the final product, post-production, will not suffice. 
This is achieved by understanding the product and its manufacturing process, the risks 
involved in product manufacturing and the best method to mitigate those risks. 
Understanding the product and its process aids in detecting quality-associated problems 
early enough to permit actions without compromise to cost, available resources or product 
quality [11-13]. 
 
The International Conference on Harmonisation (ICH) guidelines, Q8: Pharmaceutical 
Development, ICH Q9: Quality Risk Management and ICH Q10: Pharmaceutical Quality 
System provides the roadmap on how QbD affects, ensures, maintains and optimises 
product quality. The core objective of QbD is to develop a robust formulation and 
manufacturing process that facilitates any adjustment of potential variables within a design 
space [1, 4].  
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The model drug selected for this study is ethionamide, a second-line drug used in the 
treatment of multiple drug resistant tuberculosis (MDR-TB). Ethionamide, an immediate 
release tablet was introduced onto the market in the early 1960s, thus creating the 
opportunity of taking a long existing product i.e. a legacy product, and optimising it using the 
QbD approach. At present, there is only one South African pharmaceutical company 
manufacturing ethionamide 250 mg tablets [14]. In South Africa, the percentage of new 
tuberculosis (TB) cases with MDR-TB is 1.8% (95% CI: 1.4 – 2.3%) and an estimated 
number of retreatment TB cases with MDR-TB is 6.7% (95% CI: 5.4 – 8.2%). These 
estimates are unchanged since 2011 [15]. With the growing number of MDR-TB cases in 
South Africa, the need to fulfil the demand requires the manufacture of the drug on a wider 
scale. Hence, the need to implement QbD in the manufacture of ethionamide to ensure 
market demands are satisfied without compromising product quality, effectiveness and cost. 
Thus, QbD provides a better overall business model.  
 
2. Methods 
 
2.1 Materials 
The following raw materials were utilised in this study: ethionamide (Liaoning Beiqi 
Pharmaceutical Co. Ltd, China); microcrystalline cellulose (Gujurat Microwax, India); lactose 
monohydrate (DMV – Fonterra Exc, New Zealand); sodium starch glycolate (Amishi Drugs 
and Chemicals, India); Povidone K25 (BASF SE, Germany); magnesium stearate (Faci Asia 
Pacific PTE Ltd, Singapore). All raw materials were kindly donated by Aspen Pharmacare, 
Port Elizabeth. 
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2.2 Preparation of ethionamide tablets 
For each batch, the raw materials were weighed (Mettler Toledo balance SR 32001; 
Switzerland) in accordance with the experimental plan. The batches were manufactured at a 
10 litre scale using Granulator Rapid Mixer and Wet Granulator (RMG 10 LTR, India).  
Granulating medium was prepared by mixing Povidone K25 and purified water (Heidolph 
Electrical Stirrer; Model Number: 50115; Germany). Ethionamide, lactose monohydrate, 
sodium starch glycolate (SSG) and microcrystalline cellulose (MCC) were dry mixed with the 
impeller speed set at 200 rpm and chopper speed set at 2500 rpm for 240 seconds (Rapid 
Mixer & Wet Granulator; Model Number: RMG 10 LRT; India). The granulating medium was 
added to the bowl over a 90 second period, at a chopper speed of 1500 rpm and the 
impeller speed set according to the experimental plan. The granules were wet milled through 
a 6.0 mm screen at 300 rpm (Quadro Co-Mill; Model Number 197; Canada) and dried in a 40 
°C pre-heated fluid bed dryer (Retsch Fluid Bed Dryer: Model Number TG100; Germany) 
until a specified percentage moisture content (loss on drying) was reached. After being dried 
and milled through a 1.5 mm screen, SSG was sieved through a size 40-mesh screen, 
added to the bulk material and blended (IMA Pharma CanguroTurbula Bin; Model Number: 
J50; Italy) for 10 minutes at 11 rpm. Magnesium stearate, was screened through a size 40-
mesh, added to the granules and blended for five minutes at 11 rpm. The final blend was 
subsequently compressed into tablets using a Karnavati Mini Press (Karnavati Mini Press II; 
Model Number: UNIK – PC 20 MT; India).  
 
2.3 Quality target product profile (QTPP) of ethionamide tablets 
The quality target product profile (QTPP) is listed as the quality properties that the drug 
product should have to ensure the desired quality is achieved (International Conference on 
Harmonisation, 2009a). The QTPP is a strategic foundation for product development and 
optimisation, emphasising the statement „planning with the end in mind‟ and forms the basis 
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of determining the critical quality attributes (cQAs) [5, 16]. Based on the clinical, 
pharmacokinetic and its physicochemical characteristics, the QTPP of ethionamide 250 mg 
tablets was established. The QTPP includes the dosage form, dosage design, dosage 
strength, route of administration and drug product quality attributes, all of which is 
pharmaceutically equivalent to its reference counterpart. The QTPP for ethionamide tablets 
is depicted in Table 1. 
 
2.4 Identifying the product critical quality attributes (cQAs)  
The critical quality attributes (cQAs) are physical, chemical and biological properties that 
should be within an appropriate range to ensure the desired product quality. Identifying the 
product cQA from the QTPP is based on the severity of harm to the patient, should the 
product attribute fall outside its acceptable range [1]. Consequently, dissolution is the 
product cQA, as the dissolution of the drug substance under physiological conditions is 
essential for its systemic absorption.  
 
2.5 Risk assessment  
The ICH Q9 guideline introduced the concept of quality risk management for evaluating, 
communicating, controlling and reviewing quality associated risks across the product life 
cycle [8]. A qualitative risk assessment was used as part of the first evaluation to determine 
if the risks are significant enough to warrant a more detailed analysis. Risks were 
characterised into those from the API, the excipients and the manufacturing process. The 
criteria used to evaluate each risk was based on its combined severity and probability, and 
the risk were categorised using qualitative descriptors such as „low‟, „medium‟ and „high‟. 
The „low‟ risk attributes do not require any further analysis, whereas the „high‟ risk attributes 
are unacceptable and require further analysis. In general, „medium‟ risks were also 
considered acceptable; however investigations were conducted in order to reduce such 
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risks. Table 2 summarises the risk ranking system in terms of the severity and the probability 
of the risks [17]. 
 
Subsequent to the qualitative risk assessment, the FMEA method was used to analyse the 
„medium‟ and „high‟ risks by identify the failure modes that have the greatest chance of 
causing product failure, i.e. not meeting the QTPP. The failure modes were characterised 
into those from the API, excipients and the manufacturing process. The process failure 
modes were further categorised by unit operations. The failure modes were prioritised 
according to the seriousness of their consequences, how frequently they occur and how 
easily they can be detected. The relative risks were ranked according to risk priority number 
(RPN).  
 
The risks were rated on a scale of one to 10 for each of the causes i.e. severity (S), 
probability of occurrence (O) and detection (D). Based on this scaling system, a high severity 
event would be given a 10, whereas a low severity event would be given a score of one. 
With probability, if something were quite certain to happen, then a 10 would be given, 
whereas if something were very unlikely to happen, a score of one would be allocated. For 
detection, if there is a good detection system in place, a score of one is given, whereas a 
non-existent detection system would be given a 10 [18]. These severity, occurrence and 
detection numbers were multiplied together to give a RPN (Equation 1).  
 
RPN = [S] x [O] x [D]        [Equation 1] 
The RPN was generated for all risk factors and the factors with the highest RPN follows 
greater priority and were evaluated. The failure modes with a RPN > 50 were further 
examined in the subsequent DoE. Table 3 depicts the FMEA for ethionamide tablets with 
their respective RPN for each failure mode. 
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2.6 Fractional factorial design screening study 
Based on the risk assessment results, a 26-3 fractional factorial design was used to screen 
significant factors influencing the selected cQA. The selected formulation and manufacturing 
input variables selected included: API particle size, povidone binder quantity, impeller speed 
during dosing, massing time, impeller speed during wet mix and moisture content after 
drying wet mix. Each factor was set at two levels, either a low (-) or high (+) and are 
summarised in Table 4. The matrix of the experiments for the fractional factorial design 
screening study is summarised in Table 5. 
 
2.7 Central composite rotatable design optimisation study 
Relied on the results of the 26-3 fractional factorial design screening study, a response 
surface methodology (RSM) was applied to determine if the levels of the significant factors 
from the screening experiments will produce a response that is in close proximity to the 
optimum and select the optimum settings of the selected variables. In this two factor CCRD, 
13 experiments were generated for the optimisation study and are summarised in Table 6 
and Table 7. The relationship between the significant factors and the product cQA was 
defined in the design space. 
 
2.8 Statistical analysis  
Replicate measurements were represented as a means ± standard deviation (SD). Statistical 
designs and analysis were carried out using the software package Minitab® statistical 
software version 16.0 (Minitab Inc., United Kingdom). Experimental runs were randomised to 
exclude any bias. The applied fractional factorial design is a resolution III design, so only the 
main effects were considered. Pareto ranking analyses were used to select the significant 
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factors, where the length of the horizontal bar represented the magnitude of the impact on 
the response. 
 
Analysis of variance (ANOVA) was performed to evaluate the model significance. A p-value 
< 0.05 was considered statistically significant. The coefficient of determination (R2), adjusted 
R2 (Adj R2) and predicted R2 (Pred R2) were also applied to determine the suitability of the 
model. The R2 value is the maximum squared regression coefficient that can be achieved by 
the model using only the variables in it, which is an indication of how well the model fits the 
experimental data. The Adj R2 is a modified form of R2 considering the number of terms used 
within the model and the Pred R2 is an estimation of how well the model predicts a response 
value. In addition the lack-of-fit estimated the error variance independently of the model. A 
significant „lack-of-fit‟ (p>0.05) indicates that the variability measured by the replicates does 
not explain the gap between predicted and experimental data points. For the CCRD 
analyses, the regression analyses enabled a prediction equation to be obtained 
 
2.9 Granule characterisation 
 
2.9.1 Moisture content  
The moisture content after drying the wet granule was measured using a Moisture Analyser 
(Mettler Toledo LJ16, Switzerland).  The granule sample (2 g – 3 g) was placed in a heating 
pan, weighed and heated at a temperature of 105 °C and a drying time set to the automatic 
switch-off criterion (2 mg/30 seconds) The percent reduction in the weight due to moisture 
loss i.e. loss on drying (LOD) was determined. 
                  
                        
             
       
          [Equation 2] 
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2.10 Tablet characterisation 
 
2.10.1 Dissolution testing 
Dissolution studies were performed using a United States Pharmacopoeia (USP) I 
dissolution apparatus (Hanson SR II 6-flask Dissolution Test Station; Model Number 64-705-
045, United States of America), equipped with six vessels. Nine hundred millilitres (ml) of 0.1 
M hydrochloric acid (HCl), as the dissolution medium was added to each of 6 vessels sited in 
the water bath at a temperature of 37 °C ± 0.5 °C. Baskets were set to rotate at 100 rpm. 
One tablet was transferred to each of the six baskets and at time zero, the baskets were 
immersed in the dissolution medium. Ten ml aliquots were withdrawn at 10, 15, 20, 30 and 
45 minute intervals from each vessel into separate test tubes. Two ml of the filtered sample 
was transferred into a 50 ml volumetric flask and made up to volume with 0.1 M HCl.  
 
The dissolution medium was prepared by transferring 8.5 ml of HCl (32% v/v) (Merck KGaA, 
Germany) into 10 litres of purified water (Riggtek DissoPrep X8, Germany). The standard 
solution was prepared by weighing and transferring approximately 55 mg of ethionamide 
working standard into a 100 ml volumetric flask, adding 60 ml of the dissolution medium and 
sonicating until dissolved (Branson Ultasonic 8510, United States of America). The solution 
was allowed to cool to room temperature and the solution was made to volume with the 
dissolution medium. Two ml of this solution was transferred into a 100 ml volumetric flask 
and made up to volume with the dissolution medium. The dissolution was measured using 
UV-VIS Spectrophotometer (UV-Pharmaspec 1700 UV-visible spectrophotometer, Japan). 
Ethionamide concentration of each sample (n=6) at each time interval and the absorbance of 
the standard (five replicates) was spectrophotometrically determined at 274 nm with a 1 cm 
cell and the dissolution medium as the blank. Data acquisition was performed using UV 
Probe® 2.43 software. The percentage drug release per tablet was calculated using Equation 
3 below. The parameters used in the formula for the dissolution test is shown in Table 8. 
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[Equation 3] 
 
2.10.2 Disintegration Test 
Disintegration time was measured using Erweka Tablet Disintegration Test Unit (Model 
Number: ZT 304; Germany). Six tablets were randomly selected from each batch (n=6) for 
the disintegration test. One tablet was introduced on each of cylindrical (glass) tubes. Water 
was used as the disintegration medium at 37 °C ± 0.5 °C. The time it took for each tablet to 
disintegrate was recorded as the disintegration time and presented in seconds. 
 
2.10.3 Hardness Testing 
Ten tablets were randomly selected from each formulation batch and tablet strength i.e. 
hardness was measured using a hardness tester (Erweka Hardness tester; Model Number: 
TBH 320TD; Germany). The average hardness and mean SD of the 10 tablets from each 
batch was calculated. 
  
2.10.4 Friability 
Twenty tablets were randomly taken from each formulation batch. Tablet samples were 
weighed accurately (Mettler Toledo AG204; Switzerland) and placed in a friabilator 
(PharmaTest Friabilator PTF 3; Germany). Tablets were rotated at 25 rpm for four minutes, 
totalling 100 revolutions. Finally tablets were removed from the friabilator, de-dusted and 
weighed. The weight difference between the initial and final weight was recorded. The 
percentage friability was determined by using Equation 4. 
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[Equation 4] 
 
3. Results 
 
3.1 Quality target product profile (QTPP) of ethionamide tablets 
 
The purpose of this exercise was to identify the quality characteristics that ethionamide 
should possess in order to deliver the desired therapeutic effect. The parameters that will be 
focused on in the study were selected and enlisted as the QTPP for ethionamide tablets 
(Table 1). These characteristics that make up the QTPP will be designed into the product 
and will lay down the basis for determining the cQA. 
 
3.2 Identification of the critical quality attribute 
Dissolution was identified as the product cQA as this is a rate-limiting step for drug 
absorption. Failure to meet the dissolution specification can impact bioavailability. The 
formulation and process variables that may affect the dissolution profile, thus will be 
investigated. The extent of dissolution at time point 15 minutes was measured. 
 
3.3 Risk assessment 
 
As outlined in the ICH Q9 guideline, the risk identification and risk analysis are the two basic 
components of the risk assessment. Risk assessments were performed on the API, 
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excipients and the manufacturing process. The qualitative risk assessment was used as part 
of the initial risk assessment to narrow down the list of potential risk factors. The „medium‟ 
and „high‟ risk factors were further analysed using the FMEA method and aided in identifying 
how each potential risk may impact the product cQA. Each risk factor was scored in terms of 
severity, detectability and probability. The RPN scores using FMEA methodology is 
summarised in Table 3. Six risk factors were identified in the risk assessment study that has 
the potential to impact dissolution. These independent factors included: API particle size, 
quantity povidone binder, impeller speed during dosing, massing time, massing impeller 
speed and moisture content after drying the wet granule. These six factors would be used in 
the screening trial to obtain the significant factors influencing the cQA. 
 
3.3.1 Influence of various factors on the product cQA by fractional factorial 
screening study 
Six factors were identified in the risk assessment to have a potential impact on dissolution. A 
screening experimental design minimises the number of experiments required to identify the 
significant factors affecting the product cQA. The effect on the extent of dissolution at 15 
minutes for the initial model F-value of 15.60 demonstrates that the model is non-significant. 
There is only a 19.10% possibility that an F-value this large may occur due to noise. Impeller 
speed during wet mix as a non-significant term and as a term that had the lowest impact on 
dissolution (p=0.814) was removed from the analysis. Accordingly, the Pred R2 increased 
from 32.34% to 81.56%. The adjusted model with an F-value of 34.31 indicated that the 
model is significant, implying that there is only a 2.90% chance that an F-value this large 
could occur due to noise (R2= 98.85%, p=0.029). The significant factors were povidone 
binder quantity (% m/m), moisture content (% m/m) and impeller speed during dosing (rpm) 
relative to other factors influencing the extent of dissolution as shown in Figure 1 and Table 
9.  
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The mean cumulative release dissolution profile (n=6) at time intervals 10, 15, 20, 30 and 45 
minutes are shown in Figure 2. Table  10 summarises the tablet characteristics for the 
screening trial batches. Screening trial has shown that to distend the extent of dissolution 
while still maintaining acceptable tablet hardness, a friability of less than 1% loss and 
disintegration time within the acceptable limit, indicating that povidone binder quantity can be 
maintained constant at a recommended 4% m/m (Figure 3). The RSM will focus primarily on 
the optimisation of the manufacturing process. The factors evaluated in the succeeding 
experimental plan are moisture content after drying (% m/m) and impeller speed during 
dosing (rpm).  
 
3.4 The response surface obtained by the central composite rotatable design 
 
This study aimed at understanding the effects and interactions between the selected input 
variables on the product cQA. The levels used for the selected variables and the 
experimental results are listed in Table 7. ANOVA analysis for dissolution at 15 minutes are 
summarised in Table 11.  
 
A quadratic model (polynomial equation) was used to analyse the extent of dissolution. 
ANOVA analysis of the model for the response showed that the model (quadratic) chosen for 
the analysis had a significant fit relative to the noise with an F-value of 4.90 (p=0.030) and a 
lack of fit test showed that there was a non-significant lack of fit relative to the pure error 
(p=0.125), indicating that this model may be used to evaluate the design space. Of the 
squared terms for this model, dosing impeller speed had a significant effect with an F-value 
of 14.88 (p=0.006). This implies that there is significant curvature in the response surface. 
Analysis of the main effects for the extent of dissolution showed that only moisture content 
was significant, where p=0.047. No significant interactions where noted between the 
selected factors. Contour and surface plots were also analysed to visualise the effects of 
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moisture content and impeller speed during dosing and their interactions on the cQA. As 
shown in Figure 4 to maximise the extent of dissolution of the immediate release tablet 
above 85% drug release at 15 minutes, impeller speed during dosing should be within the 
region of 90 rpm to 150 rpm and a 2.5% m/m to 2.8% m/m range for the moisture content 
level. The polynomial equation derived from the model used to makes predictions about the 
response is shown below, where A is the dosing impeller speed during dosing and B is 
moisture content.  
                                                         
[Equation 5] 
 
3.5 Establishment and evaluation of the design space 
Key parameters that had been demonstrated to affect ethionamide product cQA were used 
to construct the design space as shown in Figure 5. The design space is the acceptable 
region within which the quality of the product can be built [1]. 
 
 
3.6 Optimisation using desirability function 
Desirability function was calculated for the extent of dissolution at 15 minutes. The 
composite desirability with the aid of Minitab® 16.0 software was 0.707. The weight and 
importance for the response were allotted one and five, respectively. The response optimiser 
indicated that the optimal setting for impeller speed during dosing is 115 rpm and moisture 
content is 2.5% m/m. At these settings, the % drug release at 15 minutes is calculated at 
100.6%.  
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3.7 Validation of the optimised formulation and manufacturing process 
 
To test the accuracy and robustness of the developed model, the model was validated by 
producing the optimised batch and testing it against the measured responses. Ethionamide 
tablets were prepared according to the optimised conditions and were subjected to the 
release test. The confidence interval for each response at a 95% confidence level was used. 
The actual values for each response are compared to the predicted values and are 
summarised in Table 12. The optimised product met all the required specification. The actual 
% drug release for ethionamide is 93.0% ± 1.4 and the predicted value was 100.6%. The 
actual values were within the 95% prediction interval (PI) for each observed response, 
indicating statistical equivalence of the experimental drug release profile and the predicted 
one.  
 
3.8 Determination of a control strategy 
 
The control strategy is defined as a planned set of controls derived from current product and 
process understanding that assures process performance and product quality [9]. The 
control of quality of the finished product is closely linked to the criticality and therefore to 
each dimension of the design space. By determining the extent of dissolution at 15 minutes 
as the cQA, the allowed variability of impeller speed during dosing and moisture content 
after drying wet granule is indicated.  
 
The risk mitigation and control strategy is an integrated outline of how quality is built into the 
product. Although the implementation of a control strategy is no new concept in 
pharmaceutical industry, pharmaceutical products always had a more or less unequivocal 
control concept. However, the use of risk assessment in creating a control strategy is unique 
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to QbD. Figure 6 illustrates the FMEA analysis before and after the implementation of a 
control strategy. The RPN after implementing the control strategy for all the possible failure 
modes are below 50 which make them fall in the low risk range. 
 
4. Discussion 
 
A screening trial was used to identify the significant factors influencing the cQA and using a 
fractional factorial design reduces the number of runs to a significant few. To best use the 
screening design, a risk analysis was performed and six factors were identified as potential 
high risk factors. These include API particle size, povidone binder quantity, impeller speed 
during dosing, massing time, impeller speed during wet mix and moisture content of the 
intermediate bulk material (after drying the wet granule). 
 
A 26-3 fractional factorial design was used in the screening trial. Being a resolution III design, 
the experimental design can estimate the significance of the main effects with high efficiency 
and accuracy, but it cannot separate the main effects from possible interactions (Myers & 
Montgomery, 1995). However, as the goal of this design is to simply reduce the high risk 
factors to be studied in the subsequent experiments, such a design was considered to be 
sufficient to achieve this outcome. As shown in Figure 1 and Table 9, of the six factors only 
povidone binder quantity (% m/m), moisture content (% m/m) and impeller speed during 
dosing (rpm) were significant relative to other factors influencing the extent of dissolution. At 
time point 15 minutes the extent of dissolution varied from 41% (F-4) to 102% (F-7) for the 
various factor combinations. Screening trial batches F-3 and F-4 containing 5% m/m 
povidone binder, dosed at an impeller speed of 200 rpm and dried to a moisture content of 
3% m/m, held a better attrition resistance (<1% m/m after four minutes) and tablet 
compressibility. Tablet hardness for these batches i.e. F-4 and F-3 ranged from 78.40 N ± 
6.02 to 80.40 N ± 3.75, respectively (Table 10). Notably, tablets compressed at the lower 
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ranges, disintegrated at a faster rate and showed a higher % ethionamide release during 
dissolution testing at the 15 minute time point. Batches dried to a moisture content of 1% 
m/m were found to be more friable and had a prominent effect on tablet hardness. At higher 
povidone binder quantities and at increased moisture content, tablet hardness increased and 
friability improved. Friability results showed that as the moisture content decreased, the 
tablets were more friable. Although friability was lowest for formulation F-3 and F-4, the 
extent of dissolution at 15 minutes was slower compared to the other batches. The low 
friability percentage for the formulations correlates to the average tablet hardness. According 
to the data obtained from the screening trial, all the formulations were well within the 
pharmacopoeial disintegration time limit (Table 10). Formulation F-2 had the fastest 
disintegration time of 31 seconds and the lowest average tablet hardness of 34.80 N ± 2.20 
compared to formulation F-3 that had the slowest disintegration time of 538 seconds (i.e. 8 
minutes and 58 seconds) and highest average tablet hardness of 80.40 N ± 3.75. Batches F-
6 and F-7, both contained 5% m/m povidone binder and dried to a 1% m/m moisture level 
and were compressed at 49.20 N ± 4.78 and 39.50 N ± 6.35 respectively. Although, both 
batches disintegrated within the acceptable times, friability test results were above 1% m/m.  
 
Increasing the concentration of the binder increases the viscosity of the binder solution and it 
is expected that the strength of the granules would increase as the content of the povidone 
binder quantity increased [19]. Moisture content increases the compact strength by 
increasing the tensile strength of the powder bed and decreasing the density variation within 
the tablet. Garr and Rubinstein [20] have demonstrated that moisture content is an important 
element for the mechanical strength of tablets. Reducing moisture content, increases the 
die-wall friction which contributes to an increase in stress ratio [20]. At an optimum moisture 
level, the die-wall friction is reduced which is due to the reduction in stress ratio. The 
increase in compact strength may be due to the hydrodynamic lubrication effect of moisture, 
which promotes compaction force transmission and formation of hydrogen bonds. Although 
batches F-3 and F-4 compressed to an average tablet hardness of 80.40 N ± 3.75 and 78.40 
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N ± 6.02, the extent of dissolution at 15 minutes, were 47% and 41%, respectively. However, 
after 45 minutes, the extents of dissolution for these batches were above 80%. A high 
compression may increase the specific surface and may enhance the dissolution. On the 
other hand, the high compression may also inhibit the wettability of the tablet, owing to the 
formation of a firmer and more effective sealing layer of the lubricant. The higher 
compression may also produce slower dissolution, at least in the initial period, because of an 
increased difficulty of fluid penetration into the compressed tablets [21]. Figure 7 shows that 
at a higher moisture content and higher povidone binder quantity, disintegration time was 
longer. Binders impart their cohesive qualities to the tablet formulation to ensure the tablet 
remains intact after compression as well as improving the free-flowing qualities by the 
formulation of granules of the desired hardness. The quantity of binder used had 
considerable influence on the characteristics of the compressed tablets. A higher percentage 
of binder quantity causes an extended disintegration time [22]. 
 
Dosing plays an important role in the compression characteristics of the granules and also in 
the extent of dissolution. Increasing the impeller speed generally leads to a decrease in 
granule size and an increase in growth rate. At higher impeller speeds better distribution of 
the binder over the powder bed is ensured [23]. A powder bed that is cohesive may flow 
better if its moisture content is increased. However, too much moisture may result in 
capillary bonding between particles and flow may be compromised by the increased particle-
particle adhesion. In addition, the higher compression reduces the extent of dissolution due 
to the reduction of fluid penetration into the compressed tablets. Figure 8 (a), (b) and (c) 
represents a 2-dimentional graphical contour plot of the relationship between povidone 
binder quantity, impeller speed during dosing and moisture content, and their influence on 
the extent of dissolution. 
 
The screening trial demonstrated that to distend the extent of dissolution while still 
maintaining an acceptable tablet hardness, friability of less than 1% m/m loss and 
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disintegration time within the acceptable limit, povidone binder quantity can be maintained 
constant at a recommended 4% m/m. Ethionamide is practically insoluble in water and the 
dissolution medium used during the dissolution testing is a 0.1 M HCl medium. Results 
showed that API particle size did not impact dissolution and, therefore does not pose a high 
risk to obtaining a low therapeutic level. By reason of having a larger quantity of API 
available with a particle size D50, 95.18 µm compared to 267.00 µm and maintaining batch to 
batch consistency, the low level (-1) was selected for the subsequent RSM study. Impeller 
speed during wet mix and duration of the wet mix did not have a significant influence on 
dissolution. Suggesting that at these ranges, a homogenous granulation can be obtained. 
For the RSM, the non-significant factors, massing time was set at centre point level, API 
particle size at low level and impeller speed during wet mix at low level.  
 
Following the screening trial, the significant factors, moisture content after drying (% m/m) 
and impeller speed during dosing (rpm) were evaluated using a CCRD. In contrast to a 
screening trial that determines the main effects, a response surface design mapped the 
response surface over a particular region of interest, thus predicting, in advance, the 
changes in response that will result if there are any adjustments to the input variable [24, 
25]. 
 
The quadratic model was adequate to characterise the data since a non-linear relationship 
existed between impeller speed during dosing and the product cQA. This demonstrates the 
benefit of using a 5-level design as opposed to a 2-level factorial design, where the range of 
experimental data was wide enough to detect the statistically significant variation. As shown 
in Figure 4, to maximise the extent of dissolution of the immediate release tablet above 85% 
drug release at 15 minutes, impeller speed during dosing should be within the region of 90 
rpm to 150 rpm and a 2.5% m/m to 2.8% m/m range for the moisture content level. The 
impeller speed during dosing allowed for efficient distribution of the granulating medium over 
the powered bed, rendering the particle surfaces sticky enough to allow coalescence. 
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Badaway and co-workers [26] reported that at a higher moisture content a higher fraction of 
the void spaces within the granule are filled with liquid, which increases liquid saturation of 
the granule, thus enhancing granule coalescence. The moisture content may be required for 
the binding of granules during compression in the die cavity. The higher liquid saturation 
makes the granule easily deformable and results in more liquid available to the granule 
surface both of which increases probability of successful coalescence upon granule collision 
[26]. In addition, moisture may act as a lubricant which reduces inter-particulate friction 
within the granule. Hence facilitating particle movement within the granules in response to 
densifying forces in the high shear granulation [27]. Similarly Nokhodchi and co-workers [28] 
demonstrated that moisture played a significant role in the compaction process. This may be 
due to the water forming a „monomolecular‟ layer around the API particles. This tightly bound 
water can be regarded as part of the surface molecular structure of the particles, which 
facilitates the formation of interparticle hydrogen bonding that may increase van der Waals 
forces, thus smoothing out the surface micro irregularities and reducing interparticle 
separation. In addition, the formation of pendular bonds on the particle surfaces would be 
expected to contribute to compact strength. At the impeller speed and moisture content 
ranges for the pivotal trial batches, tablets have shown an acceptable hardness and met the 
specification for friability and disintegration time, in addition to having an acceptable 
dissolution profile which may be the consequence of adequate fluid penetration into the 
compressed tablet during drug release analysis.  
 
In general, physical defects such as capping and chipping caused by low moisture levels or 
sticking and picking caused by high moisture levels are typical tablet defects [29]. However, 
these defects were not evident, and the physical appearances were satisfactory. At the 
ranges set for the input variables, friability and disintegration time met the specifications. The 
hardness for all batches were kept constant throughout experimentation between 63 N – 91 
N. Most batches presented fast disintegration time, except batch F-2 that had a 
disintegration time of 6 minutes 10 seconds and tablets from batch F-11 disintegrated at 5 
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minutes 45 seconds, but were still well within the required limit of 15 minutes (900 seconds) 
as shown in Table 13. Figure 9 illustrates the dissolution profiles for all formulations. The y-
axis represents the % ethionamide release, with the x-axis representing the time interval, in 
minutes.  
 
Figure 5 illustrates the design space which is the multidimensional interaction between 
impeller speed during dosing and moisture content, to determine their influence on the 
extent of dissolution. The white zone represents the area of acceptable quality (design 
space) and the red-lines represent the edge of failure. Movement beyond the edge of failure 
into the grey zone is the area of potential risk where the dissolution is below the acceptable 
internal control limit. A vital step of product optimisation is to achieve an appropriate 
response function for both dependencies and independencies within the design space. 
 
Figure 6 shows the FMEA before and after the implementation of a control strategy. 
Ethionamide is insoluble in water and its potential effect of failure may result in a below 
therapeutic level. Generally, weakly basic drugs like ethionamide (pKa = 4.49) tend to have 
a slower dissolution rate at higher pH levels as more drug exists in its ionised form [30]. A 
study by Vale and co-workers [31] showed that the solubility of pure ethionamide in an 
aqueous buffer at pH 1.2 was 4 mg/ml but decreased to 741 µg/ml in the pH range of 5.5 – 
7.4. This finding concurs with the weakly basic nature of the drug substance. However, its 
solubility is a physicochemical property of the API. Nonetheless, DoE has demonstrated that 
API particle size distribution with a D50 range 95.18 µm to 267.00 µm does not have a 
significant effect on dissolution in a 0.1 M HCl medium. Therefore, the potential effect and 
cause of failure is lower. API particle size, D50 may range from 95.18 to 267.00 µm and 
remain within the design specification. DoE has established that a quantity of 4% m/m 
povidone binder is sufficient to cause optimal binding activation. Tablets were hard enough 
to withstand abrasion and handling, disintegrate within 15 minutes (900 seconds) and 
demonstrated an acceptable dissolution profile. Therefore, the potential effect and cause of 
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failure is well controlled at a 4% m/m quantity and should be maintained within the design 
space specification.  
 
Impeller speed during wet mix between 100 to 200 rpm and the massing time between 120 
and 360 seconds did not impact the extent of dissolution. For a duration of 180 seconds at 
an impeller speed of 100 rpm during wet mix, the pivotal trial batches and the validation 
generated a homogenous mix and tablets were able to withstand abrasion, disintegrate 
within 15 minutes (900 seconds) and showed an acceptable dissolution profile. At these 
settings, product quality will be achieved within the design space. The potential cause and 
effect of failure has been mitigated. 
 
Impeller speed during dosing has been identified as one of the significant factors to influence 
dissolution. The validation batch indicated that at the optimal setting where the granulating 
medium is added to the powered bed over the 90 second period at an impeller speed of 115 
rpm would result in 93% drug release at time point 15 minutes. The potential cause of failure 
and its effect on the product cQA is reduced and controlled within the design space 
specification.  
 
The control for moisture content of the intermediate bulk material after drying the wet granule 
is set within the design space specification. The DoE batches showed no physical defects to 
suggest granules are over- or under- dried. Accordingly, impeller speed is a set input value 
entered onto the human machine interface (HMI) screen of the high shear mixer granulator 
compared to measuring the moisture content level. To mitigate the risk of not obtaining the 
target moisture content level of 2.5% m/m, it is feasible to set a tighter in-process control 
range within the design space of 2.4% m/m to 2.6% m/m. The prediction response for design 
points 2.4% m/m and 2.6% m/m using the model for dissolution are 102% and 98%, 
respectively. The predicted values are within the 95% prediction interval. Since moisture 
content has a significant role in the compaction process, the hardness range for the moisture 
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content between 2.4% m/m and 2.6% m/m should be within the range of 68 N and 72 N. The 
RPN for all the possible failure modes are below 50 which make them fall in the low risk 
range. Implementing quality risk management tools summarised in ICH Q10 guidelines 
(2009) may facilitate continual improvement of ethionamide 250 mg tablets. In addition, the 
control strategy for the manufacturing process stages is maintaining the in-process tablet 
characteristics of hardness, friability and disintegration time within the required ranges. End 
product testing will form a component of the control strategy as it confirms product quality. 
 
5. Conclusion 
The study presented a systematic approach of optimising the formulation and manufacturing 
process of ethionamide 250 mg tablets using QbD. By nature a historical database of the 
API, excipients and process data exist for legacy products and this information can be used 
to optimise pharmaceutical products. Optimising a long withstanding product using the 
modernised approach of QbD are void of the limitations of the traditional approach of QbT 
which assures product quality by in-process and end product testing. Therefore, the shift in 
paradigm from the traditional approach to QbD provided an astute insight for building quality 
into an immediate release oral solid dosage form.  
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Table 1  Summary of the QTPP for ethionamide 250 mg tablets 
QTPP Elements Target Justification 
Dosage form Tablet 
Product is pharmaceutically equivalent 
and has the same dosage form 
Dosage design 
Uncoated immediate release 
tablet 
Product is pharmaceutically equivalent 
and has the same dosage design 
Route of administration Oral 
Product is pharmaceutically equivalent 
and has the same route of administration 
Dosage strength 250 mg 
Product is pharmaceutically equivalent 
and has the same dosage strength 
Drug product 
quality 
attributes 
Physical 
attributes 
Round yellow, shallow concave, 
bevelled edged tablet with 
debossing on one side and scored 
 
Tablet identification and to facilitate the 
splitting of tablet into fractions for partial 
dosage 
Dissolution 
Not less than 80% of ethionamide 
is released within 45 minutes (Q = 
75%) 
Pharmaceutical equivalent requirement: 
must meet the same compendia or other 
applicable (quality) standards 
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Table 2   The risk ranking system in terms of the severity and the probability of the risks 
(Source: Frank et el., 2008) 
 Probability 
Severity Low Medium High 
High potential to 
impact product 
quality 
Medium High High 
Medium potential to 
impact product 
quality 
Medium Medium High 
Low potential to 
impact product 
quality 
Low Low Medium 
*This table has been amended and sourced from the Product Quality Research Institute (PQRI), 2107 Wilson 
Blvd, Suite 700, Arlington, Virginia 22201-3042, United States of America; website: http://www.pqri.org/index.asp 
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Table 3  The FMEA for ethionamide tablet with their respective RPN for each failure mode 
Formulation/process 
parameter component 
Failure mode Failure effects S Potential causes O 
Detectability 
method 
D RPN 
API particle size 
Low solubility in 
purified water 
Below therapeutic level 8 
Chemical property of 
the API 
 
8 Control dissolution 1 64 
Povidone binder quantity 
Low binding 
activation, slow 
dissolution 
Compression problem, bio-inequivalent to 
reference product 
 
8 
Incorrect quantity of 
binder in formulation 
5 Quality control 2 80 
Dosing 
Impeller speed 
during dosing 
Over granulation 8 
Equipment changes, 
operator training 
 
7 
Determine range 
for impeller speed 
1 56 
Wet mix 
Massing time Over granulate and under granulate 9 
Unknown range (to 
be established) 
8 Determine speed 
and duration of 
impeller 
3 216 
Impeller speed 
Over granulate and under granulate 
 
9 
Unknown range (to 
be established) 
8 3 216 
Drying 
Moisture content 
of intermediate 
bulk material 
 
Over or under drying may cause physical 
tablet defects and poor granule flow. This 
may potentially affect the content 
uniformity and uniformity of mass 
8 
Temperature and 
time 
5 
Drying time and 
moisture to be 
established 
3 120 
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Table 4  Formulation and process factors and their levels for the screening trial 
batches using a 26-3 fractional factorial design  
Independent variables (factors) Levels 
Units Low (-1) High (+1) 
1 API particle size D50 (µm) 95.18 267.00 
2 Povidone binder quantity % m/m 3 5 
3 Impeller speed during 
dosing 
rpm 100 200 
4 Massing time s 120 360 
5 Impeller speed during wet 
mix 
rpm  100 200 
6 Moisture content  % m/m 1 3 
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Table 5  Matrix of the experiments for the fractional factorial design screening study 
and results for the product cQA 
 
Standard 
Order 
 
Run 
Order 
 
Critical material attributes and process parameters 
 
Product 
cQA 
API   
particle 
size 
Binder 
quantity  
(povidone) 
Impeller 
speed 
during 
dosing 
Massing 
time 
Impeller 
speed 
during 
wet mix 
Moisture 
content 
Dissolution 
Units D50 (µm) % m/m rpm s rpm % m/m 
% drug 
release at 
15 minutes 
1 1 267.00 3 100 360 200 3 100 ± 1.3 
5 2 267.00 3 200 360 100 1 105 ± 1.5 
8 3 95.18 5 200 360 200 3 47 ± 11.7 
7 4 267.00 5 200 120 100 3 41 ± 4.4 
6 5 267.00 3 200 120 200 1 97 ± 2.8 
4 6 95.18 5 100 360 100 1 95 ± 1.4 
3 7 267.18 5 100 120 200 1 102 ± 2.8 
2 8 95.18 3 100 120 100 3 99 ± 1.9 
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Table 6  Significant factors and their levels for CCRD 
Factors Units 
Factor Level 
-α -1 0 +1 +α 
Impeller speed 
during dosing 
X1 rpm 89.64 100.00 125.00 150.00 160.36 
Moisture content X2 % m/m 2.40 2.50 2.75 3.00 3.10 
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Table 7  Matrix of experimental plan of CCRD and results of cQA 
Run Order 
(Formulation) 
Standard 
Order 
Point 
Type 
Blocks 
Risk Factors Product cQA 
Impeller 
speed during 
dosing 
Moisture 
content 
Dissolution 
Units rpm % m/m 
% drug release 
at 15 minutes 
1 10 0 1 125.00 2.75 99 ± 2.20 
2 6 -1 1 160.36 2.75 78 ± 15.50 
3 1 1 1 100.00 2.50 100 ± 1.00 
4 5 -1 1 89.64 2.75 81 ± 14.50 
5 7 -1 1 125.00 2.40 96 ± 1.00 
6 11 0 1 125.00 2.75 91 ± 2.40 
7 4 1 1 150.00 3.00 92 ± 1.70 
8 9 0 1 125.00 2.75 99 ± 1.40 
9 13 0 1 125.00 2.75 97 ± 0.80 
10 12 0 1 125.00 2.75 95 ± 2.50 
11 3 1 1 100.00 3.00 78 ± 11.20 
12 8 -1 1 125.00 3.10 91 ± 10.80 
13 2 1 1 150.00 2.50 96 ± 1.50 
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Table 8.  Parameters used in the formula for the dissolution test 
Asam Absorbance of ethionamide in the sample solution 
Astd Average absorbance of ethionamide in the standard solution 
Mass of standard Mass of ethionamide working standard taken to prepare the standard solution 
(55 mg) 
C Potency of the ethionamide working standard, expressed in percentage 
(100.6%) 
Label Claim Amount of ethionamide present in each tablet i.e. dosage unit, expressed in 
mg (250 mg) 
Requirement: Not less than 80% of active is release per dosage unit within 45 minutes 
*Note: The values in the brackets represent the mass weighed, volume of the standard 
solution, volume of the dissolution medium, label claim and the potency of ethionamide 
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Table 9  Screening trial: ANOVA analysis of the adjusted model for the product cQA 
Term Units F-value p-value Comment 
Model - 34.31 0.029 Significant 
API particle size D50 (µm) 0.46 0.568 Non-significant 
Povidone binder quantity % m/m 61.72 0.016 Significant 
Impeller speed during dosing rpm 51.54 0.019 Significant 
Massing time s 0.29 0.642 Non-significant 
Moisture content % m/m 57.54 0.017 Significant 
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Table 10  Screening study: A summary of the tablet characteristics 
Formulation Average tablet hardness Friability Disintegration time 
Units N % m/m s 
F-1 42.80 ± 5.14 0.90 156 
F-2 34.80 ± 2.20 2.70 31 
F-3 80.40 ± 3.75 0.20 538 
F-4 78.40 ± 6.02 0.15 524 
F-5 29.80 ± 2.49 9.61 33 
F-6 49.20 ± 4.78 1.07 107 
F-7 39.50 ± 6.35 1.02 352 
F-8 58.50 ± 0.01 1.16 37 
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Table 11  ANOVA analysis of the for the linear, square and interaction effects on the 
extent of dissolution at 15 minutes 
Source F-value p-value Comment 
Regression 4.900 0.030 Significant 
Model Linear 2.990 0.115 Non-significant 
Terms 
Impeller speed 
during dosing 
0.180 0.688 Non-significant 
Moisture content 5.800 0.047 Significant 
Model Square 7.54 0.018 Significant 
Terms 
Impeller speed 
during dosing * 
Impeller speed 
during dosing 
14.38 0.006 Significant 
Moisture content * 
Moisture content 
0.000 0.958 Non-significant 
Model Interaction 3.440 0.106 Non-significant 
Terms 
Impeller speed 
during dosing * 
Moisture content 
3.440 0.106 Non-significant 
Lack-of-Fit 3.58 0.125 Non-significant 
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Table 12  Summary of the predicted and measured responses of the hypothesised 
model at the optimised conditions 
Response Units Predicted mean Actual mean 95% PI low 95% PI high 
Dissolution at 15 minutes % 100.6 93.0 ± 1.4 87.56 113.75 
Disintegration time s 207.00 213.00 61.60 352.00 
Friability % m/m 0.12 0.19 0.05 0.19 
Tablet hardness N 72.58 69.30 ± 2.83 53.97 91.19 
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Table 13  RSM study: Summary of the tablet characteristics 
Formulation Average tablet 
hardness 
Friability Disintegration time Average tablet 
mass 
Units N % m/m s mg 
FT-1 66.30 ± 6.77 0.08 180 496.63 ± 4.23 
FT-2 73.30 ± 7.01 0.08 370 502.41 ± 3.19 
FT-3 71.70 ± 2.83 0.15 208 499.01 ± 4.06 
FT-4 91.00 ± 6.53 0.07 336 498.43 ± 4.43 
FT-5 66.70 ± 5.50 0.11 201 502.34 ± 2.86 
FT-6 78.90 ± 5.95 0.09 347 505.90 ± 3.93 
FT-7 72.50 ± 6.02 0.05 293 496.90 ± 2.83 
FT-8 67.40 ± 4.67 0.11 305 501.72 ± 2.77 
FT-9 66.90 ± 5.13 0.05 276 500.98 ± 2.28 
FT-10 73.30 ± 5.66 0.05 250 500.23 ± 2.35 
FT-11 63.00 ± 5.89 0.05 345 498.00 ± 3.30 
FT-12 69.30 ± 5.40 0.08 230 499.50 ± 2.62 
FT-13 69.30 ± 3.56 0.17 227 504.47 ± 1.76 
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Figure 1  Pareto analysis for the adjusted model of the influence of the input variables 
influencing the extent of dissolution at 15 minutes 
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Figure 2  Screening trial batches: A release dissolution profile of ethionamide 250 mg 
tablets 
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Figure 3  Graphical representation of the effect of the quantity of povidone binder 
between the range of 3% m/m to 5% m/m on (a) tablet hardness (b) friability 
(c) disintegration and (d) the extent of dissolution at 15 minutes 
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Figure 4  Contour and surface plot of the effect of moisture content and impeller speed 
on the extent of dissolution at 15 minutes 
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Figure 5  Design space: A contour plot of the interaction between the significant factors 
on the product cQA 
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Figure 6  FMEA analysis of ethionamide tablets depicting RPN of failure modes before 
and after implementation of control strategy 
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Figure 7  Contour plots showing the effect of povidone binder quantity and moisture 
content on the selected responses (a) tablet hardness (b) friability (c) 
disintegration time 
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Figure 8  Contour plots showing the effect of povidone binder quantity, moisture 
content and impeller speed during dosing on the extent of dissolution at 
15 minutes 
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Figure 9  RSM study: A release dissolution profile of ethionamide 250 mg tablets 
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by Design 
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Summerstrand, Port Elizabeth, 6031 
 
Purpose: Designing a pharmaceutical product and its manufacturing process that is 
efficient, safe and fit for its intended use for patients is the primary focus of pharmaceutical 
development. Quality by Design (QbD) emphasises that the product quality should be built 
into the product and not merely tested post-production.  This systematic concept of QbD is 
the successor of the empirical Quality by Testing (QbT) and forms part of the modern 
approach to pharmaceutical quality. The aim of the study is to optimise the formulation and 
manufacturing process of an immediate release tablet using QbD. 
Methodology: The methodology employed in this investigation was done in accordance with 
the International Conference on Harmonisation Q8 and Q9 guidelines. Established the 
quality target product profile (QTPP). Identified the critical quality attributes (cQAs) of the 
product. Performed a risk assessment to identify the critical material attributes and process 
parameters that may impact the cQAs. Design of experiments (DoE) was applied to the risk 
factors. The screening trial batches using a 2-level fractional factorial design screened the 
factors to determine which of the critical factors identified during the risk assessment are 
significant. Following the screening trial, the pivotal study using a central composite rotatable 
design (CCRD) determined the effects of the significant factors on the cQAs. 
Results: The risk assessment identified the active pharmaceutical ingredient (API) particle 
size; quantity of binder content (povidone); impeller speed during dosing; massing time; 
impeller speed during wet mix; and moisture content (after drying wet granule) as factors 
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that may impact the extent of dissolution (%) at 15 minutes (cQA). ANOVA analysis of the 
experimental designs showed that the model (quadratic) chosen for the analysis had a 
significant fit (p=0.030). The response optimiser, indicated that to reach optimum desirability 
for the extent of dissolution (%) at 15 minutes, i.e. 100.6%, impeller blade speed during 
dosing should be 115 rpm and moisture content at 2.5% m/m. 
Conclusion: QbD provided an effective means to optimise the formulation and 
manufacturing process of the immediate release tablet by determining the influence of the 
selected input variables on the product cQA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
